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ABSTRACT 
Gene therapy has enormous potential to treat a wide array of inherited and acquired liver-
related diseases. Among contemporary gene transfer vehicles, recombinant adeno-
associated viral vectors (rAAV) show exceptional promise for liver-targeted approaches, 
owing to its ability to transduce hepatocytes in vivo with high efficiency in pre-clinical 
models, low pathogenicity and reduced induction of liver inflammation.  
The broad focus of the studies described in this thesis is the development of rAAV-
mediated gene therapy approaches to treat Progressive Familial Intrahepatic Cholestasis 
type 3 using an Abcb4-knockout mouse model. This autosomal recessive condition is 
caused by mutations of ABCB4, which encodes a hepatocanalicular phosphatidylcholine 
floppase, MDR3. Homozygous individuals develop progressive cholestatic liver disease 
and biliary cirrhosis with approximately 50% of patients requiring liver transplantation 
before reaching adulthood. In exploring rAAV-mediated gene replacement strategies for 
this condition, host- and vector-related factors influencing rAAV transduction and 
hABCB4 expression were evaluated, in order to optimise vector design, delivery and 
timing of administration for maximal therapeutic benefit.  
Transducing the liver with rAAV2/8 vectors encoding hABCB4 led to significant 
increases in biliary phosphatidylcholine concentration in disease-free heterozygous. 
However, this was not recapitulated with equal efficacy in homozygous adults with 
established liver disease, despite varying vector genome size and routes of administration. 
Maximal transduction of homozygous murine liver was achieved prior to the onset of 
liver disease, optimally in neonates. However, an essential challenge with neonatal vector 
delivery is maintaining therapeutic benefit in the setting of rapid hepatocellular 
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proliferation and growth, which leads to loss of transgene expression as a consequence of 
rAAV episomal degradation.  
A novel, hybrid rAAV-piggyBac transposon vector strategy was devised to maintain 
prolonged hABCB4 expression in neonatally-treated homozygotes in the face of rapid 
liver growth. Of the 3 known hABCB4 variants, isoform A was demonstrated to confer 
the highest biliary phosphatidylcholine concentration. Therefore, using a hABCB4 cDNA 
of this variant in a hybrid vector configuration, successful long-term correction of liver 
disease was demonstrated in Abcb4
-/-
 mice up to 9 months post-inoculation, with 
preliminary results indicating potential reduction in disease-related hepatocarcinogenic 
risk. These results demonstrate that rAAV-mediated gene therapy has the potential to 
offer patients with this heritable cholestatic liver disease an effective alternative treatment 
to liver transplantation, but also illustrate the importance of addressing challenges, such 
as the impact of liver pathology on vector performance, which is vital before this potential 
can be realised for this and related conditions.  
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CHAPTER 1: LITERATURE REVIEW 
1.1. INTRODUCTION 
A fundamental characteristic of the liver is that it serves multiple vital functions and has 
the capacity to adapt its functional activity to suit varied physiological and 
pathophysiological demands. Hepatocytes, the liver‟s parenchymal cells, play a major 
role in numerous synthetic and catabolic pathways, including metabolism of 
carbohydrates, lipid and proteins, and detoxification and elimination of endogenous 
metabolites and xenobiotics.
1
 Furthermore, it synthesises plasma proteins as well as bile 
acids and cholesterol, and is the main storage site of iron, glycogen, and some vitamins.
1,2
 
With such diverse functions, it is not surprising that many inherited conditions, resulting 
from either a lack or an overproduction of a critical gene product, originate in liver cells.  
The burden of chronic liver disease is high. Cirrhosis is the 12
th
 leading cause of death 
worldwide with approximately 1.03 million deaths per year across the globe.
3
 
Furthermore, approximately 29 million people in the European Union suffer from a 
chronic liver condition, causing an estimated death toll of 170,000 persons per year from 
complications of liver cirrhosis.
4
 Despite enormous progress in understanding the 
molecular mechanisms underlying many of these conditions, specific treatments remain 
elusive. Currently, orthotopic liver transplantation is the only available curative therapy 
for many forms of chronic liver disease. Despite continual improvement in outcomes, the 
paucity of donor organs, surgical complications, risk of graft loss from rejection, and 
requirement for lifelong immunosuppression, which carries the added chronic risks of 
nephrotoxicity
5
, cardiovascular complications
6,7
, malignancy
8
 and susceptibility to 
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infections, remain major issues for transplant recipients. Exploration of alternative 
therapy to liver transplantation is, thus vital for chronic liver diseases. 
1.1.1. Liver Cell and Gene Therapies 
1.1.1.1. Hepatocyte transplantation 
An enticing alternative to whole organ liver transplantation is cell-based therapies. There 
are several cell sources currently being explored. Initial attempts used primary 
hepatocytes, often harvested from liver tissue deemed unsuitable for whole- or split-liver 
transplantation.
9,10
 These were infused through the portal circulation to treat genetic and 
metabolic liver diseases, as well as end-stage liver failure.
11-13
 Some studies have shown 
therapeutic benefit, particularly in conditions where infused cells have a selective growth 
advantage over diseased hepatocytes – e.g. hereditary tyrosinemia type I14, Wilson‟s 
disease
15-17
 and progressive familial intrahepatic cholestasis
18
. However, overall 
improvements in liver function are modest and of uncertain duration.
19
 Current challenges 
facing this approach include low numbers of viable hepatocytes harvested from non-
transplantable donor livers, variability in quality, and difficulties in expanding primary 
hepatocytes in vitro.
9
 Thus, transferring sufficient quantities of viable cells to exert a 
phenotypic effect is a major hurdle. Furthermore, this approach does not alleviate the 
need for immune suppression, as recipient immunity against allogeneic cells is another 
major obstacle.  
Thus, other sources of abundant, high quality hepatocytes for transplantation have also 
been recently explored including use of liver progenitor cells, induced pluripotent stem 
(iPS) cells, and bone marrow-derived stem cells.
20
 In particular, iPS cells represent a 
unique potential source for autologous hepatocyte transplantation that would negate the 
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need for chronic immune suppression, and may avoid immune responses that lead to 
reduced therapeutic benefit from current allogeneic cell sources. For genetic diseases, 
autologous iPS-derived hepatocyte transplantation could ideally be paired with gene 
transfer strategies to correct the underlying genetic defect.
21
 However, further 
development of robust protocols for in vitro differentiation of iPS cells to fully mature 
hepatocytes will be vital for iPS cells to be a future reliable source for autologous 
hepatocyte transplantation. 
1.1.1.2. Gene Therapy Strategies  
Gene therapy is another alternative that has enormous potential to provide a definitive 
cure for a wide array of inherited and acquired liver diseases.
22,23
 Liver directed gene 
therapy to correct the underlying abnormality in a number of liver-related conditions has 
been extensively investigated for more than two decades. Conceptually elegant, the 
treatment involves delivering genetic material to the target cell for therapeutic effect. 
Several different strategies have been applied to the liver.   
The most well characterised strategy involves gene replacement. This is best suited to 
monogeneic diseases caused by mutations resulting in a deficiency state such as urea 
cycle defects, and therefore involves transfer of a gene encoding a therapeutic protein that 
replaces a deficient host gene function. There are many examples of liver-targeted gene 
replacement therapy (Table 1.1). 
Gene addition therapy involves the ectopic expression of a novel gene product in the liver 
cell. An example of such treatment is gene transfer of apoptin and interlukin-24 to induce 
apoptosis of hepatocellular carcinoma cells.
24
 Therapeutic DNA vaccination against 
infections such as chronic hepatitis C also falls into this category.
25
 Furthermore, gene 
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delivery systems have been designed to utilise hepatocytes as a factory to secrete proteins 
not usually synthesised in the liver such as insulin.
26
  
Gene editing or gene repair uses short DNA sequences to alter a mutated nucleotide 
sequence within genomic DNA by homologous recombination. This application has been 
investigated for the treatment of a number of diseases including hereditary tyrosinemia 
type I
27
, haemophilia B
28
 and mucopolysaccharidosis type VII
29
. This strategy is best 
suited to diseases caused by a discrete point mutation, short insertion or deletion, 
especially where there is a dominant mutational hotspot in the affected gene – e.g. ΔF508 
mutations of CFTR that affect approximately 30 to 88% of European cystic fibrosis 
patients.
30
 Gene targeting involves transferring a DNA sequence to the nucleus that is 
homologous to the chromosomal target site except for the genetic change to be 
introduced, and employing endogenous homologous recombination pathways to repair the 
gene mutation in situ using the introduced template.  
By using recombinant adeno-associated viruses as vehicles for delivering the gene 
targeting sequence, up to 1% of human cells can undergo gene editing under optimal 
conditions.
31
 Introduced genetic changes include 1-2 bp substitutions, small deletions and 
up to 1.5 kb insertions.
27,32,33
  However at present, the frequency of gene correction, 
particularly in vivo, may be much lower than necessary to be efficacious. An appreciable 
improvement may occur in conditions favouring survival of gene-corrected cells, but this 
is not common.
27,28,34
 The efficiency of homologous recombination can be enhanced by 
inducing double-stranded breaks.
35
 More recent efforts have explored the use of site-
specific endonucleases such as zinc-finger nucleases, transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced short palindromic repeats 
(CRISPR/Cas) RNA-guided nucleases to introduce site-specific double-stranded breaks 
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and improve the frequency of precise genomic engineering, which are showing promise in 
surmounting these challenges.
36-38
 Retaining endogenous regulation of gene expression is 
one of the major advantages of this strategy. It may also be advantageous in repairing 
short mutations in large genes that cannot be entirely packaged into viral or non-viral 
vectors for gene replacement.  
Gene elimination or knock-down strategies are employed to counteract gain-of-function 
consequences of diseases such as the hepatic phenotype of alpha-1 antitrypsin 
deficiency.
39
 Targeted gene expression is reduced by post-transcriptional silencing using 
RNA interference, or ribozymes which cleaves specific mRNA sequences.
40,41
 The 
discovery of liver-specific microRNAs and understanding their role in modulating gene 
function in a number of liver diseases has also identified numerous novel gene therapy 
targets.
42
  
Owing to its many essential functions, the liver is an important target for many gene 
therapy strategies. The array of candidate diseases that are appealing targets for liver-
directed gene therapy is vast, and many are already being evaluated at the pre-clinical 
level, showing promising success. Importantly, liver-targeted gene transfer has been 
shown in 2 clinical trials to confer therapeutic benefit for haemophilia B patients by 
converting severe disease into a milder phenotype, thus reducing the risk of spontaneous, 
life-threatening bleeding and the need for regular factor IX infusions.
43,44
 Examples of 
pre-clinical successes for both inherited and acquired liver-related conditions are listed 
(Table 1.1).  
Collectively, these studies demonstrate that many forms of liver disease are amenable to 
gene transfer methodologies.
22
 They have contributed considerably to our knowledge 
about in vivo vector performance in the liver, targeting, specificity, possible 
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hepatotoxicity and host-vector interactions, and have come some way to affirm the liver‟s 
prospect as a key gene therapy target, but have also highlighted some important hurdles. 
Thus, few strategies have yet to translate into clinical application. There remain a number 
of challenges that need to be overcome, in order for pre-clinical successes to become 
clinical reality. 
Despite enormous progress in liver-targeted gene therapy approaches, one group of 
hepatic disorders that have yet to receive much attention are cholestatic liver diseases. 
They arise from impairment of hepatobiliary production and/or excretion of bile, causing 
bile duct and hepatocellular injury from retention of potentially toxic cholephiles, and can 
result in a spectrum of clinical presentations from isolated biochemical abnormalities to 
biliary cirrhosis, liver failure or hepatobiliary malignancy.
45
 Some cholestatic liver 
diseases are caused by hereditary defects in genes encoding hepatobiliary transporters 
involved in production and hepatocyte secretion of bile constituents.
46,47
  This thesis 
focuses on the development of recombinant adeno-associated virus-based (rAAV) gene 
therapy approaches to a hereditary hepatobiliary canalicular phosphatidylcholine 
transporter defect, Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3).  
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Table 1.1: Examples of pre-clinical models of liver-directed rAAV gene transfer 
Targeted Condition Gene Target 
Cell/Animal 
model 
Clinical 
Trial 
Reference 
Haemophilia A Factor VIII variants Mouse, NHP 
Dog 
- 48-50 
51 
Haemophilia B Factor IX NHP, Dog, Mouse Phase 
I/II 
43,44,52 
Urea Cycle Defects 
  OTC deficiency 
  Citrullinemia Type I 
   Arginase deficiency 
 
OTC 
ASS 
Arginase 
 
Mouse 
Mouse 
Mouse 
-  
53 
54,55 
56 
Phenylketouria PAH Mouse - 57 
Methylmalonic acidaemia MUT Mouse - 58 
Propionic academia PCCA Mouse - 59 
Hereditary Tyrosinemia Type I FAH Mouse - 27 
Familial Hypercholesterolaemia LDLR Mouse - 60,61 
Glycogen Storage Disease  Type Ia G6PC/G6Pase-α Mouse, Dog - 62-64 
Pompe Disease GAA Mouse - 65 
Primary Hyperoxaluria Type I AGXT Mouse - 66 
α-1 Antitrypsin Deficiency piZZ shRNA & AAT Mouse - 39 
Crigler Najjar Type I UGT1A1 Mouse - 67 
Acute Intermittent Porphyria PBGD NHP Phase I 68,69 
MNGIE TYMP Mouse - 70 
Ethylmalonic Encephalopathy ETHE-1 Mouse - 71 
Lysosomal Storage Diseases 
   MPS Type IIIA 
   MPS Type VI 
   Galactosialidosis 
 
Sulfamidase 
ARSB 
PPCA 
 
Mouse 
Cat 
Mouse 
-  
72 
73,74 
75 
Dyslipidaemia LCAT Mouse - 76 
Liver Fibrosis BMP-7 Mouse (CCl4) - 77 
Ischaemia-Reperfusion Injury & 
Transplant rejection  
Heme-oxygenase 1 Rat - 78 
Transplant tolerance MHC complexes Mouse - 79 
Hepatitis B Interferon-α1 
 
RNAi against S & X genes 
HepAD38  cells 
Mouse 
- 80 
 
81 
Hepatitis C HCV-miR-Cluster 5 
 
Anti-HCV shRNA 
JFH-1 (HCV) cells 
NHP 
- 82,83 
 
84 
Hepatocellular Carcinoma Apoptin, IL-24 HepG2 cells, 
Xenograft of 
immune-deficient 
mice 
- 24 
Abbreviations: OTC, ornithine transcarbamylase; MNGIE, mitochondrial neurogastrointestinal 
encephalopathy; MPS, mucopolysaccharidosis; NHP, non-human primate; HBV, hepatitis B virus; HCV, 
hepatitis C virus  
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1.2. THE UNIQUE ANATOMY AND PHYSIOLOGY OF THE LIVER 
Development of a successful gene transfer strategy relies on tailoring it to the target organ 
or cell, and the specific disease process involved. Therefore, to better appreciate the 
underlying pathophysiology of cholestatic diseases and their consequences, it is important 
to understand the unique anatomy of the liver and its role in bile formation and secretion. 
The physiology of hepatobiliary system will be discussed in Section 1.5. 
1.2.1. Liver Architecture 
The liver is the largest visceral organ in the human body, comprising of approximately 
4% of total body weight in children and 2% in adults.
85
 It is the primary site for multiple 
metabolic pathways, and as such, must be capable of handling a large and varied 
metabolic substrate load delivered via the circulation. Hence, it is a highly vascular organ, 
receiving approximately 25% of the total cardiac output via its dual blood supply: 20% of 
the blood flow is systemic oxygen-rich blood delivered via the hepatic arteries, whilst the 
portal vein delivers the remaining 80% nutrient-rich blood from the gastrointestinal 
tract.
86
  
Additionally, in order to process its large solute load, each hepatocyte must be able to 
have direct contact with blood. The organization of the hepatic lobule is central to this 
notion. It consists of a hexagonal unit centred on a terminal hepatic venule with cords of 
hepatocytes separated by sinusoids radiating outwards. Portal tracts, comprising of 
branches of the portal vein, hepatic arteries and bile ducts, sit at the periphery of the 
lobule (Figure 1.1). Blood from terminal branches of the hepatic arteries and tributaries of 
portal veins flows directly into the sinusoids, where solutes readily comes into direct 
contact with the basolateral (sinusoidal) membrane of each hepatocyte.  
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Sinusoids are lined by specialized endothelial cells that show frequent intercellular spaces 
and fenestrations.
87,88
 Unlike the vasculature in other organs, sinusoids lack a basal 
lamina that usually forms a physical barrier between the bloodstream and parenchymal 
cells. Sinusoidal fenestrae are membrane bound cytoplasmic holes that allow free flow 
directly to the space of Disse between sinusoidal endothelial cells and hepatocytes, thus 
facilitating unimpeded exchange of fluid, solutes and other particles, including small 
viruses and viral vectors, at the basolateral membrane of hepatocytes.
87
 The size and 
number of fenestrae determine the substances that can participate in this exchange, whilst 
avoiding scavenging and processing by liver sinusoidal endothelial cells (LSEC) and 
components of the resident reticuloendothelial system, including Kupffer cells, dendritic 
cells and Pit (natural killer) cells. Other non-parenchymal cells reside in the 
subendothelial space including hepatic stellate cells that store vitamin A in the quiescent 
state, but are involved in fibrogenesis when activated in response to liver injury.
89
 
Altogether, these anatomical attributes of the liver allow systemically-delivered, small 
gene therapy vectors to readily reach and bind to hepatocyte cell surface receptors, in 
order to initiate transduction. 
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Figure 1.1: Diagram of the hepatic lobule demonstrating the concept of metabolic 
zonation. Portal triads containing branches of the portal vein (PV), hepatic artery (HA) 
and bile ducts (BD) reside at the peripheries of hepatic lobules. Blood flows from portal 
veins and hepatic arteries through sinusoids towards the centre of the hepatic lobules into 
tributaries of the central hepatic vein. Functional heterogeneity is exhibited by 
hepatocytes. Their function depends on their location along the porto-central axis: a 
phenomenon termed “metabolic zonation”. Afferent hepatocytes within Zone 1 are closest 
to the portal triad and are regarded as periportal, whereas Zone 3 (efferent) hepatocytes 
closest to the central vein are designated pericentral. Hepatocytes in Zone 2 form the 
intermediary zone, as represented in this diagram. For example, zonated functions such as 
gluconeogenesis are performed largely by periportal hepatocytes, whereas complementary 
glycolysis occurs predominantly in pericentral hepatocytes. Adapted from Burke and 
Tosh.
90
 
 
1.2.1.1. Liver sinusoidal endothelial fenestrations 
Scanning electron microscopy shows that LSEC fenestrae are arranged in sieve plates and 
comprise 6 to 8% of the LSEC surface.
91
 The diameter of fenestrae varies significantly 
between different species, generally measuring between 100 and 200 nm.
91
 There are also 
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intra-individual variations, and differences are observed along the porto-venous axis such 
that the diameter of fenestrae are larger but less frequent in periportal areas compared 
with the centrilobular region.
92
 
Species differences in fenestrae size may be one of the critical factors to explain observed 
interspecies variation in hepatocyte gene transfer.
93
 Snoeys et al., demonstrated that the 
diameter of fenestrae correlated with species differences in transgene DNA uptake by 
hepatocytes using adenoviral vectors.
94
 This may also be an important limitation for other 
hepatocyte-directed viral gene transfer strategies using vectors with sizes that parallel or 
exceed fenestrae size of the targeted species. Human livers have an approximate mean 
fenestrae size of 107 nm.
95
 Therefore, this may affect hepatocyte gene transfer using 
vectors based on lentivirus (150 nm diameter) and herpes simplex virus (180 nm), and 
also non-viral vectors such as liposomes (50-1000 nm).
93,96
 In the healthy liver, this is not 
likely to affect systemically administered rAAV vectors, given its small size (22 to 26 
nm).
96
 
 
1.2.1.2. Zonation of hepatic functions 
The multitude of functions carried out by the liver are largely performed by hepatocytes 
that make up approximately 60% of the liver cell population, but 80% of its volume.
2
 
Though morphologically indistinguishable, hepatocytes exhibit functional heterogeneity, 
depending on their position along the porto-central axis.
97
 This is the basis of metabolic 
zonation, the liver‟s adaptation to meet its diverse, opposing and complementary 
metabolic demands. The liver cell plate is a cord of 15 to 25 hepatocytes extending from 
the portal triad to the central hepatic venule. Hepatocytes have specific repertoires of gene 
expression and metabolic capabilities, depending on their proximity to afferent or efferent 
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blood vessels along the liver cell plate, which is divided into 3 zones.
98
 Accordingly, 6 to 
8 periportal (afferent) hepatocytes closest to the portal triad are included in Zone 1, and 2 
to 3 pericentral (efferent) hepatocytes in close proximity to the central hepatic venule are 
termed Zone 3.
99
 The remaining, less well-defined 6 to 10 hepatocytes comprise the 
intermediate Zone 2 (Figure 1.1).  
Many liver processes appear to exhibit a particular zonal preference, but the steepness of 
gradients along the porto-central axis varies. Well-documented zonality of hepatocellular 
pathways include those involved with carbohydrate metabolism (gluconeogenesis and 
glycolysis), ammonia detoxification and ureagenesis, amino acid metabolism, cholesterol 
synthesis, lipolysis, fatty acid β-oxidation, ketogenesis, xenobiotic biotransformation, and 
bile formation (including bile salt uptake and excretion, and bilirubin elimination).
100
  
Differential gene expression that results in zonation may be static or dynamic. For 
example, enzymes involved in ammonia detoxification have a static pattern of gene 
expression with a high capacity/low affinity system of ammonia 
detoxification/ureagenesis involving carbomyl-phosphate synthetase (CPS I) in periportal 
hepatocytes, and a high affinity “scavenger” system involving glutamine synthetase (GS) 
in pericentral hepatocytes.
101
 Strict compartmentalisation of opposing urea and glutamine 
synthesis is governed by the reciprocal, mutually exclusive expression of CPS I and GS in 
periportal and pericentral hepatocytes, respectively.
102
 
In contrast, dynamic patterns of zonation may adapt to alterations in the 
microenvironment, circadian rhythm and a variety of other factors including those 
dictated by disease processes.
103,104
 For example, in the fasting state, acetyl-coA 
carboxylase (a major enzyme involved in fatty acid biosynthesis) is largely expressed in 
the periportal zone. Whereas following 24-48 hours of re-feeding with a high 
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carbohydrate diet, high levels of acetyl-coA carboxylase expression is induced with a 
several fold increase in enzyme activity, and its zonal gradient of activity across the 
hepatic lobule is abolished.
105
 Zonation of enzymes involved in carbohydrate metabolism 
can also be altered in response to localised oxygen tension, high-intensity exercise and 
changes to hepatic blood flow.
104,106,107
 Furthermore, zonal patterns of glucose and fatty 
acid metabolism can be perturbed by pathophysiological states such as diabetes and 
alcoholic fatty liver disease.
108-110
    
The molecular mechanisms by which liver zonation are established are not yet fully 
understood. Early models revealed the influence of differential neural and humoral inputs 
such as oxygenation, nutrient content and hormonal signals in blood, that are governed by 
concentration gradients established during the directional passage of blood through 
sinusoids.
98
 This best explains dynamic, but not static patterns of zonation, given that the 
composition of blood is not constant.  
Recent compelling evidence suggests that the Wnt/β-catenin pathway plays a critical role 
as the master intermediary regulator. The link between Wnt signalling and metabolic 
zonation was initially made with the discovery that aberrant β-catenin activation in human 
hepatocellular carcinoma (HCC) tumours mediated a pericentral-like transcriptome.
111,112
 
In particular, overexpression of glutamine synthetase in HCC tumours strongly correlated 
with β-catenin activation.112 Subsequently, β-catenin has been shown to exert a strict 
control favouring transcription of pericentrally-expressed genes.
111,113
 While its negative 
repressor, the adenomatous polyposis coli tumour suppressor (Apc), mediates expression 
of a periportal genetic program.
99,114
 Liver-wide inhibition of Wnt signalling or β-catenin 
inactivation leads to widespread adoption of a periportal phenotype in hepatocytes 
throughout the entire hepatic lobule with no major deleterious consequences. Conversely, 
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transgenic mice with Apc-null livers have pericentral genetic programming, which results 
in early demise of affected animals, mostly due to hyperammonaemia from absence of 
ammonia detoxification via the urea cycle.
114
 Changes in β-catenin signalling are thought 
to involve all known zonal metabolic pathways, suggesting that other factors regulating 
transcription of zonated genes occur downstream of the Wnt cascade.
99
  
The mechanisms that maintain β-catenin activation pericentrally, and Apc-mediated β-
catenin-repression periportally remains to be elucidated.
99
 Zonal activation of β-catenin 
through canonical signalling appears to be dependent on Wnt ligands.
114
 These are known 
to be secreted by hepatic parenchymal and non-parenchymal cells.
115
 Non-parenchymal 
cells such as Kupffer cells and dendritic cells, also display zonal heterogeneity 
particularly in their distribution,
116
 and it has been suggested that the heterogeneous 
distribution may contribute to differential concentrations of secreted Wnts and their 
inhibitors in the local extracellular milieu.
99
 However, the specific Wnt ligands and 
inhibitors that are involved in zone-specific transcription have yet to be identified. 
Furthermore, the mechanisms by which activated β-catenin dictates zonal specificity and 
its interactions with downstream transcriptional factors is currently under investigation. 
Liver-enriched transcriptional factor, hepatic nuclear factor 4-alpha (HNF4α), and 
members of the Lef/Tcf family including Lef1 appear to be key modulators.
117
     
Consideration of the zonal heterogeneity of metabolic pathways may be relevant for gene 
replacement therapy involving specific zonated enzymes. Targeting hepatocytes where 
the involved pathway predominates to reflect physiological gene expression will 
maximise interaction with other components of the targeted pathway. This may be 
essential for therapeutic efficacy.  
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1.3. LIVER-TARGETED GENE THERAPY 
1.3.1. Viral vs. Non-viral Vectors 
The transfer of a therapeutic gene to the targeted cell is facilitated by the use of molecular 
constructs known as vectors. Without a vector, naked DNA is very prone to rapid 
degradation by various nucleases in plasma with a half-life of 10 minutes in serum.
118
 
Uptake of DNA complexes by reticuloendothelial cells may also lead to rapid clearance 
from the circulation.
119
 Furthermore, without physical disruption of cell membranes, 
nucleic acids are not able to readily enter cells, given their large size and 
hydrophilicity.
120
 Vectors serve to allow specific access to the target tissue, entry into the 
target cell, exploitation of intracellular trafficking pathways to the nucleus and 
importantly, to protect the gene construct from degradation. 
A number of different approaches have been used in vector design including viral and 
non-viral strategies. Some non-viral approaches have utilised synthetic constructs such as 
galactosylated polymers to facilitate receptor-mediated entry via an asialoglycoprotein 
receptor on the sinusoidal membrane of hepatocytes.
121-123
 Other chemical gene delivery 
methods use cationic liposomes to protect DNA complexes from degradation, enhance 
cell surface binding and intracellular entry via endocytosis.
124
 Physical approaches have 
also been employed to permit greater cell surface permeability. These include direct 
micro-injection into the liver, ballistic bombardment/gene gun, electroporation, 
sonoporation and hydrodynamic delivery.
120
 However, the majority of these approaches 
have so far yielded low efficacy in vivo with limited duration of transgene expression, 
some have dose-limiting cytoxicity, and feasibility in translation to clinical application 
remains to be determined. 
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Vectors based on viral constructs are preferred for their higher transduction efficiency. 
Viruses are obligate intracellular parasites that have evolved efficient mechanisms to 
delivery their genome to the nucleus of targeted cells. Viral-based gene therapy vehicles 
utilise these mechanisms but most of the viral DNA or RNA genome is replaced by an 
expression cassette containing the transgene of interest as well as elements necessary to 
aid gene expression including promoter and enhancer sequences, post-transcriptional 
regulatory elements and polyadenylation signals. Vectors are generally devoid of all 
replicative machinery, leaving only non-coding viral sequences necessary for packaging 
and incorporation of vector DNA into the host cell. Genes encoding proteins required for 
proviral replication, assembly, and capsid or envelop function are provided in trans 
during the production process, but eliminated from the final vector stocks. 
A number of viral candidates have been considered in applications necessitating liver-
specific delivery, with some encouraging results in pre-clinical and clinical trials. 
Amongst the most commonly utilised vectors are those based on retroviruses including 
lentivirus, adenoviruses and adeno-associated viruses. 
1.3.1.1. Retroviral vectors 
Retroviruses are positive-sense single stranded RNA virions packaged within a lipid 
envelope. To complete their life cycle, retroviruses must integrate their genetic cargo into 
the genome of target cells. This is a major advantage as it confers prolonged, stable 
transgene expression, especially in dividing cells. Most retroviruses exclusively transduce 
mitotic cells, as targeted cells must undergo replication in order for retroviral integration 
and gene expression to occur.
125,126
 This may be beneficial in some applications such as 
those targeting stem cells or selectively transducing tumour cells. However, this would 
not be suitable for transducing quiescent non-dividing hepatocytes, such as for treatment 
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of chronic liver disease.
126
 A lentiviral based approach may be preferred in such 
circumstances, as they have the unique ability among retroviruses to also transduce non-
dividing cells. The ability to integrate into the genome is a two-edged sword: increased 
longevity of transgene expression with inherent risk of insertional mutagenesis and 
potential neoplastic transformation. This occurs when vector genetic material is integrated 
into the host genome at sites which either promote oncogenesis or disrupt tumour 
suppressor function.
127 
A recent study of conventional γ-retroviral gene therapy for X-
linked severe combined immunodeficiency suggested that acquisition of other somatic 
mutations is required in the development of leukaemia in addition to an insertional 
mutagenesis event.
128
 
A crucial consideration with employing a lentiviral based approach is the biosafety issues, 
since those based on wild-type HIV are highly pathogenic in humans. Therefore to 
generate safe vector systems for gene therapy, lentiviruses are rendered replication-
deficient by removing all viral genes necessary for self-propagation, whilst maintaining 
components needed to transduce cells.
129
 A major limitation of in vivo lentiviral gene 
therapy is immune responses directed towards the virion and encoded-transgene 
product.
130
 In addition to viral-encoded components, non-viral proteins can be 
incorporated into the virions during the packaging process including cellular molecules 
acquired from the packaging cells.
131,132
 Transgene-encoded proteins can also be 
incorporated into the viral vectors.
130
 All of these are potential foreign antigens capable of 
inducing both innate and adaptive immune responses towards the lentiviral vector, thus 
limiting its potential therapeutic success by reducing lentiviral transduction efficiency, 
eliminating transduced cells and inhibiting the effect of the transgene product. 
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1.3.1.2. Adenoviral vectors 
Some liver-targeted gene therapy strategies have employed vectors that based on 
adenoviruses, double stranded DNA viruses that exhibit natural tropism for the liver and 
can transduce post-mitotic cells with high efficiency. Adenoviral vector DNA is not 
integrated into the host genome, reducing the risk of malignant transformation due to 
insertional mutagenesis. Unfortunately, early adenoviral constructs exhibit hepatotoxic 
effects by potently inducing an inflammatory response through stimulation of cytotoxic T 
cells.
133
 This prompted the development of helper-dependent adenoviral (HDAd) vectors 
that are devoid of most non-essential viral DNA, except for cis-acting packaging signals 
and inverted terminal repeats. HDAd retain high hepatocyte transduction efficiency with 
prolonged transgene expression and low chronic immunogenicity. However, a major 
obstacle preventing clinical application of this vector system is potent innate immunity 
towards capsid protein, provoking an acute systemic inflammatory response within the 
first 48 hours following intravenous administration in a dose-dependent manner.
134
 
Capsid-mediated acute toxicity was found to be lethal at high doses ( 1 × 1013 viral 
particles/kg) in non-human primates.
135
  Nevertheless, this is a promising vector delivery 
system for hepatocyte-targeted gene transfer, but strategies to block acute innate 
inflammatory responses and surmount methodological hurdles in optimising scalable 
production processes and vector purification are vital for progress towards clinical 
application.
136
 
1.3.1.3. Adeno-associated viral vectors 
Vectors based on adeno-associated virus (AAV), a small, encapsidated DNA virus, are 
capable of transducing hepatocytes to achieve long-term transgene expression in the 
absence of significant toxicity in rodent, dog and non-human primate models.
137-139
 All 
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viral DNA sequences, except for cis-acting AAV inverted terminal repeats necessary for 
rescue of vector genome from plasmid constructs, recombinant genome replication, and 
genome packaging are removed from vectors, thus eradicating its replicative potential. 
Indeed, efficient completion of AAV replicative cycle relies on the concomitant presence 
of a helper virus such as adenovirus or herpes virus, thus adding to its safety.
140
 Despite a 
common finding of antibodies towards some AAV serotypes in the general population, 
there are no known diseases or symptoms resulting from naturally occurring AAV in 
humans.
141
 This suggests that AAV is a largely innocuous, commensal in humans. The 
lack of pathogenicity is attributable to AAV‟s ability to evade the innate immune system 
and its inefficiency in infecting dendritic cells and macrophages.
142
 These characteristics 
are central to AAV‟s utility as a vehicle of choice for liver targeted gene delivery. 
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1.4. RECOMBINANT AAV-MEDIATED LIVER-TARGETED GENE 
TRANSFER 
1.4.1. AAV Vector Biology and the Liver 
AAV is a dependovirus that belongs to the Parvoviridae family. It contains an 
approximate 4.7kb single stranded DNA genome that comprises 2 open reading frames 
encoding replication and structural capsid proteins. Flanking the genome are two short 
palindromic inverted terminal repeat (ITRs) sequences that form T-shaped hairpin 
structures containing the origin of replication and terminal resolution sites. The viral or 
vector capsid is an icosahedron made up of multiple interlinking subunits encoded by 3 
capsid genes.
143
 In order to maintain capsid integrity, AAV has a finite packaging 
capacity (Section 1.4.2).  
AAV serotype 2 is well characterised as it was the first of 12 distinct serotypes isolated 
from human and non-human primates to date.
144-146
 Understanding its vector biology has 
led to important advances in vector design aimed at optimising transduction efficiency. 
Cellular transduction of AAV is initiated by binding of the viral capsid to cell surface 
receptors. Endocytosis depends also on interaction with various co-receptors.
147,148
 For 
example, the primary receptor for AAV serotype 2 is the heparin sulfate proteoglycan 
(HSPG) moiety on the cell surface of many tissues.
149
 Binding to HSPG leads to 
conformational change of viral capsid proteins necessary for interaction with integrin 
α5β1 required for receptor mediated endocytosis via clathrin-coated pits in a dynamin-
dependent process.
150
 Critical components of the capsid proteins also interact with the 
intracellular environment to influence its navigation and trafficking to the nucleus. This is 
a major rate limiting step in transduction. Endosomal release into the perinuclear 
cytoplasm relies on exposure of the phospholipase A2 domain within the capsid.
151
 Once 
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released from endosomes, degradation of virions by proteasomes can influence gene 
transduction in different cell types. Proteasome inhibitors have been shown to potently 
increase transduction of hepatocytes ten-fold in preclinical studies.
152
  
Mechanisms that govern entry of virions into the nucleus remain unclear. In order for 
transduction to be completed, the virion must shed capsid and the single-stranded genome 
become double-stranded for genome stabilization and transgene expression. Double-
stranded genomes are formed via 2 distinct mechanisms: i) annealing of plus and minus 
single-stranded genomes, and ii) second-strand synthesis, an additional rate-limiting step 
affecting transduction efficiency. Self-complementary vectors, that package inverted 
repeat genomes that can fold into transcriptionally-active, double-stranded DNA forms by 
deletion of one terminal resolution site, have been developed to overcome this limitation 
with improved transduction efficiency demonstrated in some studies.
153-155
 This strategy, 
however, comes at the expense of effectively halving the packaging capacity.
156,157
 
The fate of rAAV vector genomes following transduction is important in determining the 
stability of transgene expression. Only vectors that persist in a transcriptionally active 
double-stranded form can contribute to expression. Double-stranded vector genomes may 
be either episomal or integrated into host chromosomal DNA. The mechanisms that 
govern vector persistence in an episomal or integrated form are still under investigation. 
The majority of functionally expressing rAAV vectors in non-dividing tissue are 
episomal.
158
 Studies have shown that functional episomal vectors can persistent for up to 
19 months in the quiescent adult murine liver, as hepatocyte turnover occurs slowly with 
the average lifespan of healthy adult murine hepatocytes ranging from 200 to 300 
days.
159,158
 However, episomes are lost during cellular proliferation, such as in response to 
injury or during growth. Only approximately 0.1% of rAAV vector genomes that enter 
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cells are integrated into the host genome, but in this form are protected from degradation 
and can undergo clonal expansion with dividing cells.
160
 Nevertheless, a low rate of 
chromosomal integration reduces the potential for long-term stable gene expression, 
particularly in dividing cells. This is an important consideration when treating children 
who are still undergoing significant liver growth, and when there is liver regeneration in a 
response to injury or disease. 
1.4.2. Packaging Capacity of Recombinant AAV 
The potential for gene therapy to treat a wide variety of inherited diseases is restricted by 
the finite packaging capacity of rAAV vectors. The optimal size of the packaged genome 
is suggested to be between 4.1 and 4.9 kb.
161
 This approximates native genome size (4.7 
kb), and must accommodate not only the transgene of interest, but also the ITR sequences 
and regulatory sequences such as promoter, enhancers, polyadenylation signals and post-
transcriptional regulatory elements. However, many common inherited diseases in 
humans, including cystic fibrosis, Duchenne muscular dystrophy, haemophilia A and 
Wilson‟s disease, are caused by mutations in genes that exceed this limitation. Exceeding 
packaging capacity results in a sharp reduction in packaging efficiency.
161
 Nevertheless, 
rAAV genomes up to 6.0 kb can successfully transduce cells and mediate meaningful 
transgene expression, though at a much lower efficiency. These vectors may have 
difficulty escaping endosomes and therefore are preferentially degraded by 
proteasomes.
162
 Thus, proteasome inhibitors may be beneficial in improving transduction 
efficiency in such circumstances.
162
 More recent studies suggest that rAAV produced 
from plasmid-encoded expression cassettes exceeding 5.2 kb can lead to truncations at the 
5‟ end.163-165 Still at high multiplicity of infection, reporter gene expression was seen in 
vitro, though at significantly lower levels compared with smaller genome packages. 
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Recombination events were proposed to have reconstituted functional expression 
cassettes.
164
 Similar findings were found in vivo, where circularized genomes over 5 kb 
were recovered from mice 21 days following vector administration, but not at 24 hours, 
suggesting that partially packaged rAAV sequences may have recombined in situ.
163
 In 
this study, oversized vector yields were approximately 10-fold lower than wild-type 
genome sized vectors.  
Several strategies have been suggested to overcome the packaging limitations of rAAV 
vectors. Packaging capacity may be dependent of AAV capsid serotype. In a recent study, 
vectors pseudo-typed with capsid 5 were able to incorporate larger, fully functional 
genomes (up to 8.9 kb) with better efficiency than other serotypes.
166
 However, this could 
not be replicated by others.
165,167
 A similar approach has been the development of hybrid 
viral vectors, which increase the capacity of rAAV genomes by packaging into the capsid 
of other viruses including herpes simplex virus, and adenovirus.
168-170
  
Another strategy to overcome packaging limitations involves dividing the therapeutic 
expression cassette into two (or more) sequences, and packaging each into upstream and 
downstream vectors. Following co-transduction of both vectors, the full expression 
cassette is reconstituted through head-to-tail vector genome recombination.
171-173
 There 
are two similar approaches using this strategy: trans-splicing vectors engineered with 
splicing signals
174,175
 and overlapping vectors which include short homologous sequences 
required for recombination.
173,176
 However, transduction efficiency using these techniques 
has been too low for effective therapeutic benefit, but further studies are optimizing this 
method.
175,177,178
  
Instead of encoding the entire transgene for gene replacement, a novel strategy to avoid 
packaging constraints would be to use homologous recombination to correct a known 
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genetic mutation in situ, as described (Section 1.1.1.2). However, using current 
techniques the efficiency of gene repair is lower than necessary for phenotype correction 
of many conditions. Nevertheless, successful gene repair was performed using rAAV 
vectors to transfer a wild-type genomic sequence for repairing mutated 
fumarylacetoacetate hydrolase gene by homologous recombination in a mouse model of 
hereditary tyrosinemia type I in vivo, in which gene corrected cells have a selective 
survival advantage.
27
 
 
1.4.3. Factors Influencing Liver-specific Transgene Expression 
The degree of liver-specific stable transgene expression is determined at several levels. In 
order for cell transduction to be initiated, vectors must have access to the appropriate cell 
surface receptor of the target cell. Access to the tissue, largely depends on the route of 
administration and the bio-distribution of vector. Anatomical barriers, such as the blood 
brain barrier, may also dictate how successfully vectors are able to access the site of 
interest. Owing to its unique architecture described above, in these regards, the liver is an 
ideal target site (Section 1.2.1).  
Interestingly, the site of cell entry may affect intracellular processing, which in turn 
determines transgene expression from vectors. In an experimental study examining the 
fate of vectors delivered to the basolateral and apical membranes of bronchial epithelial 
cells, rAAV bound more efficiently at the basolateral than apical membrane (in the order 
of 2-7 fold).
152
 Basolateral transduction was 200-fold more efficient and the majority of 
basolateral vectors had become double-stranded at 50 days post-administration, compared 
with persistently single stranded apically transduced vectors. The investigators postulated 
that polarized cells have different early endosomal trafficking patterns and processing. A 
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polarity in intracellular trafficking has also been described in Madin-Darby canine kidney 
cells.
179
 It is likely that similar processes operate in hepatocytes, which are also polarized 
epithelial cells. 
Additionally, hepatocyte-specific expression is determined by the vector‟s ability to be 
internalized and transduce the hepatocyte, as well as by specificity of encoded promoters. 
Vector capsids are a major determinant of rAAV tissue tropism and transduction 
characteristics. Tissue tropism, defined as the specificity of AAV for particular host 
tissues or cells, is governed by the cumulative effects of cell surface receptor usage, 
endocytosis efficiency, intracellular trafficking, nuclear translocation, uncoating and 
second strand synthesis.
143
 Many of these processes are influenced by capsid serotype.
180
 
Numerous studies have compared the transduction profile of a number of naturally 
occurring AAV serotypes. Although there is no definite consensus, serotypes 8 and 9 are 
considered to have the highest level of hepatocyte transduction in the murine liver.
181,182
 
Although cell-type specific transduction profiles are likely to be species-
dependent,
143,183,184
 and therefore translation of pre-clinical data should proceed with this 
in mind.  
The serotype 8 capsid has been demonstrated to mediate transduction of the majority of 
hepatocytes with long-term persistence of transgene expression in adult mouse liver using 
relatively modest vector doses delivered intraperitoneally.
181,182
 In the liver, rAAV capsid 
serotype may also influence zonal heterogeneity of hepatocyte transduction, but this too 
appears to be species-dependent. For example, rAAV serotype 8 (rAAV8) predominantly 
transduces pericentral hepatocytes in murine livers, whilst a converse pattern was evident 
in the livers of non-human primates.
185
 Furthermore, rAAV8 displays faster transduction 
kinetics with rapid conversion of input genomes to the transcriptionally active double-
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stranded form compared with other serotypes, despite equivalent uptake of vector 
particles by the liver.
183,186
 This may be advantageous in some applications where rapid 
efficacy is desired such as in cancer gene therapy. 
Although rAAV2/8 has been proven to transduce the murine liver at very high efficiency, 
it lacks specificity. Its broad tissue tropism may be undesirable in some applications. A 
number of strategies have been utilised to optimise the vector transduction pattern to fit 
specific needs, while also circumventing pre-existing immunity to naturally occurring 
serotypes. These include pseudo-serotyping rAAV vectors by cross-packaging an AAV 
genome into the capsid of another serotype (e.g. rAAV2/8 refers to a pseudo-serotyped 
vector with a serotype 2 genome and a serotype 8 capsid), generating chimeric or mosaic 
capsids by combining different capsid subunits to synergistically enhance transduction, 
and modifying capsid subunits to improve affinity for specific cell surface receptors.
187,188
 
Further specificity can also be achieved by the use of liver-specific promoters to minimize 
off-target effects such as avoiding expression in antigen presenting cells, which may lead 
to deleterious immune responses against the transgene product.
189
 Liver-specific 
promoters possess varying degrees of promoter strength, which may influence the level of 
transgene expression in hepatocytes. 
1.4.4. Host-Vector Interactions 
1.4.4.1. Immune responses to rAAV 
The innate immune system serves as the first line of defence against viruses and viral 
vectors. Phagocytic cells are recruited, through activation of pattern recognition receptors 
by highly conserved components of invading pathogens, and secretion of inflammatory 
mediators including cytokines and chemokines.
190,191
 AAV has a limited ability to induce 
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innate immune response of the host, through several described mechanisms including 
limited ability to engage pattern recognition receptors including toll-like receptors and 
failure to induce type I interferon responses.
192,193
 Furthermore, AAV is able to abrogate 
complement activation by downregulating the complement cascade through recruitment 
of factor H and generation of iC3b on its capsid surface.
194
 However, delayed humoral 
immunity with lower neutralizing antibodies seen in mice deficient in complement 
receptor 1 and 2, or C3 suggest that complement interaction is important in enhancing B-
cell responses to the vector.
194
 
Whilst innate immune responses are rapidly generated over minutes to hours, adaptive 
immune responses develop over days to weeks.
195
 The adaptive immune system relies on 
a vast repertoire of highly specific and regulated immune responses by T- and B-
lymphocytes aimed at pathogen-specific elimination, generation of lifelong immunologic 
memory and the ability to rapidly respond to the pathogen upon re-exposure.
195
   
Against rAAV vectors, there are two main protein targets: the transgene product and 
components of the vector capsid. A significant immune response directed against the 
transgene product may limit the effectiveness of ongoing gene replacement therapy, as 
well as supplementary therapeutic protein therapy.
190
 However, stimulating specific cell-
mediated immunity is beneficial in AAV-mediated therapeutic vaccination and cancer 
immunotherapy.
196,197
 Immune responses against the transgene product is particularly 
relevant for patients with null mutations who are naïve to the transgene gene product. 
This was demonstrated in an analogous situation in which individuals with progressive 
familial intrahepatic cholestasis type 2 (due to null mutations in the gene encoding the 
bile salt export pump, BSEP) developed allo-immune mediated BSEP dysfunction 
following liver transplantation due to high-titre antibodies against BSEP.
198-200
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In order for T-cell mediated responses to be generated against the transgene product, one 
of two events must occur. The main pathway is through transduction and transgene 
expression in professional antigen presenting cells (APC), such as dendritic cells. This 
results in presentation of the transgene epitope via MHC class II molecules to effector T 
cells. This pathway is largely avoided by some rAAV vectors, depending on the capsid 
serotype, due to inefficient APC transduction. In dendritic cells, blocks in post-entry 
processing interfere with efficient transduction and antigen presentation.
142
 An alternate 
route is elicited by cross-priming, where exogenous antigen is captured, internalised and 
presented to effector T cells via MHC class I molecules.
201
  
Understanding factors that mediate host immune responses against the transgene product 
is vital in the design of clinically relevant rAAV-mediated gene transfer systems, where 
long-term therapeutic gene expression is the desired goal. Such considerations include 
immunogenicity of rAAV serotypes, route of vector administration, vector dose, 
specificity of promoter/enhancer elements, and maturation status of dendritic cells at the 
site and time of rAAV encounter.
202
 Using a non-obese diabetic mouse model which has a 
hypersensitive immune phenotype, Lu and Song demonstrated that rAAV8 was unable to 
transduce dendritic cells and thus induced immune tolerance to the transgene product.
203
 
Interestingly, pre-immunisation with rAAV8 in this model also resulted in subsequent 
immune tolerance to rAAV1, a more immunogenic serotype. The rAAV nomenclature 
used to in this study refers to the capsid serotype. 
Immune tolerance induction to a number of transgene products following in vivo gene 
transfer directed to the liver has been well documented.
204-207
 The key to tolerance 
induction is specific antigen handling by the liver‟s resident APCs, independent of 
surrounding lymphoid organs.
208
 Though the underlying mechanisms are not fully 
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understood, there appears to be 3 main factors governing induction of tolerance by the 
liver: i) hepatocyte restricted transgene expression, ii) limited stimulation of host innate 
immunity and iii) avoidance of direct transduction of professional antigen presenting 
cells. CD4
+
CD25
+
 T regulatory cells are central in mediating tolerance. This was 
demonstrated by adoptive transfer studies showing that induced transgene-specific 
regulatory T cells were able to suppress antibody formation to factor IX.
207
  
Despite the liver‟s toleragenic properties, capsid protein represents another major target 
for the host‟s adaptive immune response. Exposure to wild-type virus is common in the 
general population and can lead to an anti-capsid response, which is marked by detectable 
anti-capsid antibodies in sera. It is thought that primary infection leads to development of 
memory T cells, which upon encounter with the antigen such as vectors with the same 
capsid, are capable of rapidly expanding and recruiting cytotoxic T cell to effect potent 
cytolytic activity against cells that display capsid antigen (i.e., transduced cells), thus 
limiting the durability of transgene expression.
209
  
Two recent phase I/II clinical trials used AAV-mediated gene transfer to the liver for 
therapeutic expression of coagulation factor IX in patients with X-linked haemophilia 
B.
43,44 
Though some patients had sustained therapeutic benefit, these clinical trials 
highlighted two main immunological obstacles, involving anti-capsid immune responses, 
that could be detrimental to long-term efficacy: firstly, reduced hepatic transduction due 
to pre-existing neutralising antibodies from prior AAV exposure, and secondly, activation 
of CD8
+
 memory T cells against vector capsid, leading to elimination of transduced 
hepatocytes and loss of transgene expression. During the 2006 clinical trial involving 
haemophilia B patients, there was a steady loss of transgene expression, following hepatic 
artery infusion of recombinant AAV serotype 2 expressing human factor IX, with blood 
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levels dropping to pre-treatment levels by 2 months.
44
 This was accompanied by 
asymptomatic elevation of serum transaminases and was subsequently showed to be 
associated with a capsid-specific cytotoxic T cell response, suggesting specific immune-
mediated destruction of transduced cells.
44
 These responses were not anticipated on the 
basis of pre-clinical studies, which had shown long-term, stable and sufficient factor IX 
levels detected in vivo in rodent and canine models.
52,210
 Furthermore, efforts to dissect 
the mechanisms that govern this process have been hampered by difficulties in replicating 
equivalent immune responses in animal models.
211-213
 Nevertheless, understanding and 
augmenting these host immune responses toward the gene delivery system is critical for 
advancing liver-directed, AAV-mediated gene transfer to the clinic. 
Studies have shown limited cross-reactivity to other serotypes in the presence of specific 
neutralising capsid antibodies against one serotype in animal models.
183,214
 This has lead 
some to suggest a strategy to avoid loss of vector efficacy in the presence of pre-existing 
neutralising antibodies or with subsequent re-dosing by packaging in a different serotype 
or using novel modified capsids. However, these strategies may not be effective in 
humans, given that unlike laboratory animals, they may have prior exposure to wild-type 
AAV. Furthermore, AAV2 memory T cells in humans can cross react with serotype 8 and 
1 epitopes, resulting in expansion of functional cytotoxic T cells that are indistinguishable 
from those elicited by AAV2.
209
   
Other strategies have also been suggested to reduce the impact of immune response on 
efficacy. These include improving specificity of vector transduction and transgene 
expression to target cells. This may limit off-target transduction of antigen presenting 
cells. One such novel strategy is to encode miR142 targeting sequences at the 3‟ 
untranslated region of the transgene.
215,216
 miR142 is a micro RNA expressed specifically 
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in haemopoetic cells involved in antigen presentation. Therefore, vectors encoding their 
target sequences prevents transgene expression in these cells due to targeted mRNA 
degradation. This strategy has been shown to improve vector performance in a lentiviral 
based gene therapy strategy to treat Crigler-Najjar disease type 1 in a rodent model.
217
 
However, this strategy is unlikely to overcome responses resulting from cross-priming or 
cross-presentation pathways, which is believed to be the predominant mechanism by 
which rAAV-encoded transgenes induce a cytotoxic T cell response.
216
 It is unclear what 
contribution this pathway plays in immunity against capsids in humans with pre-existing 
antibodies.
190
   
Short-term immunosuppression has also been suggested as a potentially viable approach 
to block host T-cell response at the time of vector administration to allow capsid 
clearance, thereby promote long-term efficacy.
190
 A regimen consisting of 3 months 
immunosuppression with a combination of antithymocyte globulin, cyclosporine and 
mycophenolate mofetil prior to vector administration was sufficient to sustain long-term 
expression of canine micro-dystrophin in dog model of Duchenne muscular dystrophy.
218
 
However, not all studies have shown efficacy with immunosuppressive approaches.
219
 
The most ideal immunosuppressive regimen, regarding type and combination of agents as 
well as duration of therapy, remains to be determined and is likely to be specific to 
particular targets. Nevertheless, immunosuppressive medications are certainly not devoid 
of significant adverse effects and toxicities, which may be unacceptable in some clinical 
applications, especially those where the benefit-to-risk ratios are not very high or where 
there are less toxic alternatives. Furthermore, administration of immunosuppression 
which inhibited regulatory T cell function led to the development of neutralizing 
antibodies against the transgene product in a non-human primate study
219
, indicating that 
some immunosuppressive regimens may actually diminish favourable tolerance towards 
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vector-derived transgene product. Hence, this underscores the need to carefully consider 
such measures for hepatic gene transfer. The optimal immunosuppressive regimen to 
block deleterious immune response towards both vector and encoded transgene product 
remains to be elucidated.  
1.4.4.2. The influence of liver disease on rAAV 
The unique architecture of the liver may allow small virions/vectors such as rAAV to 
have unrestricted access to hepatocytes in non-diseased livers. However when treating 
liver pathology, consideration must be paid to changes that may occur during the disease 
process as this may significantly impact vector performance. Acute and chronic liver 
injury can result in decreased number of sinusoidal endothelial fenestrae, fibrogenesis in 
the space of Disse, morphologic changes to hepatocytes including reduced microvillus 
surface area, capillarisation of the sinusoids and stimulation of hepatic angiogenesis, 
which contributes to portal hypertension and effective porto-systemic shunting.
93,220
 All 
these factors are likely to limit vector access to the diseased hepatocytes. Furthermore, 
accompanying inflammation may also have effects on intracellular processing of vectors 
leading to reduced transcription and transgene silencing.
221,222
 Additionally, if the 
transgene product either requires systemically delivered substrates or is required to be 
delivered via the bloodstream to its site of activity, alterations to intrahepatic blood flow 
in diseased livers may reduce its overall efficacy. 
1.4.5. Recombinant AAV Gene Therapy in the Face of Hepatocyte Proliferation: 
Treating the Paediatric Population 
Many inherited conditions requiring a liver-targeted approach, including PFIC diseases, 
manifest early in childhood and therefore paediatric patients are anticipated candidates for 
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such treatments. For these genetic disorders, it is imperative to have effective early 
treatment, in order to prevent or ameliorate deleterious and irreversible disease 
consequences. There are advantages to initiating therapy in newborns and infants 
including lower vector dose requirement compared with adults, high vector to cell ratio 
with lesser burden on vector production, and a greater probability of transducing 
progenitor cells that may be more abundant in the developing liver.
223
 Furthermore, a 
relatively immature immune system may predispose to immune tolerance towards vector-
encoded transgene product. For example, high dose delivery to neonatal mice, early in 
immune ontogeny, induced CD4
+
CD25
+
 regulatory T-cell activation, thereby reducing 
transgene product antibody responses even after challenge with readministration.
224
 
However, neonatal gene transfer poses several key challenges. One of the main hurdles to 
gene transfer to the paediatric population is the impact of liver growth on vector DNA 
durability and persistence of transgene expression. Due to rapid liver growth and 
hepatocyte proliferation, the proportion of transgene-expressing hepatocytes in the liver 
rapidly diminishes over time, as a consequence of both degradation and dilution of 
episomal vector.
181
 Therefore, long-term production of therapeutic protein is reliant on the 
small proportion of rAAV vectors that integrate into the host genome, as described above. 
With relatively high vector doses (≥ 2.5 × 1011 vg/mouse), integration in up to 8% of 
murine hepatocytes can result in stable, long-term transgene expression, following 
inoculation of neonatal mice.
181
  For some conditions, this level of gene transfer may be 
sufficiently efficacious. For example, long term phenotype correction was achieved using 
a single intrahepatic injection of AAV8 vectors delivered to neonates in a mouse model of 
methylmalonic acidaemia.
58
 Transgene copies detected by quantitative real-time PCR 
from extracted liver genomic DNA were 0.05 and 0.06 per diploid genome at 90 and 270 
days of life, respectively. However, such basal level of stably integrated vector is likely to 
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be insufficient to reach the threshold for phenotype correction for most conditions. 
Therefore, to achieve ongoing efficacy in such circumstances, either increased somatic 
integration or vector re-administration will be necessary. However, immune responses 
toward the vector may prevent effective vector re-delivery.  
Another consideration of neonatal gene transfer is possible maternal passive 
immunisation against AAV. As well as neutralising antibodies acquired through natural 
exposure to AAV, passive transfer of maternal antibodies to infants can lead to 
diminished efficacy from liver-directed gene delivery. In a study examining the 
prevalence of neutralising antibodies to wild-type AAV2 and AAV8 in children and 
adolescents, Calcedo et al., demonstrated that 30% and 18% of newborn infants had a 
titre of ≥ 1:20 to AAV2 and AAV8, respectively.225 This titre was sufficient to 
substantially reduce hepatic transduction and impair rAAV treatment efficacy in pre-
clinical and clinical trial settings.
44,226
 A nadir in anti-AAV antibody levels was reached 
between 7 and 11 months of age, coinciding with the loss of maternal antibodies prior to 
the development of primary immunity from natural infection with wild-type AAV. This 
may provide an ideal window for early gene therapy intervention. 
1.4.6. AAV Genotoxicity 
There are two main considerations that influence the risk of insertional mutagenesis: 
preferential pattern of integration and frequency of integration. Recombinant AAV 
vectors are known to integrate into the host genome at low frequency,
227
 and commonly 
occurs at sites of chromosomal breakage via non-homologous end-joining.
228
 Integration 
events occur with approximately 0.1% of vector genomes that enter cells.
160
 The 
remaining transduced proviruses predominate as episomal concatamers. As well as 
resulting in therapeutic efficacy, integrated vector genomes can affect host gene function 
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at integration sites in a number of ways. Possible genotoxic effects include intragenic 
insertions interrupting transcription of host genes, gain-of-function mutations due to read-
through from encoded promoters and enhancer elements, and disruption of regulatory 
regions affecting neighbouring gene transcription. Non-homologous integration of rAAV 
vectors are not random, and have been demonstrated to occur preferentially within 
actively transcribed genes, at CpG islands, within 1 kb of transcription start sites, and in 
ribosomal RNA gene repeats.
229-232
  
Though the majority of integrations do not predispose to oncogenic events, malignant 
transformation of transduced cells arising from integrations near cancer-related genes is 
of particular concern. In a study of rAAV integration in mouse liver, 3.5% of integrations 
were found in or near cancer-related genes.
232
 Furthermore, AAV-mediated 
tumourigenesis was demonstrated with an AAV vector construct expressing human β-
glucuronidase injected into neonatal mice with mucopolysaccharidosis type VII.
233
 In a 
follow-up study, 56% of mutant mice, and 33% of wild-type mice injected with the same 
vector developed hepatocellular carcinoma (HCC).
234
 Vector-chromosomal junctions 
were mapped to the Dlk1-Dio3 locus on murine chromosome 12, and resulted in 
upregulation of the Mirg and Rian genes containing several miRNAs and small nucleolar 
RNA transcripts, possibly leading to altered expression of target genes critical for 
promoting HCC development.
234
 Upregulation of miRNAs in this locus have also been 
demonstrated in other mouse models of HCC and in clinical human HCC samples.
235-238
 
Furthermore, HCC development was reproduced by insertion of a promoter-enhancer 
element to activate surrounding miRNAs within this locus, using gene targeting via 
homologous recombination.
239
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In addition to the above studies, oncogenic events arising from insertional mutagenesis 
has also been demonstrated in other neonatal models.
240
 However, large scale studies in 
older mice show no increased incidence in tumour formation following rAAV delivery, 
compared with controls.
241,242
 It is unclear how age may influence the risk of insertional 
mutagenesis. However, since rAAV has a predilection for integration within 
transcriptionally active genes
231
, it is possible that the differential gene expression profile 
in neonates, compared with adults, favour genes regulating proliferation, growth and 
differentiation, many of which are also identified oncogenes
243-245
, which in turn affect 
the rAAV vector integration pattern.
242
 Other factors affecting rAAV integration may also 
include vector encoded regulatory elements and transgenes.
246-248
  
Taken together, these studies suggest that rAAV vectors are associated with a small, but 
discernible risk of insertional mutagenesis. It is uncertain how such risk translates to 
human patients, given that exposure to wild-type AAV or rAAV have not been associated 
with malignant transformation in humans to date. Further studies are required in order to 
understand the potential genotoxicity of rAAV within the patient-, disease- and vector-
specific contexts.  
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1.5. PHYSIOLOGY OF THE HEPATOBILIARY SYSTEM  
1.5.1. Bile Formation and Secretion 
Bile formation is a vital function of the liver, necessary for elimination of cholesterol, 
bilirubin and xenobiotics, as well as absorption of digested dietary lipids in the upper 
small intestine. Bile is a complex fluid containing water, electrolytes, organic and 
inorganic solutes, which are primarily secreted by polarised hepatocytes and result from 
the co-ordinated action of transporters at the basolateral (sinusoidal) and canalicular 
(apical) membranes.
249
 This is controlled through a complex network of signals that 
regulate the activity of these transporters at several levels including gene transcription, 
protein translation, maturation, post-translational modification, dynamic intracellular 
trafficking between sequestered pools and their sites of action, and substrate 
availability.
250-252
   
1.5.2. The Enterohepatic Circulation and its Transporters 
Bile acids participate in a highly efficient entero-hepatic circulation. Over 90% of bile 
acids secreted into the intestine are reabsorbed into the portal circulation at the terminal 
ileum, taken up by the hepatocytes and re-secreted back into bile.
253
 The small amount 
lost in faeces is compensated by de novo hepatic synthesis. This highly efficient system 
relies on several members of the highly conserved adenosine triphosphate-binding 
cassette (ABC) transporter superfamily, which utilises the energy of ATP hydrolysis to 
actively transport substrates across cellular membranes.
47
 The diagrammatic 
representation of the major hepatobiliary transporters involved in bile formation is shown 
(Figure 1.2). 
Chapter 1: Literature Review 
 
38 
 
 
Figure 1.2: Schematic diagram of hepatobiliary transporters. Bile salts (BS) is taken up at the 
hepatocyte basolateral (sinusoidal) membrane by Na-Taurocholate Cotransporting Polypeptide 
(NTCP) and a family of organic anion transporters (OATPs), and re-secreted at the canalicular 
membrane by bile salt export protein (BSEP). Other bile constituents, phosphatidylcholine (PC) 
and cholesterol are transported by PC floppase (MDR3) and sterol transporters ABCG5/8, 
respectively. FIC1 maintains canalicular membrane integrity by flipping phosphatidylserine (PS) 
from the outer to inner leaflet of the membrane, thus rendering it less susceptible to bile salts-
induced detergent solubilisation. Alkalinisation of bile occurs in bile ducts by the net efflux of 
bicarbonate and chloride. At the apical surface of cholangiocytes, chloride efflux via the cystic 
fibrosis transmembrane conductance regulator (CFTR), in turn drives net bicarbonate efflux by 
the anion exchanger (AE2). Recovery of some luminal bile salts by cholehepatic shunting occurs 
via the apical bile salt transporter (ASBT) and basolateral organic solute transporters (OSTα/β). 
Adapted from Wagner et al.
254
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In the distal ileum, bile acids are reclaimed by enterocytes via the apical Na
+
-dependent 
bile-salt transporter (ASBT, SLC10A2) and reabsorbed into the portal circulation. 
Albumin-bound bile acids are delivered directly to the liver via the portal vein. At the 
basolateral membrane, bile acids dissociate from albumin and are efficiently taken up by 
sodium-dependent and sodium-independent systems (Figure 1.2). The Na-Taurocholate 
Co-transporting Polypeptide (NTCP) is the main basolateral bile acid transporter and has 
high affinity for conjugated bile salts, but is also able to take up unconjugated bile salts.
255
 
It is driven by a high extracellular to intracellular Na
+
 gradient, maintained by Na
+
/K
+
 
ATPase.
256
 Na
+
-independent hepatocellular uptake involves organic anion transporters 
(OATP1A2, OATP1B1, OATP1B3 and OATP2B1), which are predominantly responsible 
for unconjugated bile acid uptake.
255,257
  
Bile acids taken up at the basolateral membrane, traverse the hepatocyte cytoplasm to the 
canalicular membrane and are actively secreted into bile through an ATP-dependent 
process. Under typical physiological conditions, bile acids move through the intracellular 
milieu by, at least, two known mechanisms. Hydrophobic bile acids are predominantly 
bound to proteins including glutathione S-transferase, 3-α hydroxysteroid dehydrogenase 
and bile acid binding protein.
258,259
 A small, unbound hydrophilic bile acid fraction 
undergoes rapid cytosolic diffusion.
258
 At elevated bile acid loads, hydrophobic bile acids 
are increasingly sequestered into membrane-bound organelles such as the endoplasmic 
reticulum and Golgi apparatus.
259,260
 
To compensate for faecal losses, a small amount of primary bile salts (approximately 5% 
of total bile salt pool) are synthesised de novo in hepatocytes from cholesterol. In humans, 
two primary bile salts, cholate and chenodeoxycholate, are synthesised via a major 
cholesterol catabolism pathway, beginning with the key rate-limiting hydroxylation step 
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catalysed by the cytochrome P450 enzyme, CYP7A1. The pathway involves a total of 14 
different enzyme activities located in the cytoplasm, microsomes, mitochondria and 
peroxisomes.
261
 
Bile formation occurs at the canalicular membrane, where a number of active transporters 
secrete the major organic constituents in bile, which include bile salts, phospholipids 
(predominantly phosphatidylcholine), cholesterol and bilirubin. Canaliculi are the 
intercellular spaces formed by the external hemileaflet of apical plasma membrane of 
adjacent hepatocytes and surrounding tight junctions.
262
 Canaliculi connect to the canals 
of Hering, in which bile flow occurs counter-current to the direction of portal blood 
flow.
263
  
Monovalent bile acids are secreted against a steep concentration gradient, up to 1000-fold, 
across the canalicular membrane by the bile salt export protein (BSEP).
264
 This ATP-
dependent and Na
+
-dependent process represents the major rate-limiting step in hepatic 
bile formation. Divalent bile acids are transported into bile by MRP2 (also known as 
ABCC2 or the canalicular multispecific organic anion transporter, cMOAT). Other 
substrates that utilise this transporter include divalent amphipathic conjugates including 
glutathione, xenobiotics and conjugated bilirubin.   
Other constituents of bile (phospholipids and cholesterol) are also actively transported 
into the canaliculus. MDR3 (mdr2/Abcb4 in rodents) is an ATP-binding cassette floppase 
that translocates phospholipids (mainly phosphatidylcholine) from the inner to the outer 
leaflet of the canalicular membrane for subsequent extraction by bile acids.
265,266
 
Phospholipids mitigate the strong detergent effects of bile acids on hepatocyte cell 
membranes and bile duct epithelium. An additional ATP-binding cassette protein, FIC1 
(encoded by ATP8B1 gene) is responsible for flipping phosphatidylserine from the outer 
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to inner leaflet of the canalicular membrane. This is thought to be important for effective 
bile salt export and to counterbalance the action of MDR3 (encoded by ABCB4 gene), in 
order to maintain the lipid composition and integrity of the membrane, rendering it less 
sensitive to detergent solubilisation by luminal bile acids. This complementary function 
was recently demonstrated in vitro and in vivo. The deleterious effects of ABCB4 
overexpression in HEK 293 cells was attenuated by ATP8B1 co-expression. Moreover, a 
milder phenotype was seen in vivo using an Abcb4 and Atp8b1 double-knockout murine 
model, compared with Atp8b1
-/-
 mice, suggesting that this latter phenotype was at least 
partly due to unhindered Abcb4 activity.
267
 FIC1 may also play a role in maintaining 
microvillus formation at the canalicular membrane.
268
 ABCG5 and ABCG8 form 
heterodimeric complexes that are involved in the hepatobiliary excretion of plant sterols 
and cholesterol.
269
  
Bile formed in the canaliculi is then carried by an intricate network of interconnecting 
ductules and ducts that drain into the gall bladder. Ciliated epithelial cells called 
cholangiocytes line the bile ducts and modify luminal fluidity and alkalinity as bile is 
transported along the biliary tree through the action of several ion and water transporters 
with resultant net luminal flux of water, chloride and bicarbonate (Figure 1.2).
263,270,271
 
Water is passively diffused into canaliculi and bile ducts by an osmotically driven process 
and via aquaporins.
272
 Biliary alkalinisation occurs through the coordinated action of 
several ion exchangers and channels on the apical surface of cholangiocytes. Secretin 
simulates the cystic fibrosis transmembrane conductance regulator (CFTR) to secrete 
chloride via a cAMP-dependent mechanism. Net bicarbonate efflux driven by CFTR-
mediated Cl
-
 efflux is also under the hormonal control of secretin, which stimulates the 
cholangiocyte apical Cl
-
/HCO3
-
 exchanger (AE2).
47,273
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Some bile acids are also re-absorbed back into the portal circulation by cholangiocytes, 
via a Na
+
-dependent apical bile salt transporter (ASBT) and basolateral organic solute 
transporters (OSTα/β), by a process called cholehepatic shunting. This may be an 
important protective mechanism to remove toxic bile acids during pathological 
circumstances such as extrahepatic biliary obstruction.
274
 OSTα/β are also expressed at 
very low levels in hepatocytes during steady state, but can be induced during cholestasis 
and by therapeutic drugs for alternative sinusoidal bile acid export, as part of adaptive 
hepatocellular defence against intracellular bile acid toxicity.
275
 
In response to cholecytokinin and other enteric hormonal stimuli, the gall bladder 
contracts at meal times to extrude bile into the lumen of the small intestine. Together, bile 
acids, phospholipids and cholesterol form mixed micelles that solubilise dietary lipids and 
fat-soluble vitamins in the aqueous environment of the intestinal lumen. This is necessary 
for fat digestion and absorption by enterocytes.   
1.5.3. Hepatic Zonation of Bile Acid Handling 
There is zonal heterogeneity in bile acid flux across the hepatic acinus.
258
 At steady state, 
clearance of bile acids from the sinusoidal blood occurs largely by hepatocytes in the 
periportal region (Zone 1)
256,276,277
, whilst hepatocytes across the entire acinus are 
recruited during high bile acid loads, such as post-prandially or in cholestatic states.
258,278
 
Thus, a large functional reserve exists. However, biliary excretion of bile salts is slower in 
pericentral hepatocytes (Zone 3), compared with periportal hepatocytes.
276
 Furthermore, 
intracellular transport of hydrophobic bile acids are similarly faster in periportal 
hepatocytes compared with those in the pericentral region.
279
 Currently, little is known 
about the spatial and temporal patterns of expression of other hepatobiliary transporters.  
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1.5.4. Regulation of Bile Formation  
Since the major determinant of bile formation is the activity of hepatocellular transporters 
of bile constituents as described above, the main mechanisms of its regulation involve 
changes in the function, localization and expression of these transporter proteins. Both 
short- and long-term regulatory mechanisms are used to adapt to changing demands. 
Hepatocellular transporters exist both at their site of action in the plasma membrane, and 
in intracellular pools.
280
 In order to alter the transport capacity of hepatocytes, rapid 
redistribution of transporters between these two locations can be induced by intracellular 
accumulation of bile acids, changes in cell volume, and in response to hormonal and 
cytokine stimulation.
250,251,281
 Furthermore, conformational changes of transport proteins 
induced by dephosphylation as well as changes in the hepatocyte membrane potential can 
confer altered sinusoidal bile salt transporter activity, thereby changing hepatocyte bile 
acid uptake.
256
 
A group of ligand-activated nuclear receptors play a central role as major transcriptional 
regulators of bile formation. Of these, the best characterised is the farsenoid X receptor 
(FXR). FXR is activated by the preferential binding of moderately hydrophobic bile acids 
such as chenodeoxycholic acid.
282
 Binding of FXR ligands result in a conformation 
change that causes dissociation of co-repressors and recruitment of co-activators, enabling 
transcriptional activation. Furthermore this conformation change also allows dimerisation 
with retinoid X receptor (RXR) and induces expression of a short heterodimer partner 
(SHP) that is largely responsible for its down-regulatory activities.
283
 Activation of FXR 
is critically involved in maintaining bile acid homeostasis by: (i) activating expression of 
key canalicular membrane transporters: BSEP, MRP2, MDR3, (ii) increasing sinusoidal 
efflux of bile acids through expression of OSTα/OSTβ, (iii) repressing basolateral uptake 
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through reduced expression of NTCP and OATP-Bs, (iv) downregulating bile acid 
synthesis through reduced expression of cholesterol 7α-hydroxylase (CYP7A1), the rate 
limiting step in de novo bile acid synthesis, and (v) inducing bile acid detoxification 
systems.
284
 Collectively, the actions of FXR are to diminish intracellular bile acid 
accumulation, thus preventing its cytotoxic effects.  
In addition to maintaining bile acid homeostasis, FXR is also important in regulating 
triglyceride, cholesterol and glucose metabolism, and also has anti-fibrotic properties by 
interfering with collagen transcription, promoting development of a quiescent hepatic 
stellate cell phenotype and promoting stellate cell apoptosis. These effects are mediated 
via SHP and Perixisome proliferator-activated receptor (PPAR). Activated hepatic stellate 
cells are the major source of extracellular matrix deposition in liver fibrosis. Furthermore 
FXR has been shown to modulate liver regeneration, carcinogenesis, inflammation, 
intestinal bacterial overgrowth and has effects on hepatitis C replication.
284
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1.6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS 
1.6.1. Cholestasis 
Unravelling the molecular mechanisms of normal bile formation and regulation, outlined 
above, has greatly extended our understanding of the pathophysiology of cholestatic liver 
diseases. In particular, this knowledge has led to identification of novel targets for 
diagnosis and therapy, including potential gene therapy targets.
254,285
  
The hallmark of cholestasis is impaired bile secretion and flow.
286
 Potential consequences 
can arise due to lack of bile delivered to the intestine (fat malabsorption and fat-soluble 
vitamin deficiency), and hepatic and systemic accumulation of potentially toxic 
cholephiles (pruritus, cholestatic injury, biliary cirrhosis, portal hypertension, liver 
failure).
254
 Cholestatic liver diseases have hereditary and acquired aetiologies, including 
inherited mutations of hepatobiliary transporter genes, drugs, hormones, infections, 
congenital developmental abnormalities, and autoimmune conditions.
287
   
1.6.2. Introduction to Progressive Familial Intrahepatic Cholestasis 
One group of heritable cholestatic disorders are the Progressive Familial Intrahepatic 
Cholestasis (PFIC) diseases. These are a heterogeneous group of 3 autosomal recessively 
inherited conditions involving mutations in hepatocyte canalicular transporter genes, 
resulting in disruption to normal bile formation.
288
 Though the exact prevalence of these 
disorders are unknown, the collective incidence is estimated to be between 1 in 50,000 
and 100,000 births and may represent 10-15% of liver transplant indications in children in 
some populations.
289
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The PFIC disorders usually present in the infancy with jaundice, variable degrees of 
pruritus and fat-soluble vitamin deficiencies. Patients may eventually progress to cirrhosis 
and end-stage liver failure during childhood or early adulthood.
289,290 
Although some 
respond to medical therapy and/or surgical interventions, liver transplantation is 
ultimately the mainstay of long term treatment for most children with these disorders.
291
 
Affected individuals are at increased risk of hepatocellular carcinoma.
292
 Furthermore, 
pruritus can be severe and debilitating, cause irritability, poor sleep and generalized skin 
mutilation from scratching. This is often poorly responsive to medical therapy and some 
patients elect for liver transplant to improve their quality of life. However, given the risks 
related to liver transplantation and lifelong immunosuppression, there is a vital need to 
explore new treatment modalities such as gene-based therapy for these conditions. 
However, no gene therapy models have been described for PFIC disorders.  
1.6.3. PFIC Types 1 and 2 
Our current understanding of hepatocanalicular bile formation originally stems from the 
description, made by Clayton et al., in 1969
293, of a rare PFIC disorder known as Byler‟s 
disease (eponymously named after the Amish kindred in whom it was described). This 
has since been renamed PFIC type 1 or FIC1 deficiency. In recent years, the 3 canalicular 
membrane transporter genes involved in PFIC disorders (ATP8B1
294
, ABCB11
295,296
, 
ABCB4
290,297
) have been cloned and functionally characterised, advancing our knowledge 
of canalicular transport systems and the pathophysiology of the PFIC disorders. 
Features of the 3 PFIC disorders are summarised in Table 1.2. The type 3 disorder 
(PFIC3) is discussed in detail in Section 1.6.4.   
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Table 1.2 – Main characteristics of the 3 types of PFIC 
 PFIC1 PFIC2 PFIC3 
Alternative Name 
FIC1 deficiency, 
Byler‟s Disease 
BSEP deficiency MDR3 deficiency 
Gene (Protein) ATP8B1 (FIC1) ABCB11 (BSEP) ABCB4 (MDR3) 
Chromosomal 
Locus 
18q21-22 2q24 7q21 
Function Defect PS flippase Bile salt export PC floppase 
Pruritus Severe Severe Moderate 
Serum γGT Normal Normal Elevated 
Serum ALT Mildly elevated >5x normal >5x normal 
Serum Bile Acids Very High Very High High 
Bile Composition 
Low primary bile acid 
concentration 
Very low primary bile 
acid concentration 
Low phospholipid 
concentration 
Liver Histology 
Canalicular 
cholestasis, mild 
lobular fibrosis, 
granular bile 
Giant cell hepatitis, 
canalicular cholestasis, 
lobular fibrosis 
Ductular proliferation, 
biliary cirrhosis 
Extrahepatic 
Manifestations 
Diarrhoea, pancreatitis, 
hearing loss, short 
stature 
None None 
Other Associated 
Conditions 
BRIC, ICP 
BRIC, ICP, DIC, CIC, 
HC 
ICP, LPAC, DIC, CIC 
PS, Phosphatidylserine; PC, Phosphatidylcholine; γGT, Gamma-glutamyl transferase; ALT, Alanine 
aminotransferase; BRIC, Benign Recurrent Intrahepatic Cholestasis; ICP, Intrahepatic Cholestasis of 
Pregnancy; DIC, Drug-induced Cholestasis, CIC, Contraceptive-induced Cholestasis; HC, Hepatocellular 
Carcinoma; LPAC, Low-Phospholipid Associated Cholelithiasis. Adapted from Nicolaou, et al.
298
 
 
The clinical characteristics of PFIC type 1 (PFIC1) and type 2 (PFIC2) are similar. 
Cholestasis, usually manifesting as jaundice, appears within the first months of life and 
can initially be intermittent.
299
 Severe debilitating pruritus or itch can also be a significant 
feature, especially with PFIC2. A biochemical distinction of these 2 types is low or 
normal serum gamma-glutamyl transferase (γ-GT) levels, in contrast to other forms of 
cholestasis including PFIC3.
288,300
 Ursodeoxycholic acid (UDCA) therapy is considered 
as initial management for children with PFIC disorders.
288
 In low-γGT-PFIC types, a few 
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studies have shown improvement in serum transaminase levels and pruritus, but this was 
more likely in patients with missense mutations.
301,302
 However, most studies indicate 
limited efficacy for these types of PFIC and there is no evidence that UDCA alters long-
term outcomes including need for surgical interventions and liver transplantation. Greater 
benefit is seen in patients with PFIC3 (See Section 1.6.4). 
Patients with PFIC1 or PFIC2 may benefit from partial biliary diversion or ileal 
exclusion, both aimed at interrupting the enterohepatic circulation, thereby reducing 
systemic bile salt re-absorption. Partial biliary diversion may be achieved by either 
creating an external biliary fistula using a jejunal conduit from gallbladder to the 
abdominal wall (partial external biliary diversion, PEBD)
303
, or an internal connection 
between gallbladder and colon (partial internal biliary diversion, PIBD)
304
. Favourable 
outcomes have been achieved in non-cirrhotic patients including complete amelioration of 
pruritus, and biochemical and histological stabilisation.
305,306
 PIBD avoids the need for 
long-term stoma management and aesthetic concerns that are associated with PEBD. 
However, experience with PIBD is presently limited and long-term outcome data is 
awaited. When partial biliary diversion is not possible, such as with previous 
cholecystectomy, ileal exclusion is another surgical option, which involves forming an 
ileocolonic anastomosis and bypassing the distal 15% of ileum where the majority of bile 
salts are re-absorbed.
307
  
Patients with established cirrhosis have not been shown to benefit from these non-
transplant surgical interventions.
305
 Ensuing liver disease can progress rapidly to liver 
failure within the first few years. In a retrospective study of 145 patients with PFIC1 and 
PFIC2, 44% had undergone liver transplant, most in childhood or early adolescence.
299
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Childhood onset of hepatocellular carcinoma and cholangiocarcinoma has also been 
reported in PFIC2 patients.
292,308
  
PFIC1 results from mutation in ATP8B1, which encodes a putative P-type ATPase 
aminophospholipid flippase, FIC1 (as described above). FIC1 is also expressed in other 
tissues including pancreatic acinar cells, ileal and jejunal enterocytes, and cochlear hair 
cells of the inner ear.
309,310
 Disruption of FIC1 function in these tissues is associated with 
a number of extrahepatic manifestations including short stature, pancreatitis, pancreatic 
insufficiency, intractable diarrhoea and sensorineural hearing loss.
299,310,311
  In contrast, 
PFIC2, caused by mutations in the bile salt export protein gene (ABCB11), has no 
associated extrahepatic features. BSEP is primarily expressed in hepatocytes.  
Missense mutations in both ATP8B1 and ABCB11 can result in a mild phenotype, benign 
recurrent intrahepatic cholestasis (BRIC1 and BRIC2, respectively), characterised by 
episodic, cholestatic jaundice and itch without persistent liver damage between 
episodes.
312,313
 In a subset of patients, the initial diagnosis of BRIC can later evolve into 
chronic liver disease, indicating a phenotypic spectrum between PFIC and BRIC. 
1.6.4. PFIC type 3 
In contrast to PFIC1 and PFIC2, patient with progressive familial intrahepatic cholestasis 
type 3 (PFIC3) have elevated serum γ-GT and develop a chronic cholangiopathy. PFIC3 
is caused by mutations in the ABCB4 gene, which encodes the hepatobiliary canalicular 
phospholipid floppase, MDR3.
290
 Under normal physiological conditions, the bile acid 
concentration in the canaliculus can be very high, well exceeding its critical micellar 
concentration. This should cause solubilisation of cellular membranes with resulting cell 
lysis. However, coordinated excretion of phospholipid by MDR3, results in mixed micelle 
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formation and is a major protective mechanism. The importance of this mechanism is 
underscored by the deleterious consequences resulting from absent biliary phospholipid 
excretion in PFIC3 patients. 
Although there is wide phenotypic variation in clinical presentations of ABCB4 
mutations, patients with PFIC3 usually present in the first few years of life with chronic 
and progressive cholestasis due to an obliterative cholangiopathy. Liver histology reveals 
fibrosis with portal inflammation, and marked ductular proliferation with bile duct 
plugging. Approximately half of all patients progress to cirrhosis, portal hypertension and 
end-stage liver disease, requiring transplantation at a median age of 7.5 years.
288-290
  
Response to treatment with ursodeoxycholic acid (UDCA) is variable, but more likely in 
patients with a missense mutation that result in partial MDR3 activity.
288,314
 This is a 
hydrophilic bile acid, which normally accounts for a small fraction of the human bile acid 
pool.
315
 Its hepato-protective effects include replacing endogenous cytotoxic bile acid 
pool, increasing BSEP expression, inducing post-transcriptional changes to hepatobiliary 
transporters, stimulating basolateral bile acid efflux back into blood, and enhancing bile 
flow.
316-318
 Additionally, UCDA may have anti-apoptotic and anti-fibrotic properties. 
1.6.4.1. The spectrum of clinical phenotypes of ABCB4 mutations 
In addition to PFIC3, patients with identified mutations in both alleles of ABCB4 are 
associated with a spectrum of other clinical manifestations. These include low 
phospholipid-associated cholelithiasis syndrome (LPAC) characterised by early onset 
recurring cholesterol gallstones after cholecystectomy, intrahepatic cholelithiasis, mild 
chronic cholestasis, intrahepatic cholestasis of pregnancy (ICP), and adult-onset 
“idiopathic” cirrhosis. A finding of ABCB4 defects in a subset of patients with primary 
biliary cirrhosis, primary sclerosis cholangitis and granulomatous hepatitis may indicate 
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its role as a modifier gene in these conditions. Furthermore, heterozygous mutations are 
also described in patients with ICP, as well as drug-induced cholestasis and hepatocellular 
injury, thus showing an increased susceptibility for acquired cholestatic injury in these 
patients.
319,320
 
1.6.4.2. Genotype-phenotype correlation 
Molecular characterization of ABCB4 mutations in 68 index cases in a multicentre Italian 
study found 29 distinct mutations in 18 cases, which were spread over 14 of the 27 coding 
exons, indicating broad allelic heterogeneity in this condition.
321
 The majority of 
mutations identified were within functional domains and were likely to impair floppase 
activity. Homozygous truncating mutations were more often reported in patients with 
PFIC3 than other less severe phenotypes.
266
 Molecular analysis performed on 133 Italian 
children, which identified 28 children carrying 31 mutations found that disease-causing 
mutations on both alleles were associated with reduced liver expression of MDR3 protein, 
lack of response to ursodeoxycholic acid therapy, and progression to cirrhosis and end-
stage liver failure, whereas missense mutations predicted to result in benign substitutions 
or single heterozygous mutations were generally associated with less severe disease and 
often, absence of symptoms.
322
 Thus, there is some genotype-phenotype correlation in the 
Italian population, but more extensive investigation, particularly in other populations, is 
required to better define this relationship. 
1.6.4.3. MDR3/ABCB4 structure and regulation 
MDR3 is encoded by a 74 kb gene, ABCB4, containing 28 exons on the long arm of 
chromosome 7. MDR3 contains 4 distinct protein domains, organised into two 610-amino 
acid repeats joined by a 60-residue linker.
321
 Each repeat consists of a transmembrane 
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domain which encompasses specific sites for substrate binding and translocation, and a 
cytoplasmic nucleotide binding domain which includes the ATP hydrolysis site.
321
 
MDR3 expression is largely restricted to hepatocytes. Although low levels of mRNA 
transcripts are detected elsewhere (spleen, tonsils, adrenal glands, muscles, and ileum), 
the protein has not been demonstrated outside the liver using immunohistochemistry.
323
 
However, low protein expression may not be detectable if below the sensitivity of the 
antibodies used. Nevertheless, ectopic overexpression in non-hepatic tissues may have 
deleterious effects. Smit et al., generated mice transgenic for human MDR3 mini-gene 
under the control of hamster vimentin promoter, which directs gene expression in 
mesenchymal tissue including Schwann cells and ocular lens cells.
324
 These mice 
demonstrated slowed motor conduction, and dysmyelination of peripheral nerves, 
resulting in severe peripheral neuropathy and hind leg paresis. These mice also developed 
severe cataracts due to aberrant expression in ocular lenses during embryonic and post-
natal development and differentiation.
325
     
In hepatocytes, expression of the ABCB4 gene is regulated by FXR. Its promoter region 
contains an FXR response element and expression is inducible by natural and artificial 
FXR ligands.
326,327
 For example, studies in rodents showed increased expression induced 
by cholate feeding (an FXR activator), but not by ursodeoxycholic acid, which is not a 
ligand for FXR.
266,328
 Furthermore, expression of murine Mdr2 (orthologous to human 
MDR3) is reduced in FXR deficient mice.
329
 
Another nuclear receptor, Ppar-α (Perixisome proliferator-activated receptor α), is also 
thought to be involved in ABCB4 regulation, at least in vitro and in a murine model. 
Fibrates are Ppar-α activators that have been observed to induce expression of ABCB4, 
thereby causing increased biliary phospholipid excretion in wild-type but not Ppar-α-/- 
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mice.
330
 A similar observation has also been made to a lesser extent in HepG2 cell 
lines.
331
 However, these observations have not been recapitulated in patients treated with 
various fibrates (bezafibrate, fenofibrate or gemfibrozil).
332
 
1.6.4.4. Human ABCB4 transcript variants 
There are 3 identified transcript variants of the ABCB4 gene found in the human liver, 
that result from alternate in-frame splicing of pre-mRNA. They were initially isolated 
from human cDNA libraries and HepG2 cells (a human hepatoma cell line), and 
subsequently also identified from individual human liver samples, confirming that they 
are not attributable to allelic variations.
333
 The coding sequence of transcript variant A is 
3849 bp in length. Relative to variant A, transcript variant B uses an alternate in-frame 
splice site in the 3‟ coding region that results in an additional 21 bp in a region encoding a 
nucleotide binding domain. Whereas, transcript variant C lacks an alternate in-frame 
exon, compared to variant A, resulting in a protein (isoform C) that is 47 amino acids 
shorter than isoform A. The deleted exon in isoform C is predicted to involve segment 11 
of a transmembrane domain.
334
 Absence of a transmembrane loop may result in 
profoundly different membrane topology of isoform C compared with other variants, 
which could lead to improper orientation of an adjacent ATPase, and thus this isoform 
may have severely reduced function as a transmembrane floppase.
333,334
 Variant A and C 
are reported to be the most abundant mRNA transcripts.
333,334
 Some of the alternate 
transcript variants are abundantly expressed in tissues outside the liver, but their function 
in these tissues is unknown.
323
 MDR3 has been shown to be expressed in acute and 
chronic B-cell lymphocytic leukaemias, and indirect evidence suggest its role in 
mediating resistance to chemotherapeutics in this context.
335,336
 It is tempting to speculate 
that transcript variants may be involved in alternate functions, such as conferring drug 
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resistance, but this has not been studied. Furthermore, the relative phospholipid floppase 
activities of each isoform or alternate potential cellular functions are currently unknown. 
However, an understanding of their relative floppase activity is a specifically important 
consideration when optimising a potential PFIC3 therapeutic gene therapy vector 
encoding a human ABCB4 transgene. 
1.6.4.5. Murine model of PFIC3 
The use of small and large animal disease models have been invaluable to the 
investigation of gene therapy strategies to treat inherited and acquired diseases. Pre-
clinical models are essential to explore the interaction between vector, host and disease, to 
understand disease-specific vector biology, and to determine the relationship between 
vector dose and phenotypic correction. Ideally, animal models should mimic the human 
disease counterparts. Unfortunately, this is not always the case and thus, these limitations 
must be considered in any pre-clinical treatment model.  
Mouse models have been described for all 3 types of PFIC disorders. The murine model 
for BSEP deficiency, whilst displaying reduced biliary bile acid secretion compared with 
wild-type mice, have mild non-progressive cholestasis, which is less severe than the 
human PFIC2 phenotype, owing to alternate bile acid handling mechanisms via 
hydroxylation of toxic intrahepatic bile acids and an alternate canalicular transport 
mechanism in mice.
337
 Similarly, the Atp8b1
G308V/G308V
 mice, carrying orthologous 
mutations to patients with PFIC1, have mild biochemical evidence of perturbed bile acid 
homeostasis, but unimpaired bile secretion and no liver damage.
338
 In contrast, 
homozygosity for the G308V point mutation in humans results in a functional null 
mutation, which has been identified among affected Amish kindred.
294
 The lack of 
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similarity between these mouse models and their corresponding human phenotypes make 
these less ideal models to study in vivo gene-based approaches to these PFIC subtypes.   
On the other hand, the mouse model resembling PFIC3 is a more attractive model for 
gene therapy investigation. The human ABCB4 gene is akin to Abcb4 in mice. Abcb4-
knockout (Mdr2
-/-
) mice exhibit complete absence of biliary phospholipid excretion, and 
severely diminished cholesterol excretion. The serum of these mice shows elevated 
bilirubin and liver enzymes in keeping with cholestasis. Histological features become 
evident between 6 and 12 weeks of age, showing extensive portal inflammation with bile 
ductular proliferation and mild fibrosis, all suggestive of significant cholangiopathy 
analogous to the human PFIC3 phenotype.
297
 By 12 months, there is demonstrable 
disrupted hepatic lobular architecture with appearance of steatotic, dysplastic nodules.
339
 
Virtually all Abcb4
-/-
 mice develop hepatocellular carcinoma by 16 months.
340
 
Hepatocellular carcinoma has not been reported in patients with PFIC3. However, there 
was a recent report of cholangiocarcinoma in two family pedigrees with ABCB4 
mutations, suggesting malignant tendencies in this disease.
341
 
1.6.4.6. Hepatocyte transplant model for PFIC3: insights into phenotype correction 
Transgenic expression of human MDR3 in Abcb4
-/-
 (Mdr2
-/-
) mice has been shown to 
restore biliary phospholipid secretion, demonstrating that these genes are orthologs.
342
 De 
Vree et al., have shown that transgenic MDR3-expressing murine hepatocytes as well as 
normal Abcb4
+/+
 hepatocytes transplanted and partially repopulated in the livers of 
Abcb4
-/-
  mice resulted in restored phospholipid secretion in bile (based on biliary 
phospholipid to bile salt ratios) to over 20% wild-type levels, and diminished liver 
pathology.
18
 This study demonstrates that hepatocyte transplantation is a potentially 
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applicable therapy for patients with PFIC3. The Abcb4
-/-
 mouse model may also be useful 
to study the potential feasibility of gene therapy approaches to this disorder. 
In the hepatocyte transplant model described, donor cell repopulation was stronger in the 
presence of cholate supplementation, which exacerbated hepatocellular damage in 
uncorrected cells, favouring expansion of engrafted transgenic cells expressing human 
MDR3 or wild-type murine Mdr2 expressing hepatocytes.
18
 The number of MDR3 
expressing hepatocytes (per positive microscopy field) positively correlated with the 
biliary phospholipid-to-bile salt ratio.  
In a gene therapy model, there are 2 factors that influence the threshold for phenotype 
correction: the number of transduced hepatocytes and the level of transgene expression 
and its product activity from individual transduced cells. The degree of influence from 
each factor depends on whether the disease phenotype to be corrected results from cell 
autonomous or non-autonomous pathophysiology – i.e., whether neighbouring non-
corrected cells are protected by gene-corrected cells. In a cell autonomous model, the 
number of gene-corrected cells is most important as corrected cells are unable to affect 
the pathology of uncorrected cells – e.g. urea cycle defects, hereditary tyrosinemia type I. 
Whereas, PFIC3 is likely to have non-cell autonomous cell damage, in that overall 
alteration in bile composition will help protect the liver as a whole from bile-salt induced 
hepatocellular and bile duct injury.
18
 
1.6.4.7. Novel pharmacological therapies for PFIC3 
Several novel pharmacological interventions to treat PFIC3 and other chronic 
cholangiopathies are currently under investigation. A side-chain derivative of UDCA, 24-
nor UDCA, has been shown to be efficacious in reducing biochemical and histological 
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markers of liver disease in Abcb4
-/-
 mice (as a model for primary sclerosis cholangitis, 
PSC) through induction of bile salt detoxification, basolateral efflux and promotion of 
cholehepatic shunting.
343
 Phase II clinical trials with this compound involving patients 
with PSC are currently being undertaken, and verification of their clinical efficacy are 
eagerly anticipated.
344
 24-norUDCA may also be of benefit in other chronic 
cholangiopathies including PFIC3.  
FXR and other nuclear receptors, that regulate important aspects of bile formation, are 
also gaining recognition as potential therapeutic targets for treatment of cholestatic 
conditions. Synthetic ligands for FXR have already been shown to be beneficial in several 
rodent models of cholestasis.
327,345,346
 Specifically, a recent study demonstrated 
biochemical and histological efficacy in the Abcb4
-/-
 mouse model using a dual 
FXR/TGR5 (G-protein coupled membrane receptor) agonist.
347
 Such approaches may 
also be beneficial to treat patients with PFIC3. However, some FXR agonists have dose-
limiting adverse effects including debilitating pruritus, and this may limit their therapeutic 
efficacy.
348
 Also, TGR5 activation is associated with cholangiocyte proliferation and may 
confer increased resistance to apoptosis.
349
 Increased expression has been observed in 
some gastrointestinal and endometrial neoplasia
350-352
, leading some to suggest that it may 
also play a role in cholangiocyte carcinomas as well
344
, whilst others have noted possible 
protective anti-neoplastic effects
353
. Further specific evaluation of cancer risk is therefore 
warranted. Surprisingly, this study reported that a selective FXR agonist had no benefit in 
ABCB4 homozygotes but in fact exacerbated liver injury and fibrosis in this model.
347
 
Further dissection of its mechanisms suggests that this synthetic hydrophobic bile acid 
may only have selective FXR-mediated transcriptional activity, and may lack some 
hepatoprotective effects. Nevertheless, preliminary data from a phase II clinical trial 
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reported improvement in serum liver function tests in patients with another cholestatic 
condition, primary biliary cirrhosis.
344
     
As mentioned above, Ppar-α activators including bezafibrate, and fenofibrate may be 
efficacious in patients with cholestatic liver diseases.
354
 Their anti-cholestatic properties 
have been attributed to transactivation of ABCB4 gene transcription, redistribution of 
mdr2/MDR3 to the bile canaliculi and enhanced biliary phospholipid secretion. These 
have been demonstrated both in vitro as well as in rodent models including a chimeric 
mouse model with a humanised liver.
355-357
 Given their mechanisms of action, they are 
not likely to benefit patients with null mutations of ABCB4 with absence of functional 
phosphatidylcholine floppase protein. However, those that have retained partial MDR3 
function may still benefit from this therapy.   
Mutation-specific therapies may benefit some patients with PFIC3.
288
 Individualised 
identification of specific mutations, their mutation class (e.g. nonsense, missense), 
understanding residual function of the mutant protein, and assessment of its intracellular 
trafficking patterns, as well as possible level of canalicular membrane expression in vivo, 
will help guide a mutation-specific therapeutic strategy. Some examples of such strategies 
may include pharmacologically induced read-through premature stop codons using drugs 
such as aminoglycosides
358
, chaparones to restore correct folding and trafficking of 
mutant proteins to their site of action
359
, endoplasmic reticulum associated degradation 
inhibitors to rescue misfolded proteins with residual function and to redistribute them to 
their site of action (e.g. canalicular membrane), and nuclear receptor agonist, including 
FXR agonists and fibrates (Ppar-α agonists) described above, to increase expression of 
ABCB4 and redistribute mutant MDR3 protein to the canalicular membrane. 
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1.7. RATIONALE FOR GENE THERAPY FOR PFIC TYPE 3: HYPOTHESES 
AND AIMS OF RESEARCH 
Progressive Familial Intrahepatic Cholestasis type 3 represents an ideal candidate for 
liver-directed gene transfer. It is a monogeneic, autosomal recessive disorder the results 
from a deficiency state and therefore, is ideally suited to gene replacement therapy. 
Development of a gene correction strategy is not currently practicable, given the spread of 
identified mutations across many functional domains. Novel pharmacological 
interventions are currently under investigation with anticipated benefit for at least a subset 
of patients. However, none are currently licensed for use. Therefore, presently liver 
transplantation, which has many drawbacks, is the only available long-term treatment for 
those who do not respond to ursodeoxycholic acid. A suitable mouse model for preclinical 
investigation exists, which recapitulates the clinical phenotype. Previous research using 
cell based therapy in this model demonstrates that replacing the deficient MDR3 protein 
can correct the phenotype in vivo. Furthermore, recombinant AAV vectors have many 
attributes that make it suitable for liver-directed therapy. In particular, recent 
developments in understanding rAAV biology in the liver, rAAV capsid engineering to 
target hepatocytes with high efficiency and specificity, and improvements in vector 
production with advances in clinical grade manufacturing practices have thrusted this 
system into the forefront of therapeutic approaches towards the liver.
360
 
The overarching objective of this research is to develop recombinant AAV-mediated gene 
therapy approaches to treat Progressive Familial Intrahepatic Cholestasis type 3 using the 
Abcb4
-/-
 mouse model. A thorough understanding of host-vector interactions and host- 
and vector-related issues that may influence rAAV transduction and ABCB4 transgene 
expression in this disease-specific context will be necessary, in order to anticipate and 
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address potential issues that may arise during development of this gene therapy model. To 
address these issues, the following hypotheses and corresponding aims were devised: 
 
Hypothesis 1: In Abcb4
-/-
 mice, liver pathology including hepatic fibrosis and portal 
hypertension impedes rAAV vector delivery and transduction of hepatocytes. 
Aim 1: to evaluate the relative transduction efficiency of hepatocytes in Abcb4
-/-
 and 
Abcb4
+/+
 mice using a rAAV vector encoding an eGFP reporter.  
 
Hypothesis 2: Oversized vectors may have inherent in vivo instability, which leads to 
reduction in rAAV vector delivered to hepatocytes. This effect may be exacerbated 
in diseased livers. Optimising vector size, with respect to rAAV packaging 
constraints, will improve hepatocyte transduction. 
Aim 2: to compare transduction and transgene expression of different sized rAAV 
vectors, encoding hABCB4 transgene (3.9 kb), in Abcb4
+/+
, Abcb4
+/-
 and Abcb4
-/-
 mice. 
 
Hypothesis 3: Portal hypertension affects the biodistribution of rAAV vectors in 
vivo. Altering the route of administration may improve rAAV transduction. 
Aim 3: to compare transduction efficiency of rAAV vector delivered by intra-peritoneal, 
intra-venous and intra-portal routes of administration. 
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Hypothesis 4: The 3 known transcript variants of human ABCB4 confer different 
relative phosphatidylcholine floppase activity. 
Aim 4: to assess the biliary phosphatidylcholine concentration in mice that receive 
different rAAV vectors encoding one of the 3 known hABCB4 transcript variants. 
 
Hypothesis 5: If liver pathology significantly impacts rAAV hepatocyte 
transduction, initiation of therapy at a young age will be required for phenotype 
correction. Strategies to compensate for loss of rAAV episomes in the face of rapid 
liver growth in juvenile mice, such as vector re-administration, will be essential for 
maintaining transgene expression. 
Aim 5: to explore strategies to maintain hABCB4 expression in the face of episomal 
degradation with rapid liver growth in juvenile mice.    
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CHAPTER 2:  MATERIALS AND METHODS 
 
2.1.  MATERIALS 
2.1.1.  Chemical and General Reagents 
Reagents used to make up buffers, solutions and bacterial growth media were of analytical 
grade or higher, and are listed (Table 2.1). 
 
Table 2.1: Chemicals and general reagents  
Chemicals Source 
General Reagents 
Agarose  Amresco  
Ampicillin (for bacterial cultures) Sigma-Aldrich  
Ammonium acetate Chem-Supply 
Ammonium sulphate  Sigma-Aldrich  
Bacto-agar  Becton Dickinson  
Bacto-tryptone  Becton Dickinson 
Bacto-yeast Becton Dickinson 
Benzonase Sigma-Aldrich 
Boric acid Biochemicals 
Calcium chloride Amresco 
Caesium chloride Roche 
EDTA Amresco 
Ethanol  Merck 
Ethidium bromide Amresco 
Glucose Sigma-Aldrich 
Glycerol Amresco 
HEPES Biochemicals 
Magnesium Chloride Chem-Supply 
Phosphate buffered saline (PBS) tablets (without calcium 
or magnesium) 
MP Biomedicals, LLC 
Potassium Chloride Sigma-Aldrich 
Isopropanol Merck 
cOmplete Protease Inhibitor Cocktail (EDTA-free) Roche 
Sodium dodecyl sulphate (SDS) Amresco 
Sodium chloride Ajax Finechem 
Sodium hydroxide Amresco 
Sodium hydrogen phosphate Merck 
TRIzol
®
 Life Technologies 
Tri-sodium citrate (dihydrate) Merck 
Tris Base Amresco 
Triton X-100 Sigma-Aldrich 
Tween 20  Biochemicals 
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Cell Culture 
Dulbecco‟s Modified Eagle Medium (DMEM) Life Technologies 
Iscove‟s Modified Dulbecco‟s Medium (IMDM) Life Technologies 
Foetal Calf Serum (FCS) Life Technologies 
Trypan blue Solution (0.4% w/v) Sigma-Aldrich 
Tissue Fixation and Immunostaining 
4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI) Sigma-Aldrich 
3,3′-Diaminobenzidine (DAB) Sigma-Aldrich 
10% (v/v) Neutral Buffered Formalin Sigma-Aldrich 
Acetone Ajax Finechem  
Avidin/Biotin Blocking kit Vector Labs 
Hematoxylin QS Vector Labs 
Histolene Fronine 
Hydrogen Peroxide (30% w/v) Ajax 
Immu-Mount Thermo-Scientific 
Methanol Merck 
Tissue-Tek Optimal Cutting Temperature (O.C.T.) 
Compound 
Sakura Finetek 
Paraformaldehyde BDH 
Sodium citrate Sigma-Aldrich 
Sucrose Amresco 
Vectastain
®
 Elite ABC Reagent (R.T.U.) Vector Labs 
Ultramount Fronine 
Xylene Ajax 
Pharmacological Agents for Mice 
Baytril
®
 (Enrofloxacin) Bayer Healthcare 
Buprenorphine Reckitt Benckiser 
Isoflurane Abbott Australasia Pty Ltd 
Ketamine Ilium Veterinary Products 
0.9% (w/v) Sodium chloride  Baxter 
Xylazine Ilium Veterinary Products 
 
2.1.2.  Buffers and Solutions 
All prepared buffers and solutions used in the experimental methods are listed (Table 
2.2). Solutions were made up in Milli-Q water (mQwater), unless otherwise stated, and 
sterilised by either autoclave or filtration, prior to use. Solutions were stored at room 
temperature, unless otherwise stated. 
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Table 2.2: Buffers and Solutions 
Solutions Composition and Preparation 
General Buffers and Solutions 
6× Loading Dye  
(for agarose gel) 
0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanol, 
15% Ficoll 400 in dH2O 
Luria Bertani (LB) Media 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 1% 
(w/v) NaCl. Autoclaved 
Luria Bertani (LB) Agar LB media containing 1.5% (w/v) Bacto-agar. Autoclaved. 
Phosphate Buffered 
Saline (PBS) 
1 PBS (no Ca
2+
, no Mg
2+
) tablet per 100mL dH2O 
PBS (Ca
2+
/Mg
2+
) 1× PBS, 0.9 mM CaCl2 anhydrous, 0.49 mM MgCl2.6H20. 
Autoclaved or filter sterilised (0.2 µm) 
SOC media 2% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10  mM MgCl2, 10 mM MgSO4, and 20 mM 
glucose. Autoclaved. 
5× TBE 54 g Tris base, 27.5 g Boric acid, 10mM EDTA pH 8.0 in 1 L 
dH2O. Dilute 1 in 10 for working solution containing 45mM Tris-
borate, 1mM EDTA.  
Cell Culture 
Complete DMEM DMEM + 10% (v/v) heat-inactivated FCS 
Transfection media IMDM + 10% (v/v) heat-inactivated FCS 
Maintenance media DMEM + 2% (v/v) heat-inactivated FCS 
10× Citric Saline 1.35 M KCl, 0.15 M Sodium Citrate. Autoclaved 
Transfection and AAV Purification 
Ammonium Sulphate 
solution (Saturated) 
4 M ammonium sulphate, pH 7.0. Filter sterilised (0.45 µm). 
Stored at 4ºC 
Caesium Chloride 
solution (1.37 g/mL) 
50 g to 100mL PBS (Ca
2+
/Mg
2+
). Filter sterilised (0.2 µm) 
Caesium Chloride 
solution (1.5 g/mL) 
33.75 g to 50 mL PBS (Ca
2+
/Mg
2+
). Filter sterilised (0.2 µm) 
2 M CaCl2 29.404 g CaCl2.2H2O in 100 mL dH2O. Autoclaved  
Dialysis Buffer 1× PBS (Ca
2+
/Mg
2+
) ± 5% (v/v) glycerol 
1000× Ca
2+
/Mg
2+
 stock 
solution 
0.90 M CaCl2 anhydrous, 0.49 M MgCl2.6H20. Filter sterilised 
(0.2 µm). Diluted 1:1000 for dialysis and caesium chloride 
solutions. 
2× Hepes-buffered Saline 
(HBS) 
280 mM NaCl, 50 mM HEPES, pH 7.10. Autoclaved 
0.15 M Na2HPO4 10.647 g in 500 mL dH2O, pH 7.10. Autoclaved 
rAAV Resuspension 
Buffer 
100 mM NaCl, 2 mM MgCl2.6H2O, 10 mM Tris, pH 8.0. 
Autoclaved 
10% (v/v) TE 1 mM Tris, 0.1 mM EDTA, pH 8.0. Autoclaved 
Histology and Immunostaining 
4% (w/v) 
Paraformaldehyde (PFA) 
8 g Paraformaldehyde in 100 mL, dissolved at 60ºC, adjust pH 
with NaOH until dissolved (pH 7.2-7.4). Made up to 200 mL with 
2 x PBS. Stored at -20ºC 
PBST 1 x PBS, 0.1% (v/v) Tween 20.  
Sodium Citrate buffer 10 mM Tri-sodium citrate dehydrate, 0.05% (v/v) Tween 20, 
adjust to pH 6.0 with 1 N HCl 
10% (w/v) Sucrose 20 g in 200 mL 1× PBS. Filter sterilised (0.2µm). Stored at 4ºC. 
20% (w/v) Sucrose 40 g in 200 mL 1× PBS. Filter sterilised (0.2µm). Stored at 4ºC. 
30% (w/v) Sucrose 60 g in 200 mL 1× PBS. Filter sterilised (0.2µm). Stored at 4ºC. 
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2.1.3. Antibodies 
Table 2.3: Antibodies 
Antibody Species Source, Cat no. Conjugate Use, 
Dilution 
Anti-Glutamine 
Synthetase 
Rabbit polyclonal Abcam, ab16802 N/A IHC-Fr, 
1:200 
Anti- ABCB4 
(MDR3) 
Mouse monoclonal 
IgG2b 
LifeSpan Biosciences,  
LS-C134867 
N/A IHC- Fr, 
1:20 
Anti- ABCB4 
(MDR3) 
Rabbit polyclonal Abcam, ab71792 N/A IHC-P, 
1:200 
Anti-Rabbit  Donkey polyclonal Invitrogen, A21207 Alexa-594 IHC- Fr, 
1:800 
Anti-Mouse 
IgG2b 
Goat polyclonal Southern Biotechnology, 
1090-02 
FITC IHC- Fr, 
1:50 
Anti-Rabbit  Donkey polyclonal Jackson ImmunoResearch 
711-065-152 
Biotin  IHC-P, 
1:600 
Abbreviations: IHC-Fr, immunohistochemistry on frozen sections; IHC-P, immunohistochemistry on 
paraffin sections; Alexa, Alexa
®
 Fluor; FITC, Fluroscein. 
 
2.1.4. Bacterial Strains 
Bacterial host strains used for constructing plasmids are detailed (Table 2.4). 
Table 2.4: Bacterial host strains 
Strain Genotype Source 
JM109 endA1, recA1, gyrA96, thi, hsdR17 
(rk–, mk+), relA1, supE44, Δ(lac-
proAB), [F′, traD36, proAB, 
laqIqZΔM15] 
Promega 
SURE 2 
Supercompetent 
cells 
e14-(McrA-), Δ(mcrCB-hsdSMR-
mrr)171, endA1, gyrA96, thi-1, 
supE44, relA1, lac, recB, recJ, sbcC, 
umuC::Tn5 (Kanr), uvrC, 
[F´ proAB lacIqZΔM15 Tn10 (Tetr) 
Amy Camr] 
Agilent Technologies 
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2.1.5. Plasmids 
The plasmids used for experiments and cloning are listed (Table 2.5). All plasmids 
contain an Ampicillin resistance gene for antibiotic selection, unless otherwise stated.  
Table 2.5: Plasmids 
Plasmid Description Source Reference 
pGEM
®
-T Easy TA cloning vector Promega  
p5E18-VD2/8 Packaging plasmid for 
rAAV2/8 
Dr James Wilson, 
University of 
Pennsylvania 
361 
pAAV2/rh10 Packaging plasmid for 
rAAV2/rh10 
Dr James Wilson, 
University of 
Pennsylvania 
362 
pAM.LSP1.eGFP The pAM AAV2 plasmid 
containing an enhanced green 
fluorescent protein transgene 
with a liver specific promoter 
Dr Sharon Cunningham, 
Children‟s Medical 
Research Institute 
181 
pAM.EF1α.eGFP  The pAM AAV2 plasmid 
containing an enhanced green 
fluorescent protein transgene 
with an elongation factor 1α 
(EF1α) promoter  
(Constructed by Susan Siew) 
Children‟s Medical 
Research Institute 
 
ssAAV.LP1.hFIXco An AAV2 construct 
containing codon-optimised 
human Factor IX with a liver 
specific promoter (LP1) 
Dr Amit Nathwani, 
University College 
London 
157 
pXX6 AAV helper plasmid 
 
Dr R. Jude Samulski, 
University of North 
Carolina 
363 
pBluescriptR. 
hABCB4 
Cloning Vector containing 
hABCB4 cDNA (GenBank 
Acc no. BC042531) 
Thermo-Fisher-
Scientific (Open 
Biosystems) 
 
pAM.LSP1.PBase The pAM AAV2 plasmid 
encoding a piggyBac 
transposase gene under the 
control of a liver specific 
promoter (LSP1) 
Dr Sharon Cunningham, 
Children‟s Medical 
Research Institute 
 
pAM.LSP1.mOTC + 
TRS 
The pAM AAV2 plasmid 
containing a murine ornithine 
transcarbamylase transgene 
with a liver specific promoter 
(LSP1) and piggyBac 
transposon recognition sites 
Dr Sharon Cunningham, 
Children‟s Medical 
Research Institute 
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2.1.6. PCR Primers 
Table 2.6: Primers for PCR Amplification for Plasmid Cloning 
Primer Sequence - 5' to 3'  Amplicon (size) 
Annealing 
Temp, 
Extension 
Time# 
LP1-F GCGGTACCACGCGTGGGTTCCTGGAGGGGTGGAGTCG  LP1 promoter/enhancer for 
pAAV2.LP1.hABCB4v1 
(512 bp) 
60ºC, 
1 minute 
LP1-R 
GCAAGCTTGGATCCTCTAGACCGGATTCACTGTCCCAG
GTCAG 
ABCB4-F GTTCTAGAGCCGCCACCATGGATCTTGAGGCGGCAAAG  Full-length hABCB4 
cDNA from pBluescript- R 
(3970 bp) 
57ºC, 
6 minutes 
ABCB4-R2 GCAAGCTTGGCCGGATCCAGCGCTG 
LP1-F2 
GCACGCGTTGATCAACTAGTCCCTAAAATGGGCAAACA
TTGC LP1 promoter/enhancer for 
pAAV2.LP1.hABCB4v2 
(475 bp) 
59ºC, 
1 minute 
LP1-R2 GCTCTAGAATTCACTGTCCCAGGTCAGTG 
hABCp2-F GGAATTCTGTGCAGAAGGCAC 3' segment of hABCB4 
cDNA 
(1087 bp) 
58ºC, 
2 minutes 
hABCp2-R2 
CGTGATCAACGCGTCAGAAGCTTTCATAAGTTCTGTGT
CCCAGC 
SV40pA-F 
GCAAGCTTGCAGTTATCGATATGCTTTATTTGTGAAAT
TTGTGATGC SV40pA 
(159 bp) 
62ºC, 
1 minute 
SV40pA-R GCACGCTTTAAAAAACCTCCCACACCTCC 
LP1-F4 
GCAGATCTGATATCACTAGTCCCTAAAATGGGCAAACA
TTGC LP1 promoter/enhancer for 
pTRUF.LP1.hABCB4 
(513 bp) 
59ºC, 
1 minute 
LP1-R3 
GCAGATCTACCGGTACGCGTCAGAAGCTTTAGTCTAGA
GCAATTCACTGTCCCAGGTCAGTG 
LP1-F5 
GCTACGTAGCCATGCTCTAGATATCACTAGTCCCTAAA
ATGGGCAAAC LP1 promoter/enhancer for 
pAAV2.LP1.hABCB4v3 
(513 bp) 
67.6ºC 
1 minute 
LP1-R5 
GCTACGTAGCCATGCTACCGGTTAGTCTAGAGCAATTC
ACTGTCCCAGGTC 
eGFP-F2 GGTCTAGAGCCGCCACCATGGTGAGC eGFP from 
pAAV.EF1a.eGFP 
(740 bp) 
60ºC, 
30 seconds 
eGFP-R2 GCAAGCTTGTTACTTGTACAGCTCGTCCATG 
5pBTRShort-F 
GCACTAGTGATATCGGTTAACCCTAGAAAGATAATCAT
ATTG Short 5' piggyBac 
transposon recognition sites 
(91 bp) 
58ºC, 
1 minutes 
5pBTRShort-R GCACTAGTCATGCGTCAATTTTACGCATG 
3pBTRShort-F GCACGCGTGCATGCGTCAATTTTACGCAGAC Short 3' piggyBac 
transposon recognition sites 
(64 bp) 
56ºC, 
1 minutes 
3pBTRShort-R CGACGCGTACCGGTGCTTAACCCTAGAAAGATAGTC 
#PCR cycling conditions: Initial denaturation at 95°C for 2 minutes, followed by 35 cycles of denaturation at 95°C for 
30 seconds, annealing at temperature specified above for 30 seconds, and extension at 72°C for 1-2 minutes/kilobase 
(time specified above); final extension at 72°C for 10 minutes. (Section 2.2.4)  
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2.2. MOLECULAR BIOLOGY 
2.2.1. Plasmid Purification 
2.2.1.1. Small-scale plasmid purification 
Commercially available miniprep kits (Qiagen) were used for small scale plasmid DNA 
isolation from bacterial clones by an alkaline lysis method. Briefly, single bacterial 
colonies were selected from LB/ampicillin agar plates and inoculated into 3 mL LB media 
supplemented with ampicillin (100 µg/mL) in 15 mL round bottom polypropylene, 
loosely capped tubes. Cultures were incubated at 37ºC overnight in a shaking incubator 
(225 rpm, shaking orbit of 19 mm). 1.5 to 2 mL of culture was pelleted in a 1.5 mL 
eppendorf tube by centrifugation at 14000 × g for 1 minute. Plasmid DNA was isolated 
from the bacterial pellet according to manufacturer‟s instructions. In the final step DNA 
was eluted from column in 30 µL of elution buffer provided. 
2.2.1.2. Large-scale plasmid purification 
Large scale isolation of transfection-grade plasmid DNA was performed using 
Nucleobond Xtra Midi or Maxi kits (Macherey-Nagel GmbH & Co, Germany) for up to 
500 μg or 2000 µg DNA per column, respectively, or Plasmid Giga kits (Qiagen) for up 
to 10 mg DNA per column, each according to the manufacturer‟s instructions. To prepare 
cultures for plasmid purification, single colonies were inoculated into 3-5 mL 
LB/ampicillin medium and grown at 37ºC in a rotary shaking incubator until the culture 
was visibly turbid (typically ≥ 6 hours). This culture was, then diluted 1:500 into fresh LB 
media supplemented with ampicillin (100 µg/mL). Culture volumes ranged from 250 mL 
for midipreps, 0.5-1 L for maxipreps to 2.5 L for gigapreps. Cultures were incubated 
overnight at 37ºC (or at 32°C, or room temperatures for large plasmids such as pXX6, or 
plasmids that were difficult to grow) in a rotary shaking incubator oscillating at 225 rpm 
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(shaking orbit, 19mm). Glycerol stocks of bacteria harbouring the plasmid of interest 
were prepared by mixing 850 μL of log-phase culture with 150 µL of 100% sterile 
glycerol (final concentration: 15% v/v), frozen and stored at -80ºC. 
The bacteria were harvested by centrifugation at 5000 × g for 15 minutes at 4ºC 
(Beckman JA-14 rotor). DNA was extracted or pellets were frozen at -20ºC for later use. 
For DNA extraction the manufacturer‟s instructions of respective kit were followed. DNA 
pellets were resuspended in sterile 10% (v/v) TE. DNA was stored at -20ºC until required. 
 
2.2.2. Restriction Enzyme Digestion 
Restriction enzymes digests (Roche or New England Biolabs) were performed in buffers 
provided by the manufacturer. Digests to screen for correct plasmid DNA were typically 
performed on ~200-500 ng plasmid DNA with 0.5-2.5 units of enzyme in a total volume 
of 20 μL with the appropriate buffer, and 100 µg/mL bovine serum albumin, if 
recommended. Reactions were incubated at the recommended temperature (typically 
37°C) for at least 1 hour.  
To prepare DNA fragments for subsequent subcloning steps of vector construction, large-
scale digests were performed using 20-50 μg of plasmid DNA. Between 2 and 5 units per 
µg DNA of each enzyme was used in the reaction. The total volume of enzyme did not 
exceed 10% of the total reaction volume, so as to avoid reduced DNA substrate 
specificity of the restriction enzyme or excess glycerol causing inhibition.
364
 Reactions 
were incubated at the recommended temperature (typically 37°C) for at least 3 hours, 
depending on the enzyme activity.  
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2.2.3. Agarose Gel Electrophoresis 
Following restriction enzyme digests or PCR amplification, DNA fragments were 
resolved by agarose gel electrophoresis. Gel concentrations used ranged from 0.8-2% 
(w/v), according to expected fragment size. The gel was prepared with 0.5× TBE buffer 
(Table 2.2) and stained with 0.5 μg/mL ethidium bromide to allow UV detection of DNA. 
DNA samples were resuspended five parts DNA to one part 6× loading dye (Table 2.2) 
and loaded into prepared wells. Commercially available molecular weight markers 
(Bioline) were used to estimate the size of DNA fragments. Electrophoresis was carried 
out in 0.5× TBE buffer at a constant voltage of approximately 5 V/cm. DNA was 
visualised under ultra-violet light on a transilluminator (Alpha Innotech Fluorchem 5500, 
San Leandro, CA, USA). 
2.2.4. PCR Amplification of Sequences for Sub-cloning 
PCR was used to amplify DNA sequences required for cloning into AAV vectors. 
Restriction enzyme sites were incorporated into the primer sequences to allow for 
excision and ligation in subsequent sub-cloning steps. A standard 50 μL reaction 
contained 1× reaction buffer, 250 μM of dATP, dCTP, dGTP and dTTP, 0.5 μM of 
forward and reverse primers, 2.5 units PfuUltra Hotstart DNA polymerase (Agilent 
Technologies) and 30 ng template DNA. Reactions were typically cycled at 95°C for 2 
minutes followed by 35 cycles at 95°C 30 seconds, 50-65°C 30 seconds and 72°C for 1-2 
minutes/kilobase DNA to be amplified (see Table 2.6 for primer pair sequences and 
reaction conditions). Reactions were completed with a final extension at 72°C for 10 
minutes. Amplicons were resolved on an agarose gel to determine expected size and 
purity. PCR fragments were purified (Section 2.2.5) before ligation into pGEM
®
-T Easy 
cloning vector (Section 2.2.8). 
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2.2.5. Gel Purification of PCR Fragments and Digested Plasmid DNA 
Following PCR amplification (Section 2.2.4) or restriction enzyme digestion (Section 
2.2.2) DNA was loaded on to a 0.8-1.2% (w/v) agarose gel and electrophoresed (Section 
2.2.3). The desired fragment was excised from the gel under UV transillumination using a 
clean scalpel blade. DNA was extracted from the gel using the Wizard
®
 SV Gel and PCR 
Clean-up System (Promega), according to the manufacturer‟s instructions. The gel slice 
containing DNA fragment was melted with DNA binding buffer (10 μL solution/10 mg 
gel) at 50-60°C, centrifuged through the purification column, washed and eluted from the 
column in 30-50 μL nuclease-free water.  
 
2.2.6. Dephosphorylation of Digested Plasmid Vector Backbone 
For ligation reactions involving compatible cohesive ends, digested vector backbone was 
dephosphorylated with Antarctic phosphatase (New England Biolabs). Dephosphorylation 
removes the phosphate groups of the 5‟ terminus preventing re-ligation of the compatible 
ends, thereby reducing the background of non-recombinant plasmids generated by self-
ligation. The 5-10 µg of extracted and purified vector backbone was added to the reaction 
containing 1× reaction buffer and 5 units of Antarctic Phosphatase per 3 µg DNA. If the 
vector backbone involved 5‟ overhangs or blunt-ends, the reaction was incubated at 37°C 
for 15 minutes. If the cohesive ends had 3‟ extensions, the reaction time was increased to 
60 minutes, according to the manufacturer‟s instructions. Antarctic phosphatase was 
inactivated by incubation at 65ºC for 5 minutes, and samples stored at 4°C for later use.  
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2.2.7. DNA Ligation 
Ligation reactions were carried out in 10 μL of 1× Reaction Buffer, 3 units T4 DNA 
Ligase (Promega), and 50-300 ng plasmid backbone and insert. Depending on the relative 
size of insert and vector, the molar ratio of insert to vector was between 1:3 to 6:1. 
Reactions were incubated overnight at 4ºC. T4 DNA Ligase was inactivated at 70°C for 
10 mins. Then, 1-2 µL of ligation reactions were transformed into bacteria (Section 
2.2.9). 
2.2.8. TA-Cloning Vectors 
PCR-amplified fragments were TA cloned into the pGEM
®
-T Easy cloning vector 
(Promega). Inserts require single 3‟ dATP overhangs on each strand for cloning into this 
vector. PfuUltra Hotstart DNA polymerase (Agilent Technologies) used for PCR 
amplification lacks terminal transferase activity and generates blunt ended PCR products. 
Therefore, Taq DNA polymerase (Roche) was used to add dATP to the 3‟ ends of each 
strand of amplified fragments. Ten µL reactions contained 1× PCR buffer with MgCl2, 
0.2 mM dATP, 5 units Taq DNA polymerase and 100-500 ng PCR product. Reactions 
were incubated at 70ºC for 30 minutes; 1 μL of this reaction was added to a 10 µL 
ligation reaction, containing 1× Rapid Ligation Buffer, 50 ng of pGEM
®
-T Easy vector, 3 
units of T4 DNA Ligase (Promega). The ligation reaction was incubated at room 
temperature for 2 hours or at 4°C overnight. Two µL of this ligation reaction was used to 
transform 30 µL of JM109 chemically competent cells, according to the pGEM
®
-T Easy 
protocol (Promega). Following ligation and transformation, minipreps (Section 2.2.1.1) 
on colonies were performed to determine the presence of insert, prior to sequencing and 
large scale plasmid isolation and purification (Section 2.2.1.2). 
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2.2.9. Transformation of Bacterial Cells 
Using the heat shock method, chemically competent E. coli (JM109, Promega and 
SURE
®
 2 cells, Agilent – see Table 2.4) was transformed with plasmid constructs. For 
SURE
®
 2 cell transformations, cells were incubated with 1 µL β-mercaptoethanol (1.22 
M) per 50 µL cells prior to the addition of DNA, according to the manufacturer‟s 
instructions. Plasmid DNA (1-2 μL of a ligation mix or 30-50 ng DNA) was added to 30-
50 μL of chemically-competent JM109 or prepared SURE® 2 cells and incubated on ice, 
according to the manufacturer‟s instructions. The cells were then heat shocked at 42ºC for 
30-45 seconds, chilled on ice for 2 minutes before SOC or LB media was added to a total 
volume of 1 mL. Cells were incubated with shaking at 160-200 rpm (shaking orbit, 
19mm) for 1 hour at 37ºC and then plated onto LB agar plates supplemented with 
Ampicillin (100 µg/mL) for incubation overnight at 37ºC. Transformations were 
performed alongside a control uncut plasmid transformation to ensure the integrity of the 
procedure. Individual ampicillin-resistant colonies were used to inoculate ampicillin-
supplemented LB media at 37ºC for 12-16 hours and after plasmid DNA isolation, 
screened for the presence of the correct plasmid DNA by restriction site mapping and 
DNA sequencing (Sections 2.2.1.1, 2.2.2 and 2.2.10), prior to large scale plasmid 
isolation and purification (Section 2.2.1.2). 
2.2.10. DNA Sequencing 
All newly constructed plasmid constructs were sequenced to verify their DNA sequence 
and orientation. Sequencing was performed by Australian Genome Research Facility Ltd 
(AGRF). Sequencing samples were prepared as a 12 µL reaction mix containing 0.5-1 μg 
plasmid DNA and 9.6 pmol primer. 
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2.3. CELL CULTURE 
All cells were grown in sterile cell culture vessels (Becton Dickinson) in 5% (v/v) carbon 
dioxide, humidified air and water-jacketed incubators at 37ºC. All cells were maintained 
in DMEM containing 10% (v/v) foetal calf serum (Complete DMEM), unless otherwise 
stated. Fresh growth medium, pre-warmed to 37ºC, was used to replenish cells twice 
weekly. 
Human embryonic kidney cells (HEK 293) were passaged at a dilution of 1:10 every 3-4 
days in 75 mm
3
 cell culture flasks (Becton Dickinson). This was done by detaching HEK 
293 cells from the cell culture vessels by incubation in 3 mL of 1× citric saline at 37ºC for 
approximately 5 minutes. After detachment, 7 mL of pre-warmed Complete DMEM was 
added and 1 mL of this suspension was then added to a new flask with 9 mL of fresh 
growth medium. 
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2.4. VIRAL VECTOR PRODUCTION 
2.4.1. Production of rAAV Vectors by Transient Transfection of HEK 293 cells 
All rAAV vector constructs were packaged into AAV capsids via a helper virus-free 
system using HEK 293 cells as previously described by Xiao et al.
363
 This method has 
been adapted from Choi et al.
365
 Twenty-four hours prior to transfection, cells were 
seeded onto 100 mm diameter dishes at a density of 4 × 10
6
 cells per dish with pre-
warmed complete DMEM. Two to three hours before transfection, dishes were 
replenished with fresh transfection medium (IMDM + 10% FCS). Cells at 50 – 80% 
confluency were transfected with 3 plasmids: 3 μg vector plasmid, 3 μg capsid plasmid 
and 9 μg helper plasmid per dish (total of 15 µg per dish) using DNA/calcium phosphate 
co-precipitation. The precipitate was formed by slow drop-wise addition of an equal 
volume of Solution A (containing plasmid DNA, 10% v/v TE, 250 mM CaCl2) to 
Solution B (containing 2× HBS, 1.5 mM NaH2PO4). A fine precipitate was allowed to 
form at room temperature for 20 minutes prior to adding 1mL to each 100mm dish of 
cells. After an overnight incubation at 37
o
C, the medium was replaced with fresh DMEM 
containing 2% FCS. The transfected cells were incubated for a further 30 - 36 hours 
before being harvested by scraping the cell monolayer from dishes using a disposable cell 
scraper (Corning Inc., USA). The cell suspension was centrifuged (514 × g at room 
temperature for 5 minutes) to isolate the pellet, which was then resuspended in rAAV 
Resuspension buffer (containing 100 mM NaCl, 2 mM MgCl2 and 10 mM Tris) and 
stored at -80
o
C. 
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2.4.2. rAAV Purification and Concentration 
The packaged rAAV virions were purified from the cell suspensions. Cell pellets isolated 
from transfected HEK 293 cells were thawed at 37ºC and then put through three freeze 
and thaw cycles using dry ice/100% (v/v) ethanol and a waterbath set at 37ºC. The cell 
suspension was centrifuged (3210 × g at 4ºC, 15 minutes) and the supernatant treated with 
Benzonase (50 U/mL, Sigma-Aldrich) by incubation at 37ºC for 30 minutes. The 
supernatant was then centrifuged (3210 × g at 4ºC, 10 minutes) and the pellet discarded. 
Ice-cold saturated ammonium sulphate was added to the supernatant at a third the original 
volume, and incubated on ice for 10 minutes. The mixture was centrifuged (3210 × g at 
4ºC, 15 minutes) and the supernatant treated with cold, saturated ammonium sulphate at 
two-thirds the original volume and incubated on ice for 20 minutes. After further 
centrifugation (12000 × g at 4ºC, 15 minutes), the supernatant was discarded and the 
pellet resuspended in 60 mL of caesium chloride (CsCl) solution (1.37 g/mL). The 
suspension was then aliquoted into 10 mL SW41 Ultraclear
™
 centrifugation tubes 
(Beckman) and 1mL of CsCl (1.5 g/mL) was dispensed into the bottom of each tube as a 
cushion. The tubes were balanced and centrifuged at 151263 × g at 16ºC for 42 – 60 
hours. Ten 1 mL fractions were collected from each tube and pooled. An aliquot of 2 μL 
was removed from each pooled fraction and diluted into 1000 μL of sterile nuclease free 
water to estimate rAAV titres by qPCR. Three to four fractions containing the highest 
titres were then pooled and dialysed twice with 4 L of PBS (Ca
2+
/Mg
2+
) at 4ºC, minimum 
4 hours each dialysis, using a 10000 MWCO Slide-A-Lyzer Dialysis Cassette (Thermo 
Scientific). A final dialysis was performed overnight at 4ºC using 2 L PBS (Ca
2+
/Mg
2+
, 
5% v/v Glycerol). The virus was concentrated by tangential flow using a Vivaspin20 
100,000 MWCO membrane (GE Healthcare Life Sciences) at 4ºC, 4000 × g, for 15 
minute intervals until the volume was reduced to approximately 500 – 1000 µL. 
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Concentrated virus was aliquoted and frozen at  minus 80ºC. Titres were determined by 
quantitative real time PCR analysis to estimate the vector genomes per mL (Section 
2.4.3). 
 
2.4.3. Analysis of CsCl Fractions and rAAV Titering by Quantitative PCR 
Titres were assigned to rAAV vector stocks by quantitative PCR (qPCR) analyses. For 
vectors not containing a WPRE, primers were synthesised to bind to the transgene 
(hABCB4, cohABCB4, eGFP) within the expression cassette (Table 2.7). Standard curves 
were generated using linearised pAAV2.hABCB4, pAAV2.pBsh.cohABCB4 or 
pAAV2.pBRsh.eGFP to give a range between 10
3
 and 10
8
 vector genome copies, 
respectively. Amplification was carried out using Quantitect SYBR Green Master mix 
(Qiagen), according to the manufacturer‟s instructions. DNA was denatured for 15 
minutes at 95ºC, followed by 40 cycles of 95ºC for 30 seconds, annealing for 30 seconds 
at temperatures specified in Table 2.7, and 72ºC for 1 minute. Quantitative data was 
acquired during the extension phase of each cycle at 72ºC. 
For vector containing a WPRE sequence, primers and a probe were synthesised to bind 
within the WPRE region of the vector (Table 2.7).
366
 Standard curves were generated 
using linearised pAm.GFP to give a range of 10
3
 to 10
8
 vector genomes. Amplification 
was carried out using Platinum Taq (Invitrogen). The reactions were carried out in the 
supplied buffer with the addition of MgCl2 (2.5 mM), dNTPs (0.2 mM of each 
nucleotide). The 2-step PCR reaction cycling conditions were as follows: template DNA 
was denatured for 10 minutes at 95ºC, followed by 40 cycles of 95ºC 15 seconds and 
60ºC for 60 seconds. Quantitative data was acquired during the 2nd phase of cycling at 
60ºC. 
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Table 2.7: Primers for qPCR and qRT-PCR for vector stock titration and liver DNA 
and cDNA quantification. 
Target Primer  Sequence (5' to 3') 
Annealing 
Temp. (ºC) 
WPRE 
1314P (Probe) FAM-TGCTGACGCAACCCCCACTGGT-TAMRA  
60ºC 1277F CCGTTGTCAGGCAACGTG  
1361R AGCTGACAGGTGGTGGCAAT  
hABCB4 
1625F GAGGATCGCCATTGCACGTG 
59ºC 
1774R GTGCTATCACAATGGTGGTCC     
cohABCB4 
1521F GCTGTCAAGGAGGCTAATGC 
58ºC 
1779R CATTCCGCACGGTGCTCAG 
eGFP 
qEGFP2-F GTAAACGGCCACAAGTTCAGC 
61ºC 
qEGFP2-R TGGTGCAGATGAACTTCAGGG 
GAPDH 
GAPDH 1 ACGGCAAATTCAACGGCAC 
60ºC 
GAPDH 2 TAGTGGGGTCTCGCTCCTGG 
β-actin 
D278 B-actin CTAGACTTCGAGCAGGAGATGGC 
59ºC 
D279 B-actin TCTGCATCCTGTCAGCAATGCC 
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2.5. ANIMAL STUDIES 
2.5.1. Maintenance of Mouse Colonies 
All mice were housed in The Children‟s Medical Research Institute (CMRI) Bioservices 
Facility under Specific Pathogen Free (SPF) conditions. All experiments and procedures 
were approved by The Children‟s Hospital at Westmead and CMRI Animal Care and 
Ethics Committee (Certificates of Approval, Appendix A). All mice were housed under 
standard conditions of 12 hour light/dark cycles and maintained on a standard chow diet 
(Specialty Feeds) and water ad libitum. The ABCB4-knockout mouse model (FVB.129 
P2- Abcb4
tm1Bor
/J) was purchased from the Jackson Laboratory (Bar Harbor, USA) and 
bred in-house. 
 
2.5.2. Genotyping 
Genotype was determined by tail tip screening. DNA was extracted from tail tip samples 
by overnight incubation in TE/SDS (100 mM Tris pH 8.0, 1.0 mM EDTA, 0.5% w/v 
SDS) with Proteinase K (100 µg/mL) at 56°C. DNA was purified by treating with an 
equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) and 8 M ammonium 
acetate, mixed by inversion and centrifuged at 12000 × g for 10 minutes at room 
temperature. DNA was precipitated by mixing the aqueous phase with absolute ethanol 
and centrifuged at 12000 × g for 3 minutes at room temperature. The DNA pellet was 
washed in 70% (v/v) ethanol, dried and resuspended in TE buffer (10 mM Tris.HCl pH 
7.4, 1 mM EDTA pH 8.0) for analysis by PCR as follows.  
  
PCR was performed using an Eppendorf Mastercycler (Eppendorf). Two sets of primers 
were used to amplify the 350 bp wild-type allele (oIMR0705 and oIMR0706) and the 200 
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bp band (oIMR0506 and oIMR0507) from the ABCB4 mutant allele (Table 2.8). The 
DNA fragments were amplified using the following cycling conditions: initial 
denaturation at 94ºC for 3 minutes, followed by 10 cycles of 94ºC for 30 seconds, 65ºC 
minus 0.5ºC per cycle for 30 seconds, 72ºC for 1 minute, then 22 cycles of 94ºC for 30 
seconds, 51ºC for 30 seconds and 72ºC for 1 minute, and concluded by 72ºC for 7 
minutes. Bands were visualised on a 2% (w/v) agarose gel with ethidium bromide 
staining. 
Table 2.8: Primers for Genotyping PCR
#
 
Primer Sequence (5' to 3') Target 
oIMR0506 (Neo3-F) CGGCGAGGATCTCTCGTCGTGACCCA 
Mutant allele  
oIMR0507 (Neo3-R) GCGATACCGTAAAGCACGAGGAAG 
oIMR0705 (mabcb4 wt-F) GCTGAGATGGATCTTGAG 
Wild-type allele 
oIMR0706 (mabcb4 wt-R) GTCGAGTAGCCAGATGATGG 
#Primers and PCR cycling conditions adapted from Abcb4 genotyping protocols from The Jackson Laboratory.367 
2.5.3. Mouse Injections 
2.5.3.1. Adult mice injections 
Three routes of administration were used to deliver rAAV vector to adult mice: intra-
peritoneal, intra-portal and intra-venous injection. For each route of administration, 
injections were prepared by diluting appropriate amounts of rAAV vector in PBS (with 
added 0.9 mM Ca
2+
 and 0.49 mM Mg
2+
) to a maximum volume of 125 µL. 
For intraperitoneal injections, mice were restrained by hand, the site of injection was 
swabbed with alcohol, and vector was delivered, using a 29-gauge 1 mL syringe (BD 
Ultra-Fine Insulin Syringe, Becton Dickinson, USA), into the peritoneal cavity. 
For intra-portal injections, mice underwent abdominal surgery as follows. Mice were fully 
anaesthetised with Ketamine (100 mg/kg) and Xylazine (20 mg/kg), given by 
intraperitoneal injection. Using an aseptic technique and sterilised instruments, a 15-18 
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mm midline incision was made, and the portal vein exposed. Using a 33 gauge needle and 
Hamilton
®
 syringe (Hamilton Company, USA), 100 µL of vector was injected into the 
portal vein under direct vision. After establishing haemostasis, the abdominal wall and 
skin were closed in layers, and buprenorphine (0.03 mg/kg) injected subcutaneously for 
postoperative pain relief. Mice were monitored for wound healing, signs of ill health and 
weight loss. Daily subcutaneous injections of buprenorphine (0.03 mg/kg) were 
administered for the first 3 days for post-operative pain relief. The drinking water was 
supplemented with Baytril
®
 for 14 days as prophylaxis against wound infections.  
For intra-venous injections, mice were warmed under a lamp to vasodilate the tail vein, 
and then placed in a restrainer. The site of injection was swabbed with alcohol and using a 
fine 29-gauge needle & syringe, up to 125 µL of diluted rAAV vector was injected into 
the lateral tail vein, 1/3 from the base of the tail. Haemostasis was achieved with gentle 
pressure at the injection site.  
2.5.3.2. Neonatal/juvenile mice injections 
Recombinant AAV vectors were delivered to neonatal and juvenile mice via the intra-
periteoneal route. 10 - 20 µL of vector was intra-peritoneally administered to neonates 
and juvenile mice up to 2 weeks of age using a 33-gauge needle and Hamilton
®
 syringe. 
For mice older than 2 weeks, intraperitoneal injections of 50 – 100 µL volume were given 
with a 29-gauge needle and syringe.  
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2.5.4. Tissue, Blood and Bile Harvesting, and Preparation for Downstream 
Analyses 
2.5.4.1. Blood sampling 
For blood collection of adult mice and juveniles older than 3 weeks of age, mice were deeply 
anaesthetised using inhaled isoflurane (3% v/v for induction, 1-2% v/v for maintenance), a 
syringe with attached 25-gauge needle was used to collect whole blood directly from the heart 
by cardiac puncture, as a terminal procedure. The needle was then detached and blood 
dispensed into tubes coated with lithium heparin (Becton Dickinson, USA). Plasma was then 
isolated by centrifugation to 1326 × g at 4ºC for 3 minutes. Samples were immediately frozen 
stored at -20ºC. 
Blood collection in neonatal or juvenile mice (less than 14 days old) was performed by 
decapitation followed by immediate blood collection from the wound into heparin-coated 
microvette tubes (Sarstedt). Plasma was then isolated as above. 
For serum extraction, whole blood was collected using cardiac puncture method into 
uncoated collection tubes (Eppendorf). The samples were allowed to clot at room 
temperature for 1 hour before being centrifuged to 1326 × g at 4ºC for 20 minutes. The 
serum was removed and frozen at -20ºC. 
2.5.4.2. Bile collection 
For bile collection, mice were fasted without food for 4-5 hours prior to the procedure, in 
order to maximise the volume of bile in the gallbladder. Water was provided ad libitum. 
Under isoflurane inhalational anaesthesia, a midline laparotomy incision was performed 
to expose the liver and gallbladder. The common bile duct was located and occluded 
using a surgical clamp. A 1 mL syringe with attached 29-gauge needle was inserted into 
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the gallbladder, and bile was aspirated. Bile was then placed into collection tubes 
(Eppendorf) on ice, prior to storage at -20ºC. As bile was collected at the termination of 
the experiment, mice were euthanised by cervical dislocation following the procedure and 
specimens were collected for other end-point analyses.    
2.5.4.3. Liver tissue collection 
Livers were harvested for quantification of vector genomes, mRNA transcripts, and liver 
protein. As liver tissue was harvested at the termination of the experiment, mice were 
euthanised by cervical dislocation. Livers were then excised from the abdominal cavity, 
weighed, and divided. Specimens were snap frozen in liquid nitrogen to be stored at 
minus 80ºC, or fixed in 10% (v/v) neutral-buffered formalin or 4% (w/v) 
paraformaldehyde. 
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2.6. ANALYSIS OF MOUSE SAMPLES FROM IN VIVO STUDIES 
2.6.1. Isolation of Genomic DNA from Murine Liver Tissue 
DNA was extracted from snap frozen liver samples, in order to measure the number of 
vector genomes in liver tissue of transduced mice. To extract genomic DNA from murine 
liver, 30 to 60 mg liver tissue samples was homogenised using a hand-held homogeniser, 
and lysed in 500 μL of lysis buffer (10 mM Tris.HCl pH 8, 0.1 M EDTA, 0.5% w/v 
SDS). Rnase A (100 μg) was added to the homogenised sample and incubated for 60 
minutes at 37ºC. Proteinase K (20 mg/mL) was, then added at a concentration of 100 
μg/mL and samples were incubated at 57°C overnight, in order to ensure complete lysis 
and digestion. A phenol/chloroform extraction method was used to purify DNA from 
lysates. An equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added, 
mixed by inversion and centrifuged at 16000 × g for 5 minutes at room temperature. The 
upper aqueous phase was collected and subjected to a repeat treatment with 
phenol:chloroform:isoamyl alcohol. To remove residual phenol, the 2
nd
 aqueous phase 
collection was mixed with an equal volume of chloroform:isoamyl alcohol (24:1) and 
centrifuged at 16000 × g for 5 minutes at room temperature. DNA was precipitated by 
adding 0.2× volume 10M ammonium acetate and twice the volume ice-cold absolute 
ethanol, and incubating samples at -20ºC for 1-2 hours. The solution was centrifuged at 
12000 × g for 10 minutes at 4°C. The supernatant was carefully discarded and the pellet 
washed with 300 μL 70% (v/v) ethanol before centrifugation at 16000 × g for 5 minutes. 
Ethanol was removed from the pellet, which was then air-dried for approximately 5 
minutes before resuspension in 500 μL 10mM Tris, 1 mM EDTA, pH 8. DNA 
concentration determined using a Nanodrop
®
 spectrophotometer (Thermo Scientific), 
prior to sample dilution in preparation for quantitative PCR analysis. 
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2.6.2. Extraction of RNA and cDNA Synthesis 
To measure the levels of vector mRNA transcripts, total RNA was extracted from snap-
frozen liver specimens for cDNA synthesis. Approximately 50 mg of tissue was 
macerated and homogenised in 1 mL of TRIzol reagent (Life Technologies). After mixing 
by inversion, samples were incubated for 5 minutes at room temperature, followed by 
addition of 200 µl of chloroform and incubation at room temperature for 2 minutes. The 
sample was then placed in phase lock tubes (5 prime GmbH, Germany) and centrifuged at 
12000 × g at 4ºC for 15 minutes to isolate the clear aqueous phase. The RNA was 
precipitated by adding 500 µL isopropanol, incubated at room temperature for 10 
minutes, and pelleted by centrifuging at 12000 × g at 4ºC for 15 minutes. The pellet was 
then washed in 1 mL 75% (v/v) ethanol, before a final centrifugation at 7600 × g at 4ºC 
for 5 minutes. After air drying, the pellet was resuspended in UltraPure DNase / RNase 
free water (Invitrogen). Resuspension of RNA in nuclease-free water was aided by 
heating to 55-60°C for 10 minutes, prior to determining the RNA concentration using a 
Nanodrop
®
 spectrophotometer (Thermo Scientific). All RNA samples were stored at 
minus 80ºC until ready for cDNA synthesis.  
Prior to cDNA synthesis, extracted liver RNA samples were first treated using 
amplification grade DNase I kit (Invitrogen), according to the manufacturer‟s 
instructions. Briefly, approximately 1.25 µg RNA was treated with 1 unit of DNase I in 
reaction buffer containing 20 mM Tris-HCl (pH 8.4), 2 mM MgCl2, and 50 mM KCl for 
15 minutes at room temperature. To avoid Mg
2+
 dependent hydrolysis of the RNA, EDTA 
was added to a final concentration of 2.3 mM, prior to inactivating the DNase I by heating 
to 65°C for 10 minutes. Complementary DNA (cDNA) was synthesised using the 
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SuperScript
®
 III First-Strand Synthesis SuperMix reverse transcriptase kit (Invitrogen), 
according to the manufacturer‟s instructions. 
2.6.3. Analysis of Vector Genome and mRNA Copies by Quantitative PCR 
Vector genomes or mRNA copies were detected by quantitative real-time PCR analysis 
was performed on extracted DNA or cDNA synthesised from extracted murine liver RNA 
specimens, respectively (Section 2.6.1 & 2.6.2). Primers to detect rAAV2/8 vector 
genome copies or mRNA copies were directed towards the transgene, with the exception 
of rAAV2/8.pAM.eGFP, which was detected using a primer-probe set directed towards 
the WPRE (Table 2.7).  Standard curves for vector genome quantitation were generated 
using linearised pAAV2.hABCB4, pAAV2.pBsh.cohABCB4 or pAAV2.pBRsh.eGFP, 
depending on the transgene, to give a range between 10
3
 and 10
8
 vector genome copies. 
Amplification was performed using Quantitect SYBR Green Master mix (Qiagen) 
according to the manufacturer‟s instructions. Reaction mixes consisted of 12.5 μL  
QuantiTect
®
 Sybr
®
 Green 2× Master mix (Qiagen), 0.5 μM forward primer, 0.5 μM 
reverse prime, sample (150 – 250 ng DNA or 1 µL synthesised cDNA) and nuclease-free 
H2O to 25 μL. Reactions were carried out in a Rotor-Gene 6000 thermal cycler (Corbett 
Life Sciences) as follows: DNA was denatured for 15 minutes at 95ºC, followed by 40 
cycles of 95ºC for 30 seconds, annealing for 30 seconds at temperatures as specified 
according to primer set used  (Table 2.7), and 72ºC for 1 minute. Quantitative data was 
acquired during the extension phase of each cycle at 72ºC. Melt curves (60-99ºC) were 
determined at the completion of the reaction to ensure a single PCR product was 
amplified and analysed. 
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2.6.3.1. Normalisation and calculation of vector DNA copy numbers 
Normalisation of vector genome qPCR was performed by amplifying signals to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Each reactions for the detection of 
mouse GAPDH contained 12.5 µL QuantiTect® Sybr® Green 2× master mix (Qiagen), 0.5 
μM GAPDH1, 0.5 μM GAPDH2, 5 µL sample (150 – 250 ng DNA) or standard, and 
made up to 25 μL with nuclease-free water (Table 2.7). Standard curves were generated 
using serial dilutions of linearised plasmid containing GAPDH coding sequence, to give a 
range between 10
3
 and 10
8
 GAPDH copies.  Reaction conditions were: 95ºC 15 minutes 
followed by 40 cycles of 95ºC 15 seconds, 60ºC 30 seconds, 72ºC 30 seconds. 
Quantitative data was acquired during the extension phase of each cycle at 72ºC. 
Vector copy numbers, normalised against GAPDH copies, were expressed per diploid 
genome equivalent, based on the estimation that each diploid genome consist of 
approximately 6 pg genomic DNA.
368
 
2.6.3.2. Normalisation and calculation of vector mRNA copy numbers 
Normalisation of mRNA transcript quantitation using 2-step qRT-PCR was performed by 
amplifying signals to murine β-actin coding sequence. Reactions for the detection of 
murine β-actin contained QuantiTect® Sybr® Green 2× master mix (Qiagen), 0.5 μM 
D278 B-actin, 0.5 μM D279 B-actin, 1 µL synthesised cDNA sample made up to 25 μL 
with nuclease-free water (Table 2.7). Reactions were carried out in a Rotor-Gene 6000 
thermal cycler: 95ºC 15 minutes followed by 40 cycles of 95ºC 15 seconds, 59ºC 30 
seconds, 72ºC 30 seconds. Quantitative data was acquired during the extension phase of 
each cycle at 72ºC.  
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Reactions for quantitating vector mRNA transcript copies and β-actin copies for 
individual mouse samples were carried out in the same PCR run, where possible. Relative 
mRNA transcript copy numbers were determined using delta-delta CT analyses 
normalised against β-actin copies (Software: Rotor-Gene 6000 real-time rotary analyser, 
version 1.7, Corbett Research, USA). cDNA synthesised using liver RNA template 
extracted from an untransduced heterozygous adult male sample was used as the 
calibrator for all qRT-PCR reactions.   
 
2.6.4.  Protein Analyses from Murine Liver Tissue 
2.6.4.1. Extraction of protein from liver samples 
Crude protein lysates were used to measure the amount of eGFP flurorescence emission 
from transduced livers. Snap frozen livers were thawed and homogenised in 1 mL lysis 
buffer: 0.5% (v/v) Triton X-100, 10 mM HEPES, protease inhibitor cocktail (cOmplete 
EDTA-free protease inhibitor cocktail, Roche), and made up to 50 mL with mQwater. 
Homogenates were incubated on ice for 1 hour. The supernatant was then isolated after 
centrifugation to 16000 × g at 4ºC for 20 minutes. Supernatants were stored at -20ºC for 
later protein estimation and flurometric analyses (Sections 2.6.4.2 & 2.6.4.3).   
2.6.4.2. Protein estimation 
Total protein extracted from liver homogenates was quantified by colorimetric assay 
using RC DC™ Protein Assay Kit (BioRad), according to the manufacturer‟s instructions. 
Standards made with serial dilutions of known quantities of bovine serum albumin were 
run alongside samples to determine the concentration of protein in each sample.  
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2.6.4.3. eGFP flurometry of liver lysates 
Fluorescence emission from 50 mg of liver protein extracted from individual murine 
livers was measured in triplicate with a VICTOR
3
 multi-label reader, using an excitation 
and emission filters set at 485 nm and 535 nm, respectively. The amount of fluorescence 
detected was calculated based on a standard curve prepared by serial dilutions of known 
quantities of recombinant GFP (BioVision Research Products, USA) and expressed as µg 
eGFP per mg liver protein. 
2.6.5. Analysis of Plasma Samples 
Plasma samples were thawed for biochemical analyses of plasma alanine 
aminotransferase (ALT), alkaline phosphatase (ALP) and bile acids concentrations, which 
were performed in Department of Biochemistry, The Children‟s Hospital at Westmead, 
using a Vitros Chemistry Analyzer (Ortho Clinical Diagnostics, USA).  
2.6.6. Bile Composition Analyses 
2.6.6.1. Measurement of phosphatidylcholine concentration by enzymatic cycling method 
Phosphatidylcholine concentration was quantified using the EnzyChrom Phospholipid 
Assay kit (Bioassay Systems, USA). Though this assay applies to measurement of serum 
samples, similar approaches have also been applied to quantifying phospholipid in 
bile.
369,370
 In this assay, choline is cleaved from phospholipids by phospholipase D. Then, 
choline undergoes oxidation by choline oxidase to produce hydrogen peroxide (H2O2), 
which is needed for the conversion of phenol to a quinone chromophore by peroxidase. 
The optical density of the dye product at 570 nm is directly proportional to the choline-
containing phospholipid concentration in the sample.  
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Samples are measured against standards diluted from supplied 2 mM acetylcholine. Bile 
specimens were diluted 100-fold in 0.5% (v/v) Triton X-100 for detection within the 
recommended range of sensitivity (3-200 µM). The assay was performed according to the 
manufacturer‟s instructions. Briefly, 20 µL of prepared standards or diluted samples were 
transferred to separate wells of a clear, flat bottomed 96-well plate. The working reagent 
mix was prepared with 85 µL of supplied assay buffer, 1 µL of enzyme mix, 1 µL of PLD 
enzyme, and 1 µL of dye reagent per standard or sample. 80 µL of working reagent was 
mixed with each standard or sample in the 96-well plate, and incubated at room 
temperature for 30 minutes. The optical density of each well was read at 570 nm using a 
spectrophotometric platereader (VersaMax Tunable Microplate Reader, Molecular 
Devices) Sample phosphatidylcholine concentrations were calculated based on linear 
calibration curves prepared using measured standards, and multiplied by the dilution 
factor, × 100. 
2.6.6.2. Total bile acid analysis by colormetric enzymatic cycling assay 
Total bile acids were quantified using a colormetric assay based on an enzymatic cycling 
method (Diazyme Laboratories, USA) This assay is typically applied to measurement of 
serum samples, but similar approaches have also been used to quantifying biliary bile 
acids.
371
 This enzymatic cycling method is based on oxidation-reduction reactions. In the 
presence of Thio-NAD, 3-α-hydroxysteroid dehydrogenase (3-α-HSD) catalyses the 
conversion of bile acids to 3-keto steroids, and Thio-NAD is reduced to Thio-NADH. 
This reaction is reversible and efficient, such that in the presence of excess Thio-NAD, 
the rate of Thio-NADH formation is directly proportional to total bile acids in the sample. 
Thio-NADH formation is calculated by measuring the change in absorbance at 405 nm 
over 1 minute.  
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Samples are measured against a 50 µM bile acid standard supplied. Bile specimens were 
diluted 200-fold in 0.9% (w/v) NaCl for detection within the recommended range of 
sensitivity (1-180 µmol/L). The assay was performed according to the manufacturer‟s 
instructions. Briefly, 4 µL of water, standard or diluted samples is added 270 µL of R1 
buffer containing Thio-NAD (>1.0 mM) in separate wells of a clear, flat bottomed 96-
well plate. The plate is incubated at 37°C for 3 minutes, at which point a absorbance at 
405 nm is blanked. 90 µL of R2 buffer, containing 3-α-HSD (>2 kU/L) and >0.1 mM 
Thio-NADH, is then transferred to each well and optical density measurement at 405 nm 
is acquired at 1 and 2 minutes at 37°C using a spectrophotometric platereader (VersaMax 
Tunable Microplate Reader, Molecular Devices). Total bile acid concentrations in each 
sample was calculated based on change in absorbance at 405 nm at 1 and 2 minutes, 
compared against that of the 50 µm standard, and multiplied by the dilution factor, × 200.   
2.6.6.3. Measurement of cholesterol concentration by colormetric assay 
Biliary Cholesterol concentration was quantified using the EnzyChrom Cholesterol Assay 
kit (Bioassay Systems, USA). This assay is based on hydrolysis of cholesterol esters to 
free cholesterol by cholesterol esterase. The conversion of free cholesterol to cholest-4-
ene-3-one by cholesterol dehydrogenase, results in reduction of NAD to NADH. 
Formation of NADH, which is directly proportional to cholesterol concentration in the 
sample, is measured by absorbance at 340 nm using a spectrophotometric platereader 
(VersaMax Tunable Microplate Reader, Molecular Devices).  
Samples are measured against standards diluted from supplied 300 mg/dL cholesterol. 
Bile specimens were diluted 10-fold in water. The limits of detection of this assay are 
between 5 and 300 mg/dL. The assay was performed according to the manufacturer‟s 
instructions. Briefly, samples were further diluted 10-fold with supplied assay buffer, and 
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50 µL of prepared diluted samples and standards were transferred to separate wells of a 
clear, flat bottomed 96-well plate. The working reagent mix was prepared with 40 µL of 
supplied assay buffer and 18 µL of supplied NAD solution per standard or sample. 50 µL 
of working reagent was mixed with each standard or sample in the 96-well plate, and 
incubated at room temperature for 5 minutes. The background optical density of each well 
was read at 340 nm. 10 µL of enzyme containing solution, prepared by adding 1 µL of 
supplied enzyme mix to 10 µL of supplied assay buffer per reaction, was added to each 
well. The reactions were incubated at room temperature for 30 minutes, and a 2
nd
 optical 
density measurement at 340 nm was acquired. Biliary cholesterol concentrations of 
samples were calculated based on linear calibration curves prepared using measured 
standards, and multiplied by the dilution factor, × 10. The units of measurement of 
cholesterol concentration, mg/dL, was converted to µM by multiplying by a factor of 
25.86. 
2.6.7. Immunohistochemistry, Histology and Microscopy 
2.6.7.1. Tissue fixation 
Liver samples, harvested from euthanised mice were reserved for histology and 
immunohistochemical analyses. Liver tissue to be paraffin-embedded was fixed in 10% 
(v/v) neutral-buffered formalin. After fixation for 48-72 hours, tissue was transferred to 70% 
(v/v) ethanol and stored in cassettes until processing for paraffin embedding and sectioning. 
Embedding and sectioning procedures were performed by Virginia James, senior histologist 
from the Westmead Millennium Institute.  
Liver tissue for immunofluorescence was immediately placed into 4% (w/v) 
paraformaldehyde. After fixation at room temperature for 4 hours or overnight at 4ºC, the 
tissue was transferred and incubated for 4 hours into each of 10% and 20% (w/v) sucrose 
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solutions at room temperature, followed by an overnight incubation in 30% (w/v) sucrose 
at 4ºC. Samples were then embedded in plastic moulds filled with Tissue-Tek
®
 Optimal 
Cutting Temperature (OCT) compound (Sakura Finetek, Japan), frozen by immersion in 
2-methylbutane cooled using liquid nitrogen, and stored at -80ºC. 
2.6.7.2. Immunofluorescent GFP detection from frozen sections 
Frozen sections were used to assess the distribution of GFP protein across the liver lobule. 
Prior to sectioning, tissue blocks were incubated at -20°C in a Leica CM 1900 cryostat for 
60 minutes. Sections of 5 μm thickness were cut and mounted onto electrostatically- 
charged slides. Frozen sections for GFP analysis were counterstained with glutamine 
synthetase (GS) antibody to mark pericentral hepatocytes for orientation of the structures 
of the hepatic lobule and 4',6-diamidino-2-phenylindole (DAPI) (Section 2.6.7.3), before 
being coverslipped for viewing on a Olympus BX-51 TRF microscope (Olympus Optical 
Co. Ltd, Japan). Images were captured with a SPOT camera using SPOT software version 
4.01 (Diagnostic Instruments, Sterling Heights, USA). 
2.6.7.3. Antibody staining of cryosections for immunofluorescence 
For orientation of the liver lobule with respect to the porto-central axes, GS antibody was 
used to mark the pericentral hepatocytes. For liver sections from GFP-transduced animals, 
immunofluorescence was performed with due care to minimise exposure to light. Five m 
frozen sections mounted onto electrostatically-charged slides (Superfrost Plus, Menzel-
Glaser) in Coplin staining jar, were rehydrated in room temperature Phosphate buffered 
saline without added Ca
2+
 or Mg
2+
 ions (PBS
-/-
) for 10 minutes. Tissue sections were then 
permeabilised in cold methanol (stored at -20C) and incubated on ice for 15 minutes. 
Slides were washed once in PBS
-/-
 and then twice in PBS
-/-
 with 2% (v/v) FCS, each for 5 
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minutes. Blocking buffer, consisting of 10% (v/v) horse or goat serum (depending on the 
secondary antibody) and PBS
-/-
, was applied onto slides to completely cover each tissue 
section, and incubated for 1 hour at room temperature. Following removal of the blocking 
buffer, a rabbit polyclonal anti-glutamine synthetase IgG was applied to sections at a 
dilution of 1:200 with blocking buffer for 1 hour at room temperature. To examine for 
non-specific, background staining, the primary antibody was not applied to 1 section from 
each mouse sample, which was instead covered with blocking buffer during this 1 hour 
incubation.  Then, slides were washed thrice in PBS
-/-
 containing 0.1% (v/v) Tween 20 
(PBST) for 5 minutes per wash. An Alexa Fluor
®
 594 donkey anti-rabbit IgG (Invitrogen) 
diluted 1:800 in PBST in was applied to completely cover all sections and incubated for 1 
hour at room temperature. Following removal of the secondary antibody diluents, slides 
were washed once in PBST, and then in PBS
-/-
 with the addition of DAPI at a dilution of 
1:5000, for 5 minutes each. The slides were finally washed in PBS
-/-
, prior to mounting 
and coverslipping using Immu-mount (Thermo Scientific) and glass covers (HD 
Scientific Supplies Pty Ltd). 
To detect vector-derived MDR3 protein expression in Abcb4
-/-
 frozen liver sections, a 
mouse monoclonal IgG2b anti-human MDR3 primary antibody (P3II-26, LifeSpan 
Biosciences, Inc., USA) and an isotype-specific goat anti-mouse IgG2b FITC-conjugate 
(Southern Biotechnology, USA) were used. A mouse-on-mouse blocking kit was 
employed to reduce non-specific background marking of murine liver tissue sections 
(Vector
®
 M.O.M. Immunodetection kit, Vector Laboratories, USA).  
Five m frozen sections mounted onto electrostatically-charged slides (Superfrost Plus, 
Menzel-Glaser) in Coplin staining jar, were rehydrated in room temperature PBS
-/-
 for 15 
minutes. Tissue sections were then permeabilised in cold acetone (stored at -20C) and 
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incubated on ice for 15 minutes. Slides were washed twice in PBS
-/-
 for 2 minutes and 
then blocked with 10% (v/v) goat serum in PBS
-/-
 for 1 hour at room temperature. After 
removing the blocking buffer, sections were covered with M.O.M Ig blocking reagent, 
prepared by dilution of 5 drops (approximately 225 µL) of M.O.M Ig blocking reagent 
stock solution in 2.5mL PBS
-/-
, and incubated overnight at 4°C and 30 minutes at room 
temperature. Slides were washed twice in PBS
-/-
 for 2 minutes, prior to incubation with 
M.O.M diluent, prepared by the addition of 600 µL M.O.M. protein concentrate to 7.5 
mL PBS
-/-
 for 5 minutes. Sections were then covered with P3II-26 mouse monoclonal 
anti-human MDR3 antibody, diluted 1:20 with M.O.M. diluent, and incubated at room 
temperature for 1 hour. Slides were again washed twice in PBS
-/-
 for 2 minutes, prior to 
incubation with FITC-conjugated isotype-specific goat anti-mouse IgG2b secondary 
antibody at a dilution of 1:50 with M.O.M.diluent for 1 hour at room temperature. 
Following removal of the secondary antibody diluents, slides were washed once in PBST, 
and then in PBS
-/-
 with the addition of 4',6-diamidino-2-phenylindole (DAPI) at a dilution 
of 1:5000, for 5 minutes each. The slides were finally washed in PBS
-/-
, prior to mounting 
and coverslipping using Immu-mount (Thermo Scientific) and glass covers (HD 
Scientific Supplies Pty Ltd).  
2.6.7.4. Antibody staining of paraffin-embedded sections for immunohistochemistry 
To detect vector-derived MDR3 protein expression in Abcb4
-/-
 paraffin-embedded liver 
sections, a rabbit polyclonal IgG anti-human MDR3 primary antibody (ab71792, Abcam, 
USA) Paraffin sections were rehydrated in xylene and an ethanol gradient prior to an 
antigen retrieval step in which slides were boiled in a microwave oven with sodium 
citrate buffer (10 mM Tri-sodium citrate, 0.05% v/v Tween 20, pH 6.0) for a total 9 
minutes. The slides were cooled and washed in water, and then blocked with 2% (v/v) 
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hydrogen peroxide in methanol for 15 minutes. Slides were then washed in PBS
-/-
 before 
avidin & biotin blocking (Vector Laboratories, CA, USA). After rinsing with PBS
-/-
, 
slides were blocked with 10% (v/v) donkey serum in PBS
-/-
 for 1 hour. Sections were 
incubated with rabbit anti-human MDR3 antibody (Abcam) at a dilution of 1:200 in 10% 
(v/v) donkey serum in PBS
-/-
 overnight at 4°C. After washing in PBST, slides were 
incubated for 1 hour at room temperature with biotinylated donkey anti-rabbit IgG 
antibody (Jackson Immunoresearch) at a dilution of 1:600. This was then washed thrice 
with PBST for 5 minutes each, and incubated with Vectastain
®
 Elite ABC reagent (Vector 
Laboratories) for 30 minutes. After washing in PBS, the slides were developed using 3,3‟-
Diaminobenzidine liquid substrate (Sigma-Aldrich), briefly counterstained with 
haemotoxylin (Vector Laboratories), and dehydrated in an ethanol gradient and histolene. 
The slides were mounted with Ultramount (Fronine) and coverslipped for viewing on a 
Zeiss Axioimager microscope (Carl Zeiss MicroImaging GmbH, Germany). Images were 
captured using a SPOT Insight camera and SPOT software version 4.01 (Diagnostic 
Instruments, Sterling Heights, MI). 
2.6.7.5. Histological staining and Microscopy 
To examine liver tissue samples for the development of histopathological abnormalities, 
formalin-fixed, paraffin-embedded liver samples were sectioned and stained with 
haemotoxylin & eosin (H & E) and Sirius Red, and examined using a light microscope 
(Zeiss Axio Imager A1, Carl Zeiss MicroImaging GmbH, Germany). Sirius Red/Fast Green 
staining allows histological assessment of collagen deposition in fibrotic tissue. Sirius red 
is a strong anionic dye that binds to fibrillar collagens, which are commonly found in 
fibrotic liver tissue.
372
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2.7. STATISTICAL ANALYSIS 
The statistical analyses of data from animal studies were performed using GraphPad 
Prism 6, version 6.04 (GraphPad Software Inc.). Values were then expressed as means ± 
standard error of the mean (SEM), unless otherwise stated. Statistical significance between 2 
groups was determined using unpaired Student‟s t-tests. Comparisons between more than 2 
groups were analysed using one-way analysis of variance. These parametric analyses assume 
often unproven normal distribution. Although most comparisons involved biological 
parameters (e.g. biliary phosphatidylcholine concentrations) that are likely to be normally 
distributed, these have not been formally tested. Whilst non-parametric tests may be more 
robust, they are heavily impacted by small sample sizes, and may not show statistical 
significance where clear biological significance can be demonstrated. Statistical significance 
was interpreted as p ≤ 0.05. 
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CHAPTER 3: DEVELOPMENT OF RECOMBINANT AAV 
VECTORS ENCODING HUMAN ABCB4 
 
3.1. INTRODUCTION 
As outlined in Chapter 1, rAAV-mediated liver-directed gene replacement therapy has the 
potential to offer patients with PFIC3 an alternative treatment to liver transplantation. 
This chapter details the development of rAAV vectors encoding a human ABCB4 cDNA 
to treat PFIC3, and addresses issues of vector optimisation to achieve efficient vector 
delivery and transgene expression in vivo, utilising the Abcb4-knockout mouse model. 
3.1.1. Rationale for rAAV Vector Design for PFIC3 application 
Recombinant adeno-associated viral (rAAV) vectors show exceptional promise as a 
vehicle for therapeutic gene transfer to the liver with proven success demonstrated in a 
number of small and large animal models (Table 1.1). Additionally, early evidence of 
therapeutic efficacy has recently been reported in human patients in 2 clinical trials for 
haemophilia B.
43,44
  Recombinant AAV is currently considered a prime candidate for 
clinical application towards diseases involving the liver.
360
 This is attributable to its 
favourable safety profile, non-pathogenic nature, low immunogenicity compared with 
other vectors such as adenovirus, high natural tropism of some serotypes for the liver, 
stable long-term transgene expression in post-mitotic hepatocytes, and recent advances in 
rAAV gene transfer technology including engineered AAV capsids to improve 
transduction of specific targets. Thus, rAAV is the vector of choice for development of a 
PFIC3 application described herein. 
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An additional reason for choosing rAAV as a gene therapy vector for PFIC3 is that, 
unlike HIV-based lentiviral vectors, it is not enveloped in a lipid membrane. An attempt 
to develop a lentiviral gene therapy model for PFIC3 proved ultimately unsuccessful due 
to an inability to produce an effective vector of sufficiently high titre. Reduced vector 
infectivity and low vector titres were attributed to expressed ABCB4 mediating alteration 
in the lipid composition of lentiviral particle envelopes.
373
  
One of rAAV‟s key attributes is the ability to package the therapeutic transgene cassette 
into different AAV capsids, in order to exploit distinct transduction profiles, and to evade 
the host immune system in the presence of pre-existing neutralising antibodies to specific 
capsids.
374,375
 The unique configuration of each capsid primarily affects cell surface 
receptor binding affinity, internalisation and post-entry processing, thus influencing 
vector transduction efficiency of specific cellular targets.
143
 This not only dictates tropism 
in a cell-type specific manner, but is species-dependent as well.
143,183
 The serotype 8 
capsid has particularly high liver tropism, facilitating transduction of the majority of 
hepatocytes with long-term persistence of transgene expression in adult mouse liver using 
relatively modest vector doses delivered by intra-peritoneal injection.
181,182
 Additionally, 
serotype 8 capsid is known to transduce antigen presenting cells poorly, and therefore, 
vectors packaged in capsid 8 may avoid potentially deleterious immune responses against 
the encoded transgene product.
203
  Therefore, each vector described in this chapter was 
packaged in the serotype 8 capsid for in vivo functional validation in the mouse liver. For 
work described in Chapter 5 (Section 5.3.2), the ABCB4 transgene cassette was also 
packaged in another highly liver tropic capsid, rh10.
155
 This was to avoid potential pre-
existing capsid antibodies blocking vector re-administration with capsid 8 vector. 
Antibodies against capsid 8 have limited cross-reactivity with rh10 in mice.
362
 
Furthermore, rh10-encapsidated vector was reported to enable higher transgene 
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expression than that packaged in serotype 8 in neonatal mouse liver.
376
 Thus, the rh10 
capsid was chosen for vector delivery to neonatal mice in experiments described in 
Chapter 5. 
The absence of hepatocanalicular phospholipid floppases, ABCB4 in humans (also known 
as MDR3) and Abcb4 in mice (also known as mdr2), completely abrogates biliary 
phospholipid secretion.
290,297
 Transgenic expression of human ABCB4 (hABCB4) in 
Abcb4-knockout mice restored phospholipid secretion in bile, indicating that these genes 
are orthologs.
342
 In these transgenic Abcb4
-/- 
mice, complete restoration of biliary 
phospholipid secretion to wild-type levels prevented development of liver pathology seen 
in non-transgenic homozygotes. Furthermore, similar amounts of human ABCB4 protein 
were detected in transgenic mice compared with murine Abcb4 protein in wild-type mice 
on Western-blot analysis, indicating that human and murine phospholipid floppases have 
functionally homologous activity in the ABCB4-knockout mouse model.
342
 Given their 
functional similarity, a human ABCB4 cDNA of transcript variant B (GenBank Acc No 
BC042531) was sub-cloned into the therapeutic transgene expression cassettes for in vivo 
functional validation in the ABCB4-knockout mouse model.     
Regulation of vector-derived transgene expression is largely uncoupled from endogenous 
regulation. Factors that influence transcription and translation of rAAV-encoded 
transgenes include the choice of heterologous promoter and inclusion of sequences that 
affect mRNA processing such as the Woodchuck hepatitis Post-transcriptional Regulatory 
Element (WPRE) and Kozak consensus sequence.  
A strong, hepatocyte-specific transcriptional control unit (LP1), containing elements from 
the human apolipoprotein hepatocyte control region (Genbank Acc No U32510), and a 
human alpha-1 antitrypsin promoter including the 5‟ untranslated region was selected to 
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confer robust hepatocyte-specific hABCB4 expression in our therapeutic rAAV vectors. 
This promoter/enhancer combination has been used to mediate expression of human 
Factor IX in the liver with long-term therapeutic efficacy demonstrated in haemophilia B 
mouse
157
, sheep
377
 and non-human primate
378
 models, and importantly, in human subjects 
participating in the haemophilia B clinical trials.
43,44
  
An added benefit of using a hepatocyte-specific transcriptional control unit to regulate 
hABCB4 expression is to limit off-target effects such as avoiding expression in antigen 
presenting cells that may give rise to immune responses against the transgene 
product.
379,380
 Transgenic mice with a human ABCB4 mini-gene expressed under the 
control of a vimentin promoter, which directs expression in mesenchymal tissue including 
Schwann cells and ocular lens, resulted in severe peripheral neuropathy, hind-leg 
paralysis and cataracts.
324,325
 These examples further advocate the use of hepatocyte-
specific promoters, since ectopic ABCB4 expression in non-hepatic tissues could have 
significant adverse consequences. 
The WPRE effectively enhances transgene expression in a variety of vector systems 
through several described mechanisms including improved mRNA termination and 
increased nuclear export of transcripts.
381-384
  However, safety concerns have been raised 
regarding the potential oncogenic activity of an internal X-protein sequence and its 
promoter, We1, known to play pivot roles in the development of liver cancers associated 
with hepatitis B infection.
382,385
 Due to these concerns, as well as packaging constraints 
(see below), the WPRE sequence was excluded from the therapeutic hABCB4 expression 
cassette. 
In order to facilitate efficient initiation of translation, an optimised Kozak consensus 
sequence was incorporated upstream of the start codon of hABCB4 cDNA in the 
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therapeutic rAAV vector. Identified as a conserved sequence in vertebrate mRNAs, this 
5‟ non-coding region is recognised by ribosomes, and plays an important role in efficient 
initiation of translation.
386
 A Kozak sequence or variant has also been incorporated into 
several gene therapy vectors to improve protein expression.
53,387,388
 
Another important consideration in our vector design is the imposed packaging 
constraints of rAAV vectors. The encoded hABCB4 coding sequence described in this 
chapter is 3861 bp in length. Wild-type AAV has a single stranded genome of 4675 bp.
389
 
Exceeding the packaging capacity of rAAV vectors much beyond wild-type size (>5-5.3 
kb) detrimentally reduces packaging efficiency of full-length proviral cassettes, at least 
10-fold.
163
 Over-sized vectors suffer from significantly reduced transduction efficiency, 
are more likely to contain large proviral truncations, lose one or more inverted terminal 
repeats (ITR) sequences, and may be preferentially degraded by proteasomes.
161-164
 
Homologous recombination of truncated sequence with overlapping ends or non-
homologous end-joining have been implicated in the generation of oversized full-length 
transcripts, permitting some meaningful transgene expression.
162-164
  However, this is a 
relatively inefficient process and the low level of recombination sufficient to produce 
transgene expression for phenotype correction may only be limited to a few 
applications.
165
 The degree to which full-length AAV genomes can be reconstituted is 
also dependent on the transduced cells or tissue. For example, Dong et al., reported a 
dramatic reduction in the number of recovered genomes with large deletions and 
increased number of full-length (>5.4 kb) AAV genomes when vector was delivered to 
murine muscle in vivo compared with transduction of HEK 293 cells in vitro.
163
 
(Strategies to expand rAAV packaging capacity are outlined in Chapter 1)  
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Nevertheless, developing rAAV vectors within the packaging capacity is preferable, but 
could limit potential applications involving large transgenes. In order to accommodate the 
large 3.9 kb hABCB4 coding sequence within these constraints, rational selection of 
transcriptional control elements was necessary with an anticipated trade-off between 
potentially higher transgene expression mediated by stronger promoters and enhancers, 
and reduced transduction efficiency of over-sized vectors described above.  
This chapter describes the construction and functional validation of rAAV2/8 vectors 
encoding human ABCB4 cDNA under the transcriptional control of a hepatocyte specific 
promoter/enhancer unit, and outlines challenges in developing an effective gene therapy 
vector to treat PFIC type 3.  
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3.2. MATERIAL AND METHODS 
 
3.2.1.  Construction of a rAAV Vector Encoding hABCB4 
The plasmids used for construction of the rAAV vector plasmids containing a human 
ABCB4 cDNA are listed in Table 2.5. A vector plasmid encoding a human ABCB4 
transgene was generated from the pAm.EF1α.eGFP plasmid, previously constructed in 
our laboratory (Figure 3.1). In order to accommodate the large human ABCB4 cDNA 
sequence (3861 bp) with rAAV proviral construct, the WPRE sequence was excised by 
digestion of the pAm AAV2 vector at flanking ClaI sites. The plasmid backbone was 
then, gel purified, and cohesive ends were re-ligated using T4 DNA ligase (Section 2.2.5).  
The recipient pAm construct was further prepared by removing the EF1α and eGFP 
sequence with restriction enzyme digestion using KpnI and HindIII and the cohesive ends 
were dephosphorylated using Antarctic Phosphatase (Section 2.2.6). A liver-specific 
transcriptional control unit, LP1 (447 bp) described above, was amplified from 
ssAAV.LP1.hFIXco
157
 using PfuUltra Hotstart DNA polymerase (Life Technologies). 
The forward primer (LP1-F) included a KpnI and MluI sites, followed by LP1 sequence. 
The reverse primer (LP1-R) contained HindIII and XbaI sites followed by reverse 
complement sequence for LP1 (Table 2.6). The PCR product was then inserted by TA 
cloning into pGEM
®
-T Easy cloning vector (Section 2.2.8). To remove the LP1 
transcriptional control unit from pGEM
®
-T Easy, the plasmid was digested using KpnI 
and HindIII. This fragment was then ligated into the prepared recipient pAm vector 
backbone using T4 DNA ligase. 
A hABCB4 cDNA (Genbank Acc. No. NM_018849.2) was amplified by PCR using 
PfuUltra Hotstart DNA polymerase, from a pBluescript R plasmid containing the above 
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cDNA sequence. The plasmid was purified from a bacterial clone obtained from the 
Mammalian Gene Collection through Thermo Fisher Scientific.
390
 The PCR product was 
amplified using primers ABCB4-F and ABCB4-R2 (Table 2.6). The forward primer 
included an XbaI site and Kozak consensus sequence followed by coding sequence for 
hABCB4 including the start codon. The reverse primer contained a HindIII site, followed 
by reverse complement sequence of hABCB4. This PCR product was inserted by TA 
cloning into pGEM
®
-T Easy cloning plasmid, excised using XbaI and HindIII digests, 
purified by gel extraction, and inserted into the paired restriction enzyme sites 
downstream of LP1 in the recipient pAm vector. Chemically competent E. coli (JM109, 
Promega) were transformed with the resulting vector plasmid construct, designated 
pAAV2.LP1.hABCB4v1, using the heat shock method and according to the 
manufacturer‟s instructions (Section 2.2.9). Plasmid DNA was purified using commercial 
kits, according to the manufacturer‟s instructions, and verified using restriction enzyme 
mapping and sequencing (Sections 2.2.2 & 2.2.10). pAAV2.LP1.hABCB4 v1 contained 
an AAV expression cassette of 5103 bp in length, including flanking AAV2 ITRs (Figure 
3.3). For further details regarding bacterial propagation refer to Section 3.3.1 
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Figure 3.1: Flow diagram of molecular sub-cloning step taken to generate 
pAAV2.LP1.hABCB4 v1 from pAAV2.EF1a.eGFP. Detailed explanations of sub-
cloning steps are described in Section 3.2.1. The expression cassettes are flanked by AAV 
ITRs (black boxes). PCR fragments are flanked by restriction enzyme sites as marked. 
Other DNA components shown are elongation factor 1α promoter, EF1α (dark grey 
boxes, as marked), liver specific promoter/enhancer, LP1 (dark grey boxes as marked), 
human ABCB4 cDNA, hABCB4 (white boxes), woodchuck hepatitis post-transcriptional 
element, WPRE (light grey box, as marked), bovine growth hormone polyA (light grey 
boxes). Restriction enzyme digest sites are abbreviated as the following: ClaI, C; HindIII, 
H; KpnI, K; MluI, M; XbaI, X. Scale bar = 300 bp. 
 
3.2.2. Vector Redesign 
To improve transduction efficiency, the rAAV vector encoding hABCB4 was 
reconstructed, in order to reduce the expression cassette size closer to that of the wild-
type AAV (wtAAV) genome (4.7 kb).
389
 To examine the effect of vector size on 
transduction efficiency in vivo, 3 additional expression cassettes of varying size, encoding 
hABCB4 were engineered (Figure 3.2 & 3.3). Each vector construct was verified by 
restriction site mapping and Sanger sequencing. 
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Figure 3.2: Flow diagram of molecular sub-cloning step taken to generate three 
additional expression cassettes encoding human ABCB4 transgene. Detailed 
explanations of sub-cloning steps are described in Section 3.2.2. The expression cassettes 
are flanked by AAV ITRs (black boxes). PCR fragments are flanked by restriction 
enzyme sites as marked. Other DNA components shown are liver specific 
promoter/enhancer, LP1 (dark grey boxes), human ABCB4 cDNA, hABCB4 (white 
boxes), bovine growth hormone polyA (light grey boxes), and simian virus 40 polyA 
(striped boxes). Restriction enzyme digest sites are indicated by the following 
abbreviations: AgeI, A; EcoRV, E; HindIII, H; MluI, M; SacI, Sac; SnaBI, Sn; SpeI, S; 
XbaI, X. Scale bar = 300 bp. 
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3.2.2.1. pAAV2.LP1.hABCB4v2 (106% wtAAV) 
The plasmid construct designated pAAV2.LP1.hABCB4 v2 contained an expression 
cassette, which included flanking AAV ITRs, of approximately 106% wild-type AAV 
size (5004 bp). This was engineered by removing extraneous sequence at the 5‟ end of 
LP1 (27 bp) and the 3‟ end of hABCB4 (84 bp). Primers (Forward: LP1-F2, Reverse: 
LP1-R2) to amplify LP1 were re-designed to ensure that restriction enzyme sites 
necessary for further sub-cloning steps directly abutted the designated LP1 transcriptional 
control unit sequence (Table 2.6). The re-designed LP1 was PCR amplified from 
ssAAV.LP1.hFIXco using PfuUltra DNA polymerase, TA subcloned into a pGEM
®
- T 
easy cloning vector, propagated in competent E. coli (JM109, Promega) and digested at 
flanking MluI and XbaI sites. This fragment was then sub-cloned into the recipient 
hABCB4 v1 vector, which was prepared by digesting at corresponding sites with MluI 
and XbaI restriction endonucleases to remove the existing LP1 along with the 5‟ 
extraneous sequence. Similarly, superfluous sequence was removed from the 3‟ end of 
hABCB4 by sub-cloning a PCR amplified fragment from the 3‟ end of hABCB4 into a 
prepared hABCB4 v1 vector backbone with the substituted LP1 sequence. The PCR 
product was amplified from the 3‟ end of hABCB4 using primers hABCp2-F (forward) 
and hABCp2-R2 (reverse) (Table 2.6). The reverse primer (hABCp2-R2) contained a 
HindIII site directly adjacent to the reverse complement stop codon and 3‟ segment of 
hABCB4. Digesting the amplified PCR product at this HindIII site and a unique SacI site 
517 bp from the hABCB4 stop codon, produced a fragment with cohesive ends that was 
then ligated into corresponding sites in the prepared hABCB4 v1 vector backbone. 
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3.2.2.2. pAAV2.LP1.hABCB4v3 (103% wtAAV) 
The 103% wild-type AAV-sized vector (4851 bp), designated pAAV2.LP1.hABCB4v3, 
was produced by replacing the bovine growth hormone polyadenylation sequence 
(BGHpA, 261 bp) with a smaller Simian virus 40 polyA (SV40pA, 134 bp). The SV40pA 
sequence was amplified by PCR from plasmid ssAAV.LP1.hFIXco
157
 using primers 
SV40pA-F and SV40pA-R (Table 2.6). The PCR product contained a HindIII and ClaI 
sites at the 5‟ end and a MluI site at the 3‟ end. As there was no unique restriction 
endonuclease site between BGHpA and the 3‟ AAV ITR, the BGHpA sequence could not 
be easily excised and substituted with SV40pA. Therefore, the expression cassette 
including LP1, hABCB4 and BGHpA was excised at the SnaBI site located within the D 
regions of the 5‟ and 3‟ AAV ITRs. This was replaced with a PCR fragment amplified 
using primers LP1-F5 and LP1-R5 (Table 2.6). This PCR fragment contained the 
following from 5‟ to 3‟: SnaBI, excised 5‟ ITR sequence, EcoRV, SpeI, complete LP1 
sequence, XbaI, AgeI, excised 3‟ ITR sequence and a second SnaBI site.  
The hABCB4 cDNA with Kozak consensus sequence was excised from 
pAAV2.LP1.hABCB4v2 by digesting the plasmid at flanking XbaI and HindIII sites. The 
fragment was then separated from the backbone by agarose gel electrophoresis, extracted 
and purified from the gel, and inserted into a prepared plasmid construct with a multiple 
cloning region containing XbaI, HindIII, MluI and AgeI sites. In a similar manner, the 
SV40pA PCR fragment was digested at flanking HindIII and MluI sites and inserted into 
corresponding sites in this multiple cloning region, downstream of the inserted hABCB4 
cDNA. This sequence (containing hABCB4 cDNA and SV40pA) was then excised at 
XbaI and AgeI sites and inserted into the prepared AAV backbone described above 
downstream of LP1. 
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3.2.2.3. pAAV2.LP1.hABCB4v2 –prom (97% wtAAV) 
Previous studies have demonstrated that the AAV ITR has low, but measurable 
transcriptional regulatory activity in brain and airway epithelia.
391,392
 However, its 
transcriptional activity in hepatocytes in vivo is currently unknown. If sufficient gene 
expression is achieved without a heterologous promoter, this would increase the potential 
of rAAV to accommodate larger transgenes. To test this, the heterologous 
promoter/enhancer unit, LP1, was removed from pAAV2.LP1.hABCB4v2, using flanking 
SpeI and XbaI sites. Restriction digest with these enzyme resulted in identical 5‟ 
overhangs (CTAG), which could be efficiently ligated using T4 DNA ligase, forming 
pAAV2.hABCB4v2 –prom (97% wtAAV size: 4547 bp). 
Recombinant AAV vector stocks were generated from each of the plasmid vector 
constructs described above using a triple plasmid transfection system in HEK 293 cells, 
described in section 2.4. Each rAAV ITR sequences originated from serotype 2 wild-type 
AAV and each vector was packaged into the serotype 8 capsid. Therefore, the rAAV 
vectors of 109%, 106%, 103% and 97% wild-type AAV size were designated as 
rAAV2/8.LP1.hABCB4v1, rAAV2/8.LP1.hABCB4v2, rAAV2/8.LP1.hABCB4v3 and 
rAAV2/8.hABCB4v2 –prom, respectively.  
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Figure 3.3: Diagram of rAAV vector expression cassettes.  Each expression cassette 
contains a human ABCB4 cDNA with/without a hepatocyte-specific transcriptional 
control unit (LP1) and polyadenylation sequence (PolyA), and are flanked by AAV 
serotype 2 inverted terminal repeats (ITRs). Scale bar = 300 bp. Legend: AAV ITRs 
(black boxes); Liver specific promoter/enhancer, LP1 (dark grey boxes); Human ABCB4 
cDNA, hABCB4 (white boxes); Bovine growth hormone polyA (light grey boxes); 
Simian Virus 40 polyA (striped box). Transcriptional start sites are indicated by arrow. A 
transcriptional start site of pAAV2.hABCB3v2-prom is purported to arise within the 
upstream AAV ITR, but the exact location is unknown.  
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3.3. RESULTS 
3.3.1. Cloning and Bacterial Propagation Issues with Plasmids Encoding the 
Complete hABCB4 cDNA Sequence 
The production of rAAV vector particles using a transient transfection method requires a 
rAAV plasmid containing an expression cassette with the gene of interest driven by a 
heterologous promoter, and flanking palindromic AAV inverted terminal repeats (ITRs), 
cis-acting viral elements necessary for replication and packaging of the rAAV vector 
genome.
365,393
 Cloned vector plasmids are then used to transform competent E. coli for 
large-scale propagation.  
In the process of constructing rAAV vectors containing the hABCB4 sequence, several 
difficulties were encountered. Bacterial plasmids containing the hABCB4 cDNA 
sequence had lower than expected transformation efficiency. JM109 chemically 
competent E. coli cells transformed with 20% of the ligation reaction of hABCB4 PCR 
fragment, containing a full-length hABCB4 cDNA, and pGEM
®
-T Easy cloning vector 
(designated pGEMTE.hABCB4) resulted in a transformation efficiency of 3.5 × 10
5
 
cfu/ug DNA, compared to >2 × 10
9 
cfu/ug DNA with transformation of either uncut 
control plasmid, pUC18, or pGEM
®
-T easy vector ligated to a control insert. High 
transformation efficiency using pGEM
®
-T Easy ligated to the supplied control insert (542 
bp) designated pGEMTE.control, suggested that the low transformation efficiency 
observed with hABCB4 plasmid was not due to a sub-optimal ligation reaction. The 
difference in transformation efficiency can be partially accounted for by differences in 
plasmid size between pGEMTE.hABCB4 (6985 bp), pUC18 (2686 bp) and 
pGEMTE.control (3557 bp). However, using similar experimental conditions, 
transformation of JM109 bacteria with plasmids >7 kb have typically yielded 
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transformation efficiencies of >10
7 cfu/μg DNA. Furthermore, pGEMTE.hABCB4 
transformant colonies were noticeably smaller in size (~ 0.5 mm diameter). Whilst larger 
colonies (1-2 mm diameter) were present on the agar plates, they tended to contain 
plasmids without hABCB4 insert, when screened by restriction fragment mapping. 
Inadvertent hABCB4 expression in transformants carrying the pGEMTE.hABCB4 
plasmid may have led to production of a toxic protein that resulted in reduced host 
bacterial strain viability and therefore, low transformation efficiency and small colony 
size. There are several bacterial promoters flanking the multiple cloning region of the 
pGEM
®
-T Easy cloning vector that could drive expression of inserted transgene in either 
orientation. Therefore, bacterial promoters, including the T7 and SP6 RNA polymerase 
promoters, located at the 5‟ and 3‟ end of the multiple cloning region, respectively, may 
mediate aberrant expression of inserted hABCB4 cDNA. The promoter driving lac operon 
expression, permitting blue-white colony screening on agar plates supplemented with 
isopropyl-1-thio-β-D-galactopyranoside (IPTG) and 5-bromo-4-chloro-3-inodlyl-β-D-
galactopyranoside (X-gal), could also be implicated to drive inserted hABCB4 transgene 
expression. The use of Luria Bertani (LB) growth media containing trace amounts of 
lactose may have resulted in induction of the lac operon and expression of a toxic fusion 
protein. This phenomenon has been previously described.
394-396
  
In order to avoid inadvertent lac operon induction, use of IPTG was avoided and LB was 
substituted with SOC growth media containing 20 mM glucose for bacterial 
transformations and propogation. (For descriptions of growth media, see Table 2.2). The 
presence of glucose is known to induce lac repressor activity, responsible for terminating 
gene transcription in the lac operon.
397,398
 100% of JM109 clones harbouring 
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pGEMTE.hABCB4 and grown in SOC media had intact hABCB4 sequence, compared 
with only 17% of JM109 clones grown in LB media.  
The growth curves of pGEMTE.hABCB4 clones grown in SOC and LB media were 
compared with clones harbouring pGEM
®
-T Easy vector with an inserted non-coding 
sequence of similar size (pGEMTE.ctrlins). A single colony of each clone, 
pGEMTE.hABCB4 and pGEMTE.ctrlins, were selected and grown in 5 mL of SOC 
media (Table 2.2) supplemented with Ampicillin at 100 µg/mL at 37°C with vigorous 
shaking until each reached similar turbidity, as measured by absorbance at 600 nm 
(OD600) using a UV spectrophotometer. Plasmid was extracted from 2 mL of the initial 
pGEMTE.hABCB4 starter culture, purified and digested with restriction enzymes to 
confirm presence of intact hABCB4 sequence. Then, 30 µL of each clone was introduced 
into separate flasks containing 15 mL sterile growth media (SOC, LB with 20 mM 
glucose or LB alone) supplemented with Ampicillin. Each culture was grown in duplicate 
at 37°C with vigorous shaking. To monitor the turbidity of each culture, OD600 was 
measured every 1-2 hours until reaching the stationary phase. 
Faster growth was observed with clones propagated in SOC media and LB containing 20 
mM glucose, compared to those grown in LB alone. Clones harbouring 
pGEMTE.hABCB4 propagated slower in all 3 types of media compared with 
pGEMTE.ctrlins clones. (Figure 3.4) Despite faster growth and reduced recombination, 
plasmid DNA yielded from pGEMTE.hABCB4 clones grown in SOC were more than 3-
fold less than from clones grown in LB, indicating that growth in SOC media may have 
favoured low copy number clones and that large-scale propagation using SOC media was 
inefficient. 
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Figure 3.4: Comparison of growth curves of pGEMTE.hABCB4 and 
pGEMTE.ctrlins propagated in either Luria Bertani (LB) media, LB with added glucose 
(20 mM), or SOC media, containing 20 mM glucose. Each plasmid was grown in 15 mL 
of media, supplemented with Ampicillin (100 µg/mL) and turbidity was monitored by 
measuring absorbance at 600 nm using a UV spectrophotometer every 1-2 hours until the 
stationary phase was reached.  
 
Attempts to transform SURE
®
 2 supercompetent cells with sequence-verified hABCB4 
ligated into the pAm AAV2 backbone containing the LP1 transcriptional control unit 
(Section 3.2.1) also resulted in a very low transformation efficiency of 5.9 × 10
3 cfu/μg 
DNA, compared with > 2 × 10
8 cfu/μg DNA with pUC18 transformation. SURE® 2 cells 
are a sbcC mutant strain commonly used to propagate plasmids containing palindromic 
AAV ITRs. However, this strain has only moderate recombination deficiency, carrying 
recB and recJ mutation. None of the 48 screened clones obtained from 4 separate 
transformation reactions had intact pAAV2.LP1.hABCB4v1 plasmid. This suggests that 
there is a strong selection pressure against clones harbouring intact 
pAAV2.LP1.hABCB4v1.  
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In order to prevent recombination events, stringently recombination-deficient recA mutant 
strain, JM109 cells, were transformed with 10% of the same ligation reaction used for the 
SURE
®
 2 cell transformations. From 12 colonies screened, 12 clones had intact 
pAAV2.LP1.hABCB4v1 plasmid, as verified by restriction site mapping and 
subsequently, by sequencing. Half of these clones were propagated in SOC and the 
remainder in LB media; > 5-fold lower plasmid DNA yields were obtained from clones 
grown in SOC media.  
Large-scale plasmid isolation and purification was performed from 500mL LB cultures 
supplemented with Ampicillin and inoculated with a sequence verified clone (Section 
2.2.1.2). Restriction site mapping of the purified plasmid DNA was used to verify the 
presence of intact pAAV2.LP1.hABCB4v1. DNA fragments from restriction digests were 
resolved by agarose gel electrophoresis (Section 2.2.3). This revealed the presence of a 
2
nd
 smaller plasmid, in addition to complete pAAV2.LP1.hABCB4v1. The smaller 
plasmid was not visualised on the starter culture gel image, though a minute amount (less 
than 2 ng) may be below the detectable limit of the ethidium bromide-stained gel (Figure 
3.5a).
399
  
Subsequently, each plasmid was separated using agarose gel electrophoresis, excised and 
purified using the Wizard Gel Purification kit (Section 2.2.5). Further restriction site 
mapping showed that the smaller plasmid of approximately 3 kb in length, contained the 
pAAV2 vector backbone including the Ampicillin resistance gene, with deletion of the 
proviral sequence including each terminal resolution site, and pointed to the likely site of 
recombination being within either the A′ or D region of each ITR, proximal to the 
terminal resolution sites (Figure 3.5b). However, lack of digestion within the ITRs due to 
inefficient endonuclease activity within the secondary structure could not be excluded. 
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Sequencing of each plasmid verified a full-length pAAV2.LP1.hABCB4v1, but the 
precise site of recombination affecting the smaller pAAV2 backbone plasmid could not be 
resolved due to difficulty sequencing through the palindromic AAV2 ITRs.  
In order to eliminate the presence of the smaller plasmid, further propagation of JM109 
clones harbouring pAAV2.LP1.hABCB4v1 were performed at lower, presumably less 
metabolically-active temperatures (32°C and room temperature). This resulted in lesser 
propagation of the smaller backbone plasmid. The amount of backbone plasmid could 
also be reduced or eliminated by growing cultures for shorter periods and isolating 
plasmid from bacterial cultures at low optical density, measured at 600 nm. However, 
there was a substantial trade-off with plasmid DNA yields.  
The presence of the smaller backbone plasmid was identified in all subsequent 
recombinant plasmid constructs containing intact, full length hABCB4 sequence 
(described in Section 3.2.2). Interestingly, plasmid clones harbouring codon-optimised 
hABCB4 cDNA (described in Chapter 5) were less susceptible to provirus deletion and 
propagation of the backbone plasmid, perhaps due to reduced expression from specific 
codon usage inefficiencies in bacteria. Plasmid DNA isolated from bacterial clones 
harbouring intact AAV2 ITRs, but with incomplete hABCB4 sequence, did not contain 
smaller backbone plasmid, despite being propagated in JM109 cells. This suggests that 
propagation of intact AAV ITRs is possible in bacterial strains without sbcC mutation.  
To prepare the expression cassette plasmid for transfection of HEK 293 cells to produce 
recombinant AAV vector stocks, the smaller backbone plasmid was separated from full-
length pAAV2.hABCB4 constructs by size selection using agarose gel electrophoresis. 
The supercoiled DNA band of the larger pAAV2.hABCB4 plasmids were excised, 
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extracted and purified from the gel fragment using the Wizard Gel Purification kit 
(Section 2.2.5). 
 
Figure 3.5: Recombination resulted in propagation of AAV backbone plasmid with 
deleted expression cassette. (a) Agarose gel image showing restriction digests of 
plasmids isolated from propagated cultures arising from a single JM109 colony 
harbouring pAAV2.LP1.hABCB4v1. Inoculation of the starter culture (lanes 1-6) into the 
large-scale culture (lanes 7-12) resulted in propagation of a smaller plasmid (indicated in 
lanes 7-11 by the black arrow). Restriction digests: lanes 1 & 7 – undigested plasmid, 2 & 
8: XbaI, 3 & 9: HindIII, 4 & 10: BamHI, 5 & 11: MscI, 6 & 12: BglI. (b) The smaller 
plasmid was isolated by size selection using gel electrophoresis, excised and purified 
from the gel fragment (Section 2.2.5) and digested with restriction enzymes: PvuI (lane 
2), AseI (lane 3), MscI (lane 4) and BglI (lane 5). Undigested plasmid was loaded into 
lane 1. Absence of digestion with MscI indicates disruption/absence of the terminal 
resolution sites from the smaller pAAV2 backbone plasmid. Molecular weight marker, 
Hyperladder I (HLI, Bioline) was used to estimate fragment size. (c) Table of restriction 
enzyme digest positions in pAAV2.LP1.hABCB4v1 (8240 bp). Position 1 is located at the 
proximal end of the AAV2 ITR upstream of the expression cassette. Position numbers in 
bold are those located in the pAAV2 backbone. Italicised position numbers refer to those 
within the ITRs. 
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3.3.2. Functional Validation of rAAV.hABCB4 Vectors in vivo 
The performance of rAAV2/8.LP1.hABCB4v1 vector was tested in vivo in heterozygous 
(Abcb4
+/-
) young adult (8-10 week old) males using doses ranging from 10
11
 to 10
12 
vector genomes (vg) per mouse (n = 3 per group). Vector was diluted in PBS with 0.90 
mM Ca
2+
 and 0.49 mM Mg
2+
 to a total volume of 100 µL per injection and delivered via 
the intraperitoneal (i.p.) route without incident (Section 2.5.3.1). Liver tissue and bile 
samples were obtained 2 weeks post-inoculation.  
To test the functionality of rAAV vectors encoding hABCB4, biliary phosphatidylcholine 
(PC) concentration was used as a direct measure of Abcb4 function. In the absence of a 
dominant negative effect, biliary PC concentration is expected to correlate with Abcb4 
genotype, thus validating this marker as a direct measure of endogenous Abcb4 P-
glycoprotein function. The biliary PC concentrations of fasted, wild-type, heterozygous 
and homozygous Abcb4 control young adult male mice were determined using the 
colorimetric PC assay (n ≥ 3 per group), described in Section 2.6.6.1. There was a linear 
correlation between biliary PC concentration and genotype (One-way analysis of 
variance, p = 0.0003, Figure 3.6). If transduced hepatocytes expressed functional 
hABCB4 P-glycoprotein at a sufficient level in this mouse model, the biliary PC 
concentration should increase above background concentrations of mice with the same 
genotype. 
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Figure 3.6: Biliary phosphatidylcholine concentrations of experimental control mice. 
Mean phosphatidylcholine (PC) concentration of bile, collected from the gallbladder of 
fasted, wild-type, heterozygous and homozygous adult controls. PC concentration was 
measured against defined standards by quantitative colorimetry. Error bars represent 
SEM. Statistical significance was determined by one-way analysis of variance (p = 
0.0003). 
 
Molecular transduction was detected by quantitative real-time PCR (qPCR), measuring 
vectors copies in RNase-treated DNA extracted from bulk liver samples and normalised 
against genomic GAPDH copies (Section 2.6.1 & 2.6.3). Vector DNA copies were 
expressed per diploid genome equivalent (DGE), and detected using primers directed 
towards the hABCB4 transgene, producing a 129 bp amplicon. The site of annealing of 
the forward primer contained 3 base mismatches and the reverse primer contained 2 base 
mismatches when aligned with the corresponding coding sequence of murine ABCB4 
(GenBank Acc no. NM_008830.2). The amplified fragment was predicted to span intron 
14 of murine ABCB4 gene. Nevertheless, vector copies were detectable at very low levels 
in control heterozygous males that received a PBS-only injection (1.6 ± 0.4 × 10
-3 
vg/DGE, Mean ± SEM), possibly due to either mis-priming with other regions of genomic 
DNA or less likely, inadvertent cross-priming with murine ABCB4 sequence (Figure 3.6). 
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Male heterozygotes given an intraperitoneal injection of 1 × 10
11 
vg per mouse had a low 
mean normalised vector copy number of 0.63 ± 0.40 vg/DGE (Mean ± SEM) in the liver, 
2 weeks post-inoculation. Increasing the dose to 1 × 10
12 
vg resulted in a 32-fold higher 
mean vector copy number (20.46 ± 2.23 vector DNA copies/DGE, Mean ± SEM, p = 
0.0005; Figure 3.7a).  
Figure 3.7: Molecular and functional analysis of rAAV2/8.LP1.hABCB4v1 (109 % 
wt) vector liver transduction. Young adult male heterozygotes received an 
intraperitoneal injection of 1x10
11 
vg (grey column) or 1 × 10
12
 vg of 
rAAV2/8.LP1.hABCB4v1 (109 % wt) vector (black columns), and liver and bile samples 
obtained 2 weeks post-inoculation. (a) Vector copies were quantified by qPCR analysis of 
liver DNA from transduced mice (n = 3), and (b) bile samples were analysed for PC 
concentration, and compared with PBS-injected control heterozygotes (white columns).  
Error bars represent SEM. Statistical analysis was performed using unpaired Student‟s t-
test. 
 
 
As expected given the low vector copy number in mice that received 1 × 10
11 
vg, biliary 
PC concentrations in this group were not increased above background heterozygote 
levels. However, a dose of 1 × 10
12
 vg was sufficient to significantly raise biliary PC from 
a background heterozygous level of 8.19 mM (48% wild-type) to 13.81 mM (81% wild-
type) (p = 0.04; Figure 3.7b). 
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Heterozygote Wild-type 
3.3.3. Low Liver Transduction of Homozygous Adult Mice 
After establishing the functionality of the rAAV2/8.LP1.hABCB4 vector in heterozygous 
adult males, an identical experiment was carried out to test therapeutic efficacy in the 
disease-relevant genotype: homozygotes. 8-week old Abcb4
-/- 
 males were injected with 1 
× 10
12 
vg rAAV2/8.LP1.hABCB4v1 via the intraperitoneal route (n = 3). Liver and bile 
were obtained 2 weeks post-inoculation for analysis. Liver histopathology of rAAV-
inoculated and control adult homozygotes were similar, and revealed that established liver 
disease in these young adult males. Wild-type and heterozygous adults exhibited no 
visible pathology (Figure 3.8). 
 
Figure 3.8: Histological images of wild-type, heterozygous and homozygous adult 
liver sections. Using haematoxylin and eosin (H & E) staining, wild-type and 
heterozygous livers showing no visible pathology, in contrast to homozygous liver 
sections that exhibit distorted architecture with periportal inflammation. Bridging fibrosis 
is evident on the Sirius red stained homozygous liver section. Scale bar = 50µm. 
 
 
Analysis of vector copy number using qPCR showed 59-fold less vector copies in the 
homozygous livers compared with disease-free heterozygous livers (p = 0.0008; Figure 
3.9a) Correspondingly, there was a resultant 165-fold difference in relative mRNA 
transcripts detected in homozygotes versus heterozygotes; though this was not statistically 
significant (p = 0.156; Figure 3.9b) Inoculated homozygous mice did not exhibit an 
increase in biliary PC concentration above background (Figure 3.9c). 
 Chapter 3: Development of Recombinant AAV Vectors Encoding Human ABCB4 
123 
 
 
Figure 3.9: Comparison of molecular transduction of liver, and biliary 
phosphatidylcholine concentration of heterozygous and homozygous adult males. 
Young adult heterozygous (black columns) and homozygous (grey columns) males 
received 1 × 10
12 
vg per mouse by intraperitoneal injection. 2 weeks post-inoculation, 
liver tissue was analysed for (a) vector copy number and (b) relative mRNA transcripts. 
(c) PC concentration of gallbladder bile from inoculated homozygous mice (grey 
columns) were analysed, and compared with controls (white columns) of the same 
genotype. Statistical significance was determined by unpaired Student‟s t-test. Error bars 
represent mean ± SEM. n ≥ 3 per group. 
 
The results from these experiments raised 3 hypotheses to explain the reduction in 
transduction efficiency in homozygous mice, compared with age-matched, disease-free 
heterozygotes.  
i. The presence of liver pathology including hepatic fibrosis and portal hypertension 
reduced the ability of the vector to be efficiently delivered to hepatocytes. This 
will be further explored and addressed in Chapter 4 
ii. A large over-sized AAV vector has inherent in vivo instability and may have 
reduced ability to transduce a diseased liver due to this inherent instability coupled 
with inefficient delivery of the vector to the site of interest. This will be addressed 
in Section 3.3.4 of this chapter. Furthermore, since the route of administration 
determines the bio-distribution and circulating half-life of the administered vector 
particles, it could also affect the number of intact oversized vectors that are 
capable of transducing hepatocytes. Therefore, changing the route of 
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administration may improve vector transduction. This will be addressed in Section 
3.3.5 of this chapter. 
iii. The development of portal hypertension in homozygotes with liver disease could 
alter the vector bio-distribution pattern in homozygous mice, compared with 
heterozygous mice. Changing the route of administration may improve rAAV 
vector transduction of the diseased liver. This will be also addressed in Section 
3.3.5 of this chapter.  
3.3.4. Impact of Vector Size on Liver Transduction and Transgene Expression 
Recombinant AAV vectors that exceed the packaging capacity are known to significantly 
reduce transduction efficiency at least 10-fold. To examine the effect of vector size on 
transduction efficiency in vivo, 3 additional expression cassettes of varying size encoding 
hABCB4 were engineered, as described in Section 3.2.2. 
Wild-type, heterozygous and homozygous, young adult males were injected intra-
peritoneally with 1 × 10
12 
vg/mouse, and liver tissue was analysed for vector copy number 
and relative mRNA concentration, and bile for phosphatidylcholine concentration, 2 
weeks post-inoculation (Section 2.6.1 & 2.6.2). There were ≥ 3 males in each genotype 
and vector group. 
There was a significant difference in liver vector copies between wild-type and 
homozygous groups, independent of vector size (unpaired Student‟s t-test, p ≤ 0.0001; 
Figure 3.10a). Notably, compared with 109% wtAAV sized vector, there was a marked 
increase in vector copy numbers recovered from the liver of homozygous mice transduced 
with vectors of 106% wtAAV (38-fold higher, p = 0.0003) or 103% wtAAV size (31-fold 
higher, p = 0.0111). A corresponding 41-fold increase in mean relative mRNA levels in 
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106% wtAAV compared with 109% wtAAV vector transduced liver samples was also 
observed (p = 0.0198; Figure 3.10b). Despite the improved vector transduction and 
transgene transcription, this was insufficient to produce a significant increase in biliary 
PC concentration above homozygous background (Figure 3.10c). 
Removing the heterologous promoter/enhancer unit, LP1 to shorten the vector genome to 
under wild-type AAV size, permitted an increase in normalised vector copies (NVC) 
recovered from the livers of inoculated wild-type and homozygous mice. However, there 
was a marked reduction in transcriptional activity compared with the 106% wtAAV vector, 
containing identical sequence except for inclusion of LP1. To determine the specific 
transcriptional activity of each vector, the relative mRNA transcript copies were 
expressed per NVC (Figure 3.10d). This showed that the transcriptional activity of the 
“promoterless” vector was 34-fold and 67-fold lower in wild-type and homozygous mice, 
respectively (Wild-type: p = 0.0091, Homozygotes: p < 0.0001). 
Interestingly, there was a significant decrease in the specific transcriptional activity of the 
109% wtAAV vector when administered to homozygotes (1773 ± 203 relative mRNA 
copies per NVC), compared to wild-type mice (5868 ± 299 relative mRNA copies per 
NVC, p = 0.0003). (Figure 3.10d) This suggested that in addition to significantly lower 
transduction of disease livers, reduced transcription from oversized vectors that transduce 
the liver may further impede effective hABCB4 expression.     
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Figure 3.10: Analysis of transduction of different sized rAAV2/8 vector encoding 
hABCB4 transgene. (a) For a given vector dose, homozygous adult mice had reduced 
mean liver vector copies per diploid genome equivalent (DGE), compared with wild-type 
or heterozygous counterparts, independent of vector size. (b) Relative mRNA transcript 
levels measured by qRT PCR shows corresponding reduced relative mRNA transcripts in 
homozygous livers. 97% wtAAV vector without heterologous LP1 promoter had 1.5 × 
log10 lower relative transcription compared with similar vectors with LP1. (c) As a 
functional measure of hABCB4 expression, biliary phosphatidylcholine (PC) 
concentrations of homozygous mice injected intraperitoneally with rAAV2/8 vectors of 
various sized genomes were compared. Legend for graphs a, b & c: 109% wtAAV vector 
(black columns); 106% wtAAV vector (white columns); 103% wtAAV vector (dark grey 
columns); 97% wtAAV vector (horizontal striped columns); homozygous controls (light 
grey column). (d) The specific transcriptional activity of each vector was determined by 
calculating the relative mRNA transcript copies per NVC. Transduced wild-type 
(diagonally striped black columns) and homozygous (dotted columns) liver sample were 
compared, showing significantly reduced specific transcriptional activity of the 109% 
wtAAV vector in homozygous liver samples compared with wild-type samples transduced 
with the same vector. n  3 per group. Statistical significance was assessed by unpaired 
Student‟s t-tests. Error bars represent mean ± SEM.  
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3.3.5. Changes in Route of Administration Did Not Alter Liver Transduction 
Efficiencies 
We hypothesized that exceeding the packaging capacity may place undue stress on capsid 
structural integrity, possibly leading to inherent capsid instability of oversized vectors.
400
 
Since the route of administration affects the bio-distribution and importantly, the half-life 
of the administered substance in the circulation, it could also affect the number of intact 
oversized vectors that are capable of transducing hepatocytes. Therefore, we compared 
transduction and transgene expression using 3 different routes to administer the 109% 
wtAAV vector.  
Young adult (8-10 week old), heterozygous males were injected with 1 × 10
12
 vg/mouse 
rAAV2/8.LP1.hABCB4v1 (109% wtAAV) via intraperitoneal (IP), portal vein (PV) or tail 
vein (IV) injections (n ≥ 3 per route) (Section 2.5.3.1). Liver and bile were obtained for 
analysis 2 weeks post-inoculation. 
There was no statistically or biologically significant difference in the normalised vector 
genomes recovered from liver, 2 weeks after intraperitoneal (IP), intraportal (PV) or 
intravenous (IV) rAAV delivery. (Figure 3.11a) The relative number transgene-specific 
mRNA transcripts and the specific transcriptional activities of vectors delivered by the 3 
routes of administration were both similar between these groups (One-way analysis of 
variance, p = 0.3525 & p = 0.1763, respectively) (Figure 3.11b & 3.11c). There was no 
statistically significant difference in the biliary PC concentration between males that 
received the same dose of rAAV vector via intra-peritoneal, intra-portal or intravenous 
injection (One-way analysis of variance, p = 0.6497) (Figure 3.11d). 
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Figure 3.11: Comparison of routes of administration. Molecular transduction 
efficiency and transgene expression at 2 weeks post-inoculation of rAAV vector 
administered to heterozygous young adult males via the intraperitoneal (IP, diagonal 
striped columns), intraportal (PV, dotted bars) and intravenous (IV, horizontal striped 
columns) routes were compared. Error bars represent mean ± SEM. Statistical 
significance was determined using unpaired Student‟s t-tests. 
To assess whether systemic delivery of vector may improve efficacy in homozygotes with 
liver disease, 8-week old homozygous males were injected with 1 × 10
12
 vg/mouse 
rAAV2/8.LP1.hABCB4v1 (109% wtAAV) via the tail vein (n = 5), and their molecular 
transduction efficiency and biliary PC concentrations 2 weeks post-inoculation were 
compared with homozygous adult males that had received intraperitoneal vector. 
Intraportal vein injection was not attempted in homozygotes as this was not likely to be 
efficacious, due to probable portal hypertension as a result of chronic liver disease.  
Both IP- and IV-injected homozygotes had similarly low levels of normalised vector 
genomes recovered from liver samples (IP: 0.35 ± 0.098 vg/DGE; IV: 0.411 ± 0.168 
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vg/DGE, p = 0.7611, Figure 3.12a). There was no significant improvement in biliary 
phosphatidylcholine concentration by altering the route of administration (Figure 3.12b). 
 
Figure 3.12: Molecular transduction and biliary phosphatidycholine concentrations 
of homozygous adult males. The vector copy numbers (a) and biliary 
phosphatidylcholine concentration (b) of mice injected with 109% wtAAV vector 
encoding hABCB4 via the intraperitoneal (IP, diagonal striped columns) and intravenous 
(IV, horizontal striped columns) routes were compared with untransduced homozygotes. 
Error bars represent mean ± SEM. Statistical significance was determined using unpaired 
Student‟s t-tests. 
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3.4. DISCUSSION 
The experiments outlined in this chapter describe the successful development of 
functional rAAV2/8 vectors encoding human ABCB4 and highlight potential challenges 
specifically relevant to treating PFIC3 with AAV-mediated, liver-direct gene transfer. In 
particular, there were two major hurdles to developing an efficacious rAAV vector for 
PFIC3: poor transduction and hABCB4 expression in the liver of adult homozygotes with 
established liver pathology, and difficulties in propagating vector plasmids.  
In order to develop effective gene therapy for PFIC3, it is important to evaluate vector 
performance in the context of the level of transgene expression and the transgene product 
activity, necessary to correct the disease pathology. This threshold is dictated by many 
aspects of disease-specific biology and is reliant on a relevant and accurate outcome 
measure that reflects the pathophysiology of the disease of interest. Since there is 
currently an absence of gene therapy models for PFIC3, this threshold is yet to be 
established.  
However, transgenic mouse models expressing human MDR3 in the Abcb4-knockout 
mice provide some important insights. Using a transgenic Abcb4-knockout mouse model, 
Smith et al., demonstrated that transgenic mice with hepatocytes expressing human 
MDR3 on a homozygous background had approximately 25% wild-type levels of biliary 
phospholipid secretion, but clearly exhibited liver pathology (bile ductular proliferation 
and portal inflammation) at 12 weeks of age.
342
 Therefore, this level of MDR3 activity 
was not sufficient to prevent liver disease. Biliary phospholipid secretion in this study 
was measured as phospholipid output during the first 10 minutes after gallbladder 
cannulation as nmol/min per 100 g body weight. Data from a previous study showed that 
heterozygotes with no visible pathology had 78% of wild-type biliary phospholipid 
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secretion.
401
 Therefore, the threshold for phenotype correction must lie between these two 
points. 
In functionally validating the rAAV2/8.LP1.hABCB4v1 vector described herein, the 
phosphatidylcholine (PC) concentration of bile was used as a direct measure of 
phospholipid floppase P-glycoprotein function (both endogenous murine Abcb4 and 
vector-derived human ABCB4). After demonstrating a linear correlation between biliary 
PC concentration and genotype in control animals, the functionality of the 109% wtAAV-
sized vector construct (rAAV2/8.LP1.hABCB4v1) was initially tested in heterozygous 
adult males. With a dose of 1 × 10
12
 vg/mouse, a statistically significant increase from a 
background heterozygous level of 48% to 81% wild-type PC concentration demonstrated 
functionality of the rAAV2/8.hABCB4v1 vector. However, it was uncertain whether this 
33% increase in biliary phospholipid above background would be sufficient to prevent 
liver disease in homozygotes. Unfortunately, vector performance determined in young 
adult male heterozygotes was not recapitulated with equal efficacy in homozygotes of 
similar age, when an equivalent vector dose was administered by the same route. Reduced 
transduction of homozygous livers was insufficient to raise biliary phospholipid 
concentrations above background levels. (Figure 3.9c) 
This observation raised 3 hypotheses: poor transduction by intraperitoneally delivered 
rAAV2/8 vector of homozygous livers was due to i) the presence of liver pathology 
impeding vector delivery to hepatocytes, ii) potential inherent in vivo instability of over-
sized rAAV vectors, which may contribute to its reduced ability to transduce a diseased 
liver, and iii) altered bio-distribution of rAAV vector due to vascular changes 
accompanying chronic liver disease including portal hypertension. The impact of vector 
size in the context of liver pathology has not been previously reported in the literature. 
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Still, this is an essential challenge in rAAV-mediated gene therapy for PFIC3 and 
possibly, other forms of chronic liver disease, especially those involving large transgenes. 
There was a significant decrease in vector DNA copies recovered from all homozygous 
livers, compared with wild-type or heterozygous counterparts, independent of vector size. 
This suggested that a major impediment to transgene expression in this model is likely to 
involve rAAV delivery, transduction and potential differential rates of hepatocellular 
proliferation in the homozygous liver, possibly due to the presence of established liver 
pathology in homozygous adults. This will be further explored and discussed in Chapter 
4. 
To evaluate the impact of vector size on transduction efficiency, three additional 
constructs with smaller expression cassettes encoding hABCB4 were engineered. Smaller 
rAAV vectors transduced the homozygous liver more efficiently with higher normalised 
vector genome copies recovered from the liver and consequently, higher relative mRNA 
transcription. However, this was insufficient to raise biliary PC levels above background 
(Figure 3.10c). 
Reducing rAAV vector genome size from 109% wtAAV to 106% wtAAV size led to a 
significantly higher molecular transduction, in both heterozygotes and homozygotes, but 
further reduction in vector genome size did not result in additional benefit. The 106% 
wtAAV vector had a genome of approximately 5 kb. This data is in keeping with recent 
published studies demonstrating a finite packaging limitation of rAAV vectors, in that 
packaged vector genomes rarely exceeded 5.2 kb, irrespective of the expression cassette 
size in the vector plasmid.
162-165
 And packaging of expression cassettes over 5 kb led to 
heterogeneity of resultant fragmented genomes due to deletions, predominantly from the 
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5′ end.164 These truncated genomes were more likely to undergo proteasomal degradation 
and less able to form transcriptionally active vector genomes due to presumed disruption 
of upstream promoters, enhancers and encoded transgene.
162,164
  It has been proposed that 
transgene expression resulting from over-sized vector genomes is likely the result of 
homologous recombination of genome fragments.
163,165
 
Furthermore, when the difference in normalised vector copies was taken into account, 
there were still significantly lower relative mRNA transcript copies per normalised vector 
DNA copy from the 109% wtAAV vector in homozygotes, compared with wild-type 
(Figure 3.10d). This implicated reduced specific transcriptional activity of over-sized 
109% wtAAV sized vectors (5.1kb) in the homozygous liver as a further barrier to 
transgene expression. This appeared to be vector size-dependent, as differences were not 
significant with vectors of 106% wtAAV size or lower. 
The mechanisms which led to reduced specific transcriptional activity of vectors >5 kb in 
the homozygous livers are currently unknown. The 109% wtAAV vector is at the upper 
limit of proposed rAAV packaging constraints. In agreement with published data, we did 
not observe a decline in the specific transcriptional activity from this vector, compared 
with smaller packaged rAAV when used to transduce wild-type mice. However, this was 
in stark contrast to transduction of homozygous liver. It is possible that intracellular 
changes of diseased hepatocytes may have led to altered post-entry processing of 
oversized rAAV genomes, and therefore reduced recovery of full-length transcriptionally 
active oversized genomes, perhaps via alteration in the homologous recombination 
pathways, sequestration of genomes in intracellular organelles such as proteasomes with 
possibly enhanced proteasomal degradation. Additionally, qPCR analyses may be 
detecting non-transcriptionally active forms in homozygous livers such as single-stranded 
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DNA or truncated vector genomes. However, such mechanisms require further 
elucidation. 
Compared with age-matched wild-type or heterozygous counterparts, Abcb4 
homozygotes exhibit marked liver inflammation and bridging fibrosis by 8 weeks of age 
(Figure 3.8). It is possible that oversized vectors may be sequestered by infiltrating 
activated inflammatory cells or non-parenchymal cells, such as Kupffer cells or sinusoidal 
endothelial cells in the diseased liver, and therefore the encoded transgene is unable to be 
expressed, due to use of a hepatocyte-specific promoter/enhancer. Moreover, liver 
inflammation has also recently been shown to mediate reduced rAAV encoded transgene 
expression through transcriptional silencing.
221,222
 However, vectors used in these studies 
were within rAAV packaging capacity. Nevertheless, various proinflammatory cytokines 
such as TNFα and IFNγ, expressed in inflamed livers, have been shown to inhibit gene 
transcription.
402,403
 In the presence of IL12-induced liver inflammation, Gil-Fariña et al., 
demonstrated that loss of AAV-mediated luciferase expression could be rescued by the 
use of a DNA-demethylating agent.
221
 This implicated DNA methylation as a mechanism 
for transcriptional silencing of yet unknown factors that are important in the formation of 
transcriptionally active rAAV genomes. Abnormal patterns of DNA methylation are also 
well described in liver fibrosis.
404
 Hypermethylation leading to transcriptional repression 
are thought to play a pivotal role in hepatic stellate cell activation, fibrogenesis and 
hepatocellular carcinogenesis.
405-409
 Therefore, transcriptional silencing through DNA 
methylation may be a further mechanism to explain decreased transcriptional activity of 
vector genomes in homozygous mice with established liver pathology.  
Consistent with reports in the literature
391,392
, the AAV ITR sequence upstream of the 
encoded hABCB4 had apparent transcriptional activity, as evidenced by detectable 
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transgene-specific mRNA transcripts recovered from livers transduced with 
rAAV2/8.hABCB4v2 ‒prom. However, in this model removing the heterologous 
hepatocyte-specific promoter/enhancer, LP1, resulted in lower levels of hABCB4 
transcription compared to vectors with LP1, which was both biologically and statistically 
significant. The improved vector delivery to the liver was not sufficient to compensate for 
the lower relative mRNA transcript levels. When the difference in vector copies were 
taken into account, the specific transcriptional activity of this “promoterless” vector was 
at least 34-fold lower than rAAV2/8.LP1.hABCB4v2 vector containing an identical 
expression cassette, apart from inclusion of LP1 (Figure 3.10d). 
As well as the challenge of achieving efficient transduction in homozygous mice with 
established liver disease, the other major hurdle was propagating vector plasmids 
encoding hABCB4. Bacterial hosts harbouring plasmid constructs containing full-length 
hABCB4 had reduced viability, as evidenced by low transformation efficiency, slow 
growth of bacterial clones, and loss of full-length expression cassette through DNA 
recombination. Although the mechanisms for this requires further evaluation, we 
hypothesised that a strong selection pressure against clones harbouring full-length 
hABCB4 may be a consequence of „leaky‟ expression of hABCB4, forming a toxic 
transgene product that affected host bacterial replication. Ensuing recombination events 
resulted in loss of AAV ITR integrity and deletion of the rAAV proviral cassette.  
Propagation of plasmids containing secondary structures such as that formed by 
palindromic ITR sequences can be challenging. DNA palindromes interfere with 
replication and are prone to deletion through strand slippage.
410
 Bacterial host 
recombination systems can catalyse rearrangement of the recombinant DNA, especially 
that which contains palindromes. Careful selection of host strains based on recombination 
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properties is relevant in ensuring efficient and faithful replication of cloned DNA. 
Mutations that suppress recombination can maintain the integrity of cloned DNA. There 
are 3 main recombination pathways in E. coli: recBCD, rec E and rec F pathways.
411
 All 
are dependent on the product of the recA gene. Therefore, recA mutants have the most 
stringent recombination deficiency, reducing recombination events 10,000 fold compared 
to wild-type E. coli.
411
  DNA palindromes, such as AAV ITRs, interfere with bacterial 
replication and lead to reduced viability of recombination deficient strains.
412
 This is 
overcome by mutations in the sbcCD complex that stabilise cloned palindromes.
410
 
Recent evidence suggests that the sbcCD complex induces double-stranded breaks at 
palindromic sites, which then rely on the RecBCD pathway for repair, allowing 
replication.
413
 Therefore, sbcC mutants, such as SURE
®
 2 cells (Strategene) are 
commonly used to propagate rAAV vector plasmids containing ITR sequences. This 
strain has only moderate recombination deficiency, carrying recB and recJ mutation. 
SURE
®
 2 cell transformations of our AAV plasmids were unsuccessful. Only stringently, 
recombination deficient recA mutant (JM109) permitted faithful propagation of 
expression cassette plasmids containing AAV ITRs and full-length hABCB4 cDNA. Still, 
recombination events occurred during large-scale propagation of JM109 clones 
harbouring the complete expression cassette that resulted in deletion of proviral sequence 
between AAV ITRs. Deletions included the D region of each ITR, which contain viral 
packaging signals and terminal resolution sites,
414,415
 and therefore, it is unlikely that 
incidental transfection with the backbone plasmids during rAAV production would give 
rise to infectious particles. Nevertheless, the backbone plasmids were separated from 
vector plasmids using agarose gel electrophoresis and gel extraction, prior to rAAV 
production and purification. 
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Utilising a triple plasmid transfection method involving HEK 293 cell to produce 
recombinant AAV vectors requires large-scale propagation of expression cassette 
plasmids, which contain AAV ITRs. Challenges in producing large quantities of AAV 
plasmids containing full-length hABCB4 for rAAV vector production may prove an 
Achilles‟ heel for potential future scale-up towards treating larger animal models and 
PFIC3 clinical application. Development of plasmids without cryptic transgene 
expression is likely to be possible. For example, use of genetic insulators on either side of 
the rAAV ITRs may prevent read-through from bacterial promoters in the plasmid 
backbone. Elimination of these bacterial promoters may also diminish cryptic hABCB4 
expression. However, neither of these strategies would alleviate transgene expression 
from the heterologous mammalian or viral promoter contained within the rAAV 
expression cassette. This is likely to be a lesser contributor to cryptic transgene 
expression in bacterial clones. 
Another strategy to overcome expression cassette plasmid propagation issues would be to 
employ an alternate vector production system such as the baculovirus-Sf9 insect cell 
system. This may produce higher and better quality yields as they are less reliant on large-
scale plasmid production in bacterial hosts. To produce recombinant AAV, between 1 and 
4 recombinant baculovirus carrying rAAV vector genomes, and AAV rep and cap genes 
are used to initiate a productive infection in Spodoptera frugiperda (Sf9) insect 
cells.
416,417
 Foreign genes are introduced into baculovirus shuttle vectors (bacmids) by 
donor plasmids using site-specific transposition or homologous recombination. Bacmids 
are then propagated in modified E. coli hosts and purified. Transfection of the 
recombinant bacmid DNA into Sf9 cells leads to the generation of recombinant 
baculovirus particles that can be amplified in successive rounds of infection.
418
 
Replication and expression of AAV rep and cap genes, as well as the rAAV vector 
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genome containing the gene of interest, results in assembly of rAAV vector particles, 
which can then be harvested from the Sf9 cells and supernatant.
416
  
This system requires generation and propagation of the rAAV expression cassette in the 
bacmid backbone in E. coli hosts. It is unclear how hABCB4 sequence in bacmids may 
affect bacterial host strain replication and viability. However, only a relatively small 
amount (< 5 μg) of purified bacmid DNA is required for transfection of insect cells, thus 
reducing the burden of large plasmid quantity requirements of rAAV manufacturing 
systems such as HEK 293 cell transfections. 
In summary, developing efficacious rAAV vectors for PFIC3 gene therapy proved 
challenging, owing to two major hurdles. Firstly, slow bacterial growth, reduced bacterial 
host viability and frequent recombination events reflect difficulties propagating plasmids 
harbouring full-length hABCB4 in bacterial hosts, potentially due to transgene product 
toxicity. This was partially overcome by using bacterial hosts with stringent 
recombination deficiency and less metabolically-active growth conditions. Secondly, both 
poor transduction of homozygous livers with over-sized vectors, and reduced 
transcriptional activity from vectors that entered the liver were identified as barriers to 
effective transgene expression. Transduction inefficiencies could be partially improved by 
the use of vectors with genomes ≤ 5 kb in length, but this was insufficient to raise biliary 
phospholipid secretion above background levels in homozygotes. Reduced molecular 
transduction in homozygotes, independent of vector size, suggests that this could be due 
to barriers to vector delivery to hepatocytes in this disease model. This will be explored 
further in the following chapter, which examines the effect of liver pathology on rAAV 
transduction using vectors under wild-type size. 
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CHAPTER 4: IMPACT OF LIVER PATHOLOGY ON rAAV 
HEPATOCYTE TRANSDUCTION 
4.1. INTRODUCTION 
As described in the previous chapter, poor AAV transduction of hepatocytes was 
observed in homozygous adult males with established liver disease, compared with 
disease-free wild-type or heterozygous counterparts. This was found to be independent of 
vector size, suggesting that host factors influenced by the homozygous state impeded 
AAV vector delivery and/or transduction in these animals. The liver histology of young 
adult homozygous males exhibited marked periportal inflammation, bile ductular 
proliferation with fibrous tracts bridging portal areas (Figure 3.6).  
Fibrosis is a common wound healing response to chronic liver injury, characterised by 
progressive accumulation of extracellular matrix (ECM) components.
419
 It can be caused 
by various noxious stimuli, including inflammatory processes, parasites, viruses, 
exogenous toxins, noxious metabolites and cholestasis. If the causative insult is sustained, 
normal liver parenchyma is progressively substituted by scar tissue. Ultimately, cirrhosis 
ensues with progressive distortion of liver architecture, haemodynamic disturbances to 
hepatic blood flow and a decline in functional hepatic reserve. This is associated with 
high morbidity and mortality due to complications of liver failure (hepatic 
encephalopathy, coagulopathy, increased susceptibility to bacterial infections) and portal 
hypertension (ascites, variceal haemorrhage, hepatorenal syndrome).
420,421
 
The mechanistic processes underpinning the advent and progression of hepatic fibrosis is 
complicated and knowledge is continually evolving. A highly orchestrated network of 
autocrine and paracrine signals promotes trans-differentiation of resident hepatic stellate 
 Chapter 4: Impact of Liver Pathology on rAAV Hepatocyte Transduction 
140 
 
cells and portal fibroblasts to a myofibroblastic phenotype.
422,423
 This leads to a marked 
increase in the synthesis and deposition of ECM components within the liver, inhibition 
of matrix remodelling, and recruitment of other pro-fibrogenic and inflammatory 
cells.
89,424,425
 The liver architecture is gradually disrupted by fibrotic tissue. 
In a healthy state, the unique architecture of the liver enables nutrients and other solutes, 
delivered to the liver via the bloodstream, to freely diffuse through sinusoidal endothelial 
cell fenestrae and the subendothelial space of Disse, to reach the surface of hepatocytes. 
Normally, the hepatic ECM provides functional and structural integrity for the liver 
parenchyma.
426,427
 However, following a significant liver insult, the low density matrix in 
the space of Disse is replaced by excessive deposition of ECM components, highly 
enriched with type I and III fibrillar collagens.
428
 The altered matrix micro-environment 
creates both a functional and physical impediment to bidirectional metabolic exchange 
between sinusoidal blood and hepatic parenchyma. During this process, changes at the 
cellular and molecular level, affecting activated hepatic stellate cells, sinusoidal 
endothelial cells, resident and recruited fibroblast and hepatocytes, lead to loss of 
endothelial cell fenestrations (in number and size)
429
, reduced hepatocyte microvilli, 
increased sinusoidal vasoconstriction
430
, and elevated intrahepatic blood flow 
resistance.
422
 These changes likewise, promote impaired solute exchange and diminished 
liver function. Increased resistance to intrahepatic blood flow also results in consequential 
portal hypertension and its sequelae including porto-systemic shunting, which can allow 
up to 65% of blood to bypass the liver,
431
 further reducing the effective solute load 
delivered to hepatocytes. 
In addition to impairment of solute exchange, clearance rates of some xenobiotics are also 
known to be compromised in the diseased, fibrotic/cirrhotic liver.
432,433
 Reduced hepatic 
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drug clearance rates are related to several factors including reduced effective blood flow 
to hepatocytes, development of shunts, altered protein binding kinetics and altered 
transport across the hepatocyte membrane, possibly related to reduce microvillus surface 
area as well as changes to cell surface receptor expression.
434,435
 The clearance of 
substrates with a high hepatic fractional extraction, which diffuse unimpeded through 
sinusoidal endothelial fenestrae and space of Disse and are readily taken up by 
hepatocytes in the healthy liver, is primarily influence by total hepatic blood flow. The 
clearance of these substrates has been shown to be inversely proportional to the degree of 
defenestration and shunting in cirrhotic livers.
436-438
  
In the gene therapy setting, similar pharmacokinetic changes in the diseased liver may 
influence hepatocyte gene transfer using viral and non-viral vectors. In particular, marked 
changes to sinusoidal endothelium, space of Disse and hepatocyte membrane are likely to 
impede gene delivery to hepatocytes, with important clinical implications. Here, we 
aimed to assess the impact of liver pathology on rAAV transduction and transgene 
expression in the Abcb4
-/-
 mouse model, in order to determine the optimal timing of 
initiating therapy to correct the PFIC3 liver disease phenotype. 
Hypotheses: i) The presence of liver pathology including hepatic fibrosis and portal 
hypertension impedes efficient delivery of rAAV vectors to hepatocytes. ii) Transduction 
prior to onset of liver pathology is more efficacious than when liver disease is established. 
Aims:    
1. To characterise the progression of liver disease in Abcb4-/-  juvenile mice 
2. To examine the impact of liver pathology on rAAV vector transduction and transgene 
expression with respect to age and gender. 
3. To determine the optimal age to initiate rAAV therapy in the Abcb4-/- mouse model.  
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4.2. RESULTS 
4.2.1. Characterisation of Disease Pathology in Abcb4-/- Mice 
In order to evaluate the impact of liver pathology on rAAV transduction, the progression 
of liver disease was first characterised in homozygous juveniles in the Abcb4-knockout 
mouse model. Homozygous knockout mice are known to develop progressive 
hepatobiliary disease including liver fibrosis, in keeping with the synonymous PFIC3 
phenotype in humans.
297
  
Characterisation of liver pathology was performed on mice that received eGFP reporter 
AAV vector in experiments as described (Section 4.2.2 & 4.2.3). Wild-type and 
homozygous juvenile male and female Abcb4
-/-
 mice were culled at 1, 3, 5, 7 and 9 weeks 
of age, and liver and blood samples were obtained for analysis (n ≥ 3 per group). 
Anthropometric measurements were obtained from all mice. Whole livers and spleens 
were weighed and expressed as a percentage of total body weight. Homozygous male and 
females develop progressive hepatosplenomegaly with age (Table 4.1). Blood sampling 
was performed by cardiac puncture in fully anaesthetised mice from 3 weeks of age. 
Blood sampling from 1 week olds were inadequate for analysis. Biochemical analyses 
were performed in Department of Biochemistry, The Children‟s Hospital at Westmead, 
using a Vitros Chemistry Analyzer (Ortho Clinical Diagnostics, NY, USA) (Section 
2.6.5). Elevations in serum alanine aminotransferase levels were seen in all homozygous 
mice from 3 weeks of age. Mean serum alkaline phosphatase levels, as a marker of biliary 
inflammation, were 1.8 to 4.1-fold higher than that of age-matched wild-type counterparts 
(Table 4.1). Elevated serum gamma-glutamyltransferase (γ-GT) concentrations are a 
hallmark biochemical distinction between PFIC3 and other PFIC types. However, γ-GT 
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levels in both wild-type and homozygous mice were below the detectable limit (5 U/L) of 
the chemical analyser. Previous studies have shown that serum γ-GT concentrations are 
found at very low levels in juvenile and adult mice (≤1.1 U/L),439 due to interspecies 
differences, and thus have limited utility as a marker of hepatobiliary disease in murine 
models using standard analytical techniques. 
Liver specimens obtained from wild-type and homozygous juvenile Abcb4 mice were 
fixed in formalin, embedded in paraffin, and sectioned for histological comparison. Liver 
sections were stained with haematoxylin & eosin to examine for liver inflammation and 
architectural distortion, and Sirius Red, which marks tissue collagen to highlight the 
development of liver fibrosis.  
Similar to paediatric patients with PFIC3 with a severe functional MDR3 defect, juvenile 
Abcb4
-/-
 mice exhibited progressive liver disease.
288,297
 Periportal inflammation was 
evident from 3 weeks of age. Increased collagen deposition around and between portal 
tracts was observed from 5 weeks of age, whilst incomplete bridging fibrosis and early 
cirrhosis was seen at 7 and 9 weeks, respectively (Figure 4.1). No visible pathology was 
evident in histological sections from wild-type mice. 
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4.2.2. Liver Transduction of Disease-Free Wild-Type Mice Compared with 
Diseased Homozygous Juvenile Mice 
To evaluate liver transduction in juvenile wild-type and homozygous mice, a rAAV 
reporter vector
181
, previously constructed in our laboratory was used. This vector encoded 
an enhanced green fluorescent protein (eGFP) reporter under the transcriptional control of 
a liver specific promoter and enhancer unit containing a human alpha-1 antitrypsin 
promoter and 2 copies of the hepatocyte control region of a human apolipoprotein E 
enhancer to confer strong hepatocyte specific expression.  Enhanced GFP expression was 
also enhanced with the inclusion of a woodchuck hepatitis post-transcriptional regulator 
element (WPRE) (Figure 4.2). The vector construct was packaged in an AAV serotype 8 
capsid for efficient murine hepatocyte transduction. 
Juvenile wild-type (Abcb4
+/+
) and homozygous (Abcb4
-/-
) mice were injected with 2.5 × 
10
11
 vector genomes (vg) into the intraperitoneal cavity at birth, 2, 4, 6, and 8 weeks of 
age (n ≥ 3 per group). Males and females were analysed separately as there are known 
sexual dimorphic differences in AAV vector transduction, as well as possible gender 
differences in disease progression. Liver and blood samples were obtained from each 
mouse 1 week post-inoculation to analyse for vector transduction and transgene 
expression. Characterisation of liver disease progression was also performed on these 
samples. AAV vector transduction is not known to affect liver function or cause any 
significant liver pathology in mice (Section 4.2.1). A short time-frame was selected to 
minimise the effect of transgene expression loss due to liver growth. 
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Figure 4.2: Schematic diagram of reporter vector (rAAV2/8.LSP.eGFP). The vector 
has a 3131bp expression cassette and encodes an enhanced green fluorescent protein 
(eGFP) under the transcriptional control of a human alpha-1 antitrypsin promoter 
(hAAT), downstream of 2 copies of the hepatic control region of the human 
apolipoprotein E enhancers (apoE). Abbreviations: ITR, AAV inverted terminal repeats; 
WPRE, woodchuck hepatitis post-transcriptional regulatory element; BGHpA, bovine 
growth hormone polyadenylation signal; bp, base pairs. 
 
To assess vector delivery and molecular transduction of the liver, DNA was extracted 
from bulk liver samples from vector-injected mice (Section 2.6.1). Quantitative real-time 
PCR was performed to detect the number of vector copies using a primer set and probe 
directed against the WPRE sequence, and normalised against genomic GAPDH copies 
(Sections 2.6.1 & 2.6.3).  
A comparison between wild-types and homozygotes of the mean vector copies per diploid 
genomes from each age group as shown (Figure 4.3). Across all age groups, the mean 
vector copies detect in homozygous livers were lower compared to age-matched wild-
types, indicating lower levels of vector delivery and/or transduction in homozygotes. 
Although not statistically significant, small differences were also observed in male and 
female mice treated as neonates, in whom no detectable liver pathology was evident. 
There may be changes at an ultra-structural level and subtle microscopic differences 
which were not apparent on sections examined. Unfortunately, biochemical analyses for 
hepatobiliary abnormality using the automated chemical analyser were also not possible 
due to inadequate volumes of plasma samples obtained from these young mice. 
3131bp 
200bp 
ITR apoE/apoE/hAAT eGFP BGHpA ITR WPRE 
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As expected, female mice at all ages, except those injected at birth, had lower levels of 
vector transduction compared with age-matched male counterparts of the same genotype. 
This was due to well-described gender differences in murine liver transduction, related to 
hormonal influences.
440
  
 
Figure 4.3: Comparison of Molecular Transduction between Wild-type and 
Homozygous Juvenile Mice. Age-matched wild-type (black columns) and homozygous 
(white columns) males (a) and females (b) were intraperitoneally inoculated with rAAV 
vector at different ages from birth to 8 weeks. Vector copies from DNA extracted from 
bulk liver samples obtained 1 week post-inoculation were analysed using qPCR. Mean 
vector copies detected in liver samples were normalised against genomic GAPDH copies. 
Error bars represent standard error of the mean. Statistical significance was defined by p ≤ 
0.05, using unpaired Student‟s t-tests. 
 
4.2.3. eGFP Expression is Reduced in Homozygous Animals Compared with Age-
Matched Wild-Type Controls 
Histological assessment of eGFP expression using fluorescence microscopy was 
performed on 5 µm sections of cryopreserved rAAV-transduced murine liver tissue. For 
orientation of hepatic acini, histological sections from mice older than 2 weeks of age 
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were counterstained with an antibody raised against glutamine synthetase that marks 
hepatocytes immediately adjacent to central veins. Glutamine synthetase counterstaining 
was not possible in mice injected at birth because this enzyme protein is not readily 
detectable in perinatal liver tissue.
441
 
A clear difference in the distribution of GFP-expressing hepatocytes was observed 
between wild-type and homozygous liver from mice inoculated at 2 weeks or older, 
irrespective of gender (Figure 4.4). The differences between genotypes of both male and 
female neonates injected at birth were more subtle. Previous studies demonstrate that 
rAAV2/8 vectors preferentially mediate a centrilobular pattern of hepatocyte transduction 
and transgene expression in mice in the short-term.
185,442,443
 This centrilobular pattern of 
eGFP expression was also observed in wild-type male and female mice from 5 weeks of 
age. However, in the presence of liver disease, this zonal pattern was less apparent. In 
fact, a lack of clustering of eGFP-expressing hepatocytes around central veins was 
observed in some homozygous mouse livers samples (Figure 4.5). 
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Figure 4.4: Fluorescent Microscopy Images of Liver Sections from Wild-type and 
Homozygous Mice.  At the defined ages, each mouse received identical doses of the 
reporter rAAV vector encoding enhanced green fluorescent protein (eGFP) and liver 
tissue was analysed 1 week post-inoculation. Sections were counterstained with a 
glutamine synthetase antibody, and marked with a red fluorophore to identify hepatocytes 
surrounding the central veins. Sections were also stained with 4',6-diamidino-2-
phenylindole (DAPI) to mark nuclei. Scale bar = 50 µm  
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Figure 4.5: Comparison of eGFP expression pattern across the hepatic porto-central 
axis in wild-type and homozygous mice. Representative images from 7 week old wild-
type and homozygous males injected with eGFP vector at 6 weeks of age. The zonal 
pattern of transgene expression with pericentral predominance seen in the wild-type liver 
is not evident in the homozygous liver at 7 weeks of age. The portal triads (PT) in the 
homozygous liver are markedly infiltrated with inflammatory cells. Hepatocytes around 
the central veins were immunostained with anti-glutamine synthetase antibody and 
marked with an Alexa Fluor 594 secondary antibody (red).Scale bar = 50µm. 
 
Enhanced GFP expression was quantified by flurometry (Section 2.6.4) Fluorescence 
detection, with an excitation and emission filter set at 485nm/535 nm, of 50 mg of whole 
liver protein from each mouse was performed in triplicate using a VICTOR
3
 multi-label 
reader (PerkinElmer, USA). The amount per sample was calculated based a standard 
curve formed by serial dilutions of known quantities of recombinant GFP (BioVision 
Research Products, USA). 
Consistent with the levels of normalised liver vector copies, homozygotes had reduced 
amount of eGFP expression compared with their age-matched wild-type counterparts, 
across all ages (Figure 4.6). Neonatally injected homozygous mice had higher relative 
levels of eGFP expression, whilst there was a precipitous drop in transgene expression in 
older homozygotes. This was consistent with observations made on fluorescent 
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microscopy. Wild-type and homozygous females had lower levels of liver eGFP 
compared with males, also in keeping with transduction data and known sexual dimorphic 
patterns, as described. 
 
Figure 4.6: Quantitation of eGFP expression by fluorometry of liver protein lysates. 
Homozygous liver samples (white bars) had reduced levels of eGFP expression, compared with 
age-matched wild-types (black bars).  The highest level of relative eGFP expression occurred in 
neonatally injected mice, irrespective of gender. Error bars represent standard error of the mean. 
Statistical significance was defined by p ≤ 0.05, using unpaired Student‟s t-tests (marked by #). 
 
  
 Chapter 4: Impact of Liver Pathology on rAAV Hepatocyte Transduction 
153 
 
4.3. DISCUSSION 
Experiments outlined in the previous chapter demonstrated that poor AAV vector 
transduction of the liver of homozygous adult males was responsible for the lack of 
therapeutic response in these animals with established chronic liver disease. The effect 
appeared to be independent of vector genome size, suggesting that homozygous host- 
rather than vector-derived factors impeded AAV vector delivery and transduction. 
Nevertheless, exceeding rAAV packaging capacity is known to be detrimental to 
transduction. We hypothesised that the presence of liver pathology independently led to 
ineffective rAAV delivery and transduction of hepatocytes.  
Here, the impact of progressive liver disease of juvenile Abcb4
-/-
 mice on rAAV-mediated 
hepatocyte transduction and transgene expression was characterised using an eGFP 
reporter vector that was 67% wild-type AAV size, in order to evaluate the impact of liver 
pathology without the influence of oversized vectors on rAAV transduction. Hepatocyte 
transduction was evaluated in juvenile mice of different ages from birth to young 
adulthood (8 weeks), in order to understand the impact of liver disease progression, and to 
determine the optimal age for administering gene therapy to maximise efficacy in this 
model.  
In comparison to disease-free age-matched wild-type mice, there was a trend towards 
lower levels of rAAV transduction in homozygotes at all ages with correspondingly 
reduced transgene expression. However, due to small sample sizes, statistical significance 
was not established in all age groups. More replicates will be necessary to confirm these 
results. Nevertheless, there appeared to be an effect even before histopathological changes 
were visible on light microscopy. It is possible that changes at an ultrastructural level 
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and/or differences in intra-hepatocyte processing of rAAV in the homozygous liver could 
be responsible for the discrepancy in rAAV transduction at early time-points. 
Additionally, as discussed in the previous chapter, cytokine-mediated transcriptional 
silencing was implicated to result in reduced rAAV-encoded transgene expression in the 
inflamed liver.
221
 This may also explain differences in transgene expression in this model, 
given that Abcb4
-/-
 mice exhibited increased periportal inflammatory infiltration with age 
and disease progression. To better define why rAAV transduction is limited in Abcb4
-/-
 
mice, further studies to empirically assess each potential mechanism will be necessary. 
In addition to liver fibrosis and inflammation seen on light microscopy, the use of 
electron microscopy to examine changes in sinusoidal endothelial fenestrae, 
perisinusoidal spaces and basolateral hepatocyte surface area may identify potential 
barriers to rAAV delivery to hepatocytes. Direct and indirect assessments of portal 
pressures in this disease model may help substantiate whether a link between portal 
hypertension and reduced rAAV delivery and transduction exists. The potential 
contribution of rAAV episomal loss through high cell turnover in the diseased liver could 
be evaluated using cell proliferation markers such as by Ki67 staining or 
Bromodeoxyuridine (BrdU) incorporation studies. Furthermore, careful mapping of 
intracellular trafficking patterns in diseased and non-diseased livers would also be of 
value. For example, intracellular tracking of rAAV, possibly by fluorescence in-situ 
hybridisation together with confocal microscopy at various time-points post-inoculation, 
and evaluating the effect of proteasome inhibitors may shed light on potential temporal 
differences in intracellular rAAV trafficking to the nucleus, possible sequestration in 
intracellular organelles and contribution of proteasomal degradation. Southern blot 
analyses of low molecular weight DNA extracted from hepatocytes may determine if 
homozygotes have differential rates of conversion from single-stranded to double-
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stranded forms. Understanding rAAV biology in a disease-specific context has important 
implications for developing a therapeutic strategy targeting hepatocytes for PFIC3, and 
possibly other chronic liver diseases. In such circumstances, the presence of chronic liver 
pathology and other disease-related changes may limit the potential efficacy of 
hepatocyte-targeted rAAV therapy.  
The effects of liver pathology on gene transfer using viral vector systems have previously 
been reported in the literature. In a comparative study using adenoviral vectors expressing 
a β-galactosidase reporter, Garcia-Bañuelos et al., demonstrated greater than 80% of 
hepatocytes could be transduced in healthy rat livers, compared with 40% in carbon 
tetrachloride (CCl4)-induced fibrotic livers and 10% transduction in livers with bile duct 
ligation-mediated cirrhosis.
444
  
This study also suggests that different experimental models of hepatic fibrosis may have 
variable effects on viral vector transduction. In the early stages of cirrhosis development, 
histopathological patterns can vary depending on the aetiology. The same is also true for 
experimental models of cirrhosis. CCl4 initially mediates a centrilobular (Zone 1) pattern 
of liver injury, whereas bile duct ligation causes a cholangiopathy that initially affects 
Zone 3 (which is similar to the pattern of progressive liver disease in the Abcb4
-/-
 mouse 
model). The pattern of liver injury may potentially affect the biodistribution of rAAV 
vectors, delivery and transduction of hepatocytes across the hepatic acini. Another study, 
using a bile duct ligation rat model showed significant reduction in vector uptake by 
cirrhotic livers with unanticipated redistribution of vector to pulmonary macrophages.
445
  
One important factor to consider in these studies is the relative size of recombinant 
adenoviral vectors (Ad5 vector diameter: 93 nm with 30 nm protrusions) in comparison to 
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recipient sinusoidal endothelial fenestrae diameter (e.g. Sprague Dawley rats: 150-175 
nm
91
), which has been shown to be an important determinant of hepatocyte 
transduction.
94,446
 Indeed, the degree of transgene expression from adenoviral-mediated 
transduction correlated with the diameter of sinusoidal endothelial fenestrations amongst 
healthy animals of different species,
93,94
 and strategies used to increase fenestrae size such 
as provoking transient liver ischemia to induce nitric oxide production, and increasing 
intrahepatic pressure by hepatic venous outflow occlusion, resulted in improved 
hepatocyte transduction and transgene expression.
94,447
 Therefore, it would be reasonable 
to suggest that the major obstacle to hepatocyte transduction using adenoviral vectors in 
cirrhotic livers may be defenestration and smaller fenestrae size accompanying the 
disease process, and that transduction mediated by smaller vectors such as rAAV (22-25 
nm diameter) are less likely to be affected. However, hepatocyte transfection by 
hydrodynamic injection of naked DNA (<1 nm diameter
96
) was impeded in rats with 
thioacetamide-induced cirrhosis, despite the procedure forcing large endothelial gaps.
448
 
Thus, having adequate endothelial gap size by itself is not sufficient for effective gene 
transfer. This study used a type I collagen inhibitor to reduce ECM load, which improved 
gene delivery, suggesting that peri-sinusoidal fibrosis is a further barrier to gene transfer 
in the diseased liver, and could affect rAAV transduction. 
Interestingly, a recently published article showed that changing the route of 
administration had significant impacts on the rAAV transduction efficiency in rats with 
CCl4-induced cirrhosis.
449
 The authors showed that in infusion of rAAV vectors directly 
into the hepatic artery was as efficient in healthy and cirrhotic livers, whereas delivery 
into the portal vein lead to lower levels of transgene expression in the presence of 
cirrhosis and in contrast to expression in healthy rat liver. These findings are in keeping 
with vascular changes accompanying cirrhosis, which leads to proportionally higher 
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hepatic arterial (systemic) rather than portal blood supplying cirrhotic liver.
86,450
 Though, 
hepatic arterial injection was not technically feasible in mice, systemic delivery via the 
tail vein in adult homozygous males did not confer higher efficacy compared with the 
intraperitoneal route, and did not improve vector delivery to the diseased livers (Section 
3.3.5). Other potential mechanisms that may contribute to reduced transduction in 
diseased livers such as porto-systemic shunting, altered efficiency of endocytosis at the 
hepatocyte membrane, and sequestration of rAAV into inflammatory or non-parenchymal 
cells with subsequent degradation (as discussed in Chapter 3) warrants further 
exploration. Furthermore, as outlined in the previous chapter, transcriptional silencing due 
to DNA methylation in the presence of liver inflammation may also lead to reduced 
transgene expression in homozygotes. 
Using a rAAV2/8 vector, an altered pattern of eGFP expression along the porto-central 
axis was observed in homozygous liver sections, compared with wild-type liver. Previous 
studies demonstrated a pericentral (zone 3) predominance of transgene expression using 
rAAV2/8 vectors in murine liver tissue,
185,443
 but this may also depend on the age of 
inoculation, duration post-inoculation and the heterologous promoter used (Dane AP, 
unpublished data).
443
 In keeping with findings in Abcb4
+/+
 mice, Dane et al., showed that 
male and female adult mice exhibited a distinct preferentially pericentral pattern of eGFP 
expression in the short term, using the same vector construct as experiments described 
herein.
443
 However, this zonal pattern was not observed in homozygous livers.  
As outlined in Chapter 1, heterogeneity in expression and concentration of many key 
hepatic enzymes, and subcellular structures along the porto-central axis, known as 
metabolic zonation, involves a number of important hepatocellular pathways.
97,98
 It is 
thought to be governed by the differential humoral and neural inputs received by 
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periportal and pericentral hepatocytes due to concentration gradients of oxygen, hormones 
and substrates established during the passage of blood from afferent terminal portal 
venules to efferent tributaries of the hepatic central veins.
99,451
 Functional heterogeneity 
involving some hepatocellular pathways is a dynamic state, as adaptive alterations to 
particular zonated enzymes occur during various physiological and pathological 
situations.
103
 Similarly, loss of the normal hepatocellular zonation pattern has been 
demonstrated in experimental models of cirrhosis.
104,452
 Alterations to the 
microcirculation in chronic liver disease and therefore, changes to input gradients were 
proposed to be the likely cause.
104,453
 Although the mechanisms underlying the zonal 
transduction pattern of specific rAAV pseudo-serotypes are currently unknown, it is 
possible that changes that govern loss of normal hepatocellular zonation in the diseased 
liver also impacts on these underlying mechanisms so as to change the preferential pattern 
of rAAV transduction across the hepatic acinus. Observed alterations in the zonal 
transduction pattern in diseased livers are likely to inform vector design in this context, 
particularly with dynamically zonated transgene targets. Furthermore, they highlight the 
importance of vector optimisation and pre-clinical evaluation using disease relevant 
models. 
Our data indicates that rAAV transduction is blunted in this disease model, and is largely 
ineffective once liver disease is established in the homozygous liver. Therefore, maximal 
efficacy is likely to be achieved prior to onset of liver disease, optimally in the neonatal 
period in the Abcb4
-/-
 mouse. However, an essential challenge with neonatal vector 
delivery is the impact of liver growth and hepatocyte proliferation on vector DNA 
durability and persistence of transgene expression, as a consequence of both degradation 
and dilution of episomes.
181
 Delaying the age of vector administration may increase gene 
transfer stability
454
, but this must be weighed against diminished rAAV-mediated 
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hepatocyte transduction efficiency with progressive liver disease in Abcb4
-/-
 mice. 
Strategies for neonatal rAAV therapy in Abcb4
-/-
 mice will be explored in the Chapter 5. 
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CHAPTER 5: PHENOTYPE CORRECTION OF THE PFIC TYPE 3  
MOUSE MODEL IN VIVO 
 
5.1. INTRODUCTION 
The previous chapter examined the impact of liver pathology on rAAV transduction in the 
Abcb4-knockout mouse model. Limited hepatocyte transduction with rAAV was 
observed in Abcb4
-/-
 mice, particularly in the presence of established liver disease. 
Therefore, for a given input vector dose, maximum therapeutic benefit was conferred 
prior to onset of liver pathology in Abcb4
-/-
 mice, optimally in the neonatal period.  
Cunningham et al., previously demonstrated that degradation of episomal rAAV vector 
occurred rapidly following neonatal administration, resulting in a sharp fall in transgene 
expression to a low steady-state after 2 weeks of age.
181
 In mice intraperitoneally injected 
with 2.5 × 10
11
 vg or higher at birth, ongoing therapeutic benefit beyond 2 weeks of ages 
was dependent on a small population of approximately 4 - 8% of hepatocytes with stably 
integrated vector genomes.
181
 For some potential candidate diseases with early onset, this 
level of residual transgene expression may be inadequate to completely correct the 
disease phenotype. Thus an essential challenge with neonatal vector delivery is to 
maintain sufficient transgene expression in the face of precipitous loss of episomal vector 
during liver growth.  
Delaying the age of vector administration may lead to increased gene transfer stability, as 
progressively more durable transgene expression correlates with slowing of liver 
growth.
181,454
 However in the PFIC3 murine model, potential gains from delaying the 
initiation of therapy must be weighed against waning rAAV-mediated hepatocyte 
transduction efficiency with progressive liver disease. 
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Several strategies have been proposed to maintain transgene expression following 
neonatal vector administration. Firstly, re-administering rAAV vector at later time points 
may keep transgene expression above a disease-specific threshold necessary to prevent or 
halt symptoms and/or pathology. Recombinant AAV vector readministration strategies 
have been used to successfully confer long-term efficacy in some pre-clinical disease 
models, in particular when directly targeting immunoprivileged sites – e.g. selected 
compartments of the eye and brain.
214,455-457
 In other more immunogenic target tissues 
such as liver, muscle and lung, addressing humoral immune responses that blunt 
therapeutic efficacy of re-administered vector becomes a vital consideration in devising 
an effective multiple-dosing strategy.
54
  
Following initial rAAV exposure, the immune system may be primed to produce 
neutralising antibodies against either capsid protein or transgene product. Thus, upon re-
exposure, induction of anti-capsid antibody production and activation of memory CD8
+
 
T-cells may lead to clearance of subsequently delivered rAAV vector and T-cell mediated 
destruction of transduced cells that display capsid epitopes, resulting in marked 
attenuation of the therapeutic effect.
209,458
 Additionally, delaying the initial age of 
administration has been associated with an increased anti-AAV capsid neutralising 
antibody response.
459
 Therefore, timing of both initial and subsequent rAAV delivery is 
another crucial issue. 
One way of circumventing anti-capsid responses is to substitute the packaging capsid to 
produce an alternate pseudo-serotyped vector for subsequent doses, in order to avoid 
antibody-mediated destruction of re-delivered rAAV vectors and transduced cells.
214
 For 
this strategy to be effective, antibodies and capsid-specific T cells that are produced 
following the initial rAAV exposure must have limited cross-reactivity against the 
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substitute capsid protein.
214,460,461
 However, there is a high degree of conservation of 
AAV capsid structure and sequence, and substantial cross-reactivity between naturally 
occurring serotypes.
462-464
 This has prompted engineering of new AAV variants with 
limited cross-recognition by pre-existing neutralising antibodies, through identification 
and modification of immunogenic domains of the AAV capsid or screening of capsid 
libraries generated by error-prone PCR.
464-466
 Pseudo-serotyping with new AAV capsid 
variants specifically engineered to evade humoral immunity as well as to increase target 
cell transduction may be necessary for effective vector re-administration. 
Additionally, adjuvant short-term immunosuppressant therapy may help attenuate 
antibody responses towards re-delivered vector. Combinatorial immunosuppression using 
rituximab (B-cell depleting monoclonal antibody) with cyclosporine A (calcineurin 
inhibitor) designed to eradicate anti-human factor IX antibodies in non-human primates 
during rAAV vector re-delivery, also lead to diminished neutralising anti-capsid 
responses sufficient to permit effective rAAV re-administration.
467
 However, an 
observational study involving rheumatoid arthritis patients, aimed at evaluating the effects 
of rituximab on anti-AAV antibody titres in the serum and synovial fluid, found modest 
reduction in neutralising anti-AAV antibodies only in a subset of patients with low, but 
not high antibody titres. This highlights the challenge of using such manoeuvres in the 
clinical setting.
468
 It is possible that immunosuppression could be more effective if used 
in conjunction with other measures to reduce circulating or localised neutralising 
antibodies. These include plasmapheresis
469,470
, flushing the liver with saline prior to 
portal vein administration of rAAV to reduce direct contact between vector and 
neutralising antibodies
471
, or loading the vector formulation with empty capsid decoys, 
that are aimed at adsorbing neutralising antibodies without transducing target cells.
472
 
Since pre-existing anti-AAV antibodies are prevalent in humans, even among young 
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infants via maternally-transferred passive immunity
225,463
, these manouvres are likely to 
be important adjuncts to make AAV-mediated gene therapy available to more patients. 
A second strategy to achieve long-term transgene expression with neonatally-initiated 
therapy is by increasing somatic integration of the transgene expression cassette. This 
could be achieved by using an integrating gene transfer system. One of the most studied 
integrating viral vectors is based on lipid-enveloped lentiviruses, which belong to the 
retroviridae family.
473
 Upon transduction, lentiviruses use reverse transcriptase to 
transcribe its single-stranded RNA genome into linear double-stranded proviral DNA that 
is integrated into the host genome.
129
 Whilst to date lentiviral-mediated gene transfer has 
been clinically approved only for ex vivo approaches, pre-clinical evaluation of in vivo 
gene therapy applications using this vector system have also been undertaken for a 
number of human diseases.
130
  
HIV-based lentiviral vectors are capable of transducing a wide array of both mitotic and 
post-mitotic cells
129
, and have been used as a platform for in vivo liver-directed therapy in 
pre-clinical models of diseases such as Crigler Najjar Type I
217,474
, Haemophilia A
475
, von 
Willebrand Disease
476
, Type I Diabetes Mellitus
477
, Methylmalonic aciduria
478, Wilson‟s 
Disease
479,480
, Familial Hypercholesterolaemia
481
 and Mucopolysaccharidosis Type I
482
.  
A lentiviral-based approach to correct the PFIC3 disease phenotype was attempted, but 
proved ultimately unsuccessful due to an inability to produce an effective vector of 
sufficiently high titre.
483,373
 During the packaging process, expressed phosphatidylcholine 
floppase, ABCB4 (MDR3), led to altered phospholipid composition of the lentiviral 
particle envelop, which was highly enriched with phosphatidylcholine and cholesterol. 
This resulted in reduced lentiviral infectivity and an approximate 6-fold drop in 
transducing titres, which was not demonstrated by co-expressing an inactive mutant 
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ABCB4 or an unrelated ABC transporter.
373
 In this study, wild-type ABCB4 was 
expressed under a ubiquitous cytomegalovirus promoter in HEK 293 cells. It is possible 
that restricting ABCB4 expression during the lentiviral production process by the use of a 
liver-specific promoter may lessen its detrimental impact on viral vector production and 
transducibility. Nevertheless given these challenges, a lentiviral-based approach may not 
be able to surmount the greater demands of neonatal therapy to allow long-term PFIC3 
phenotype correction.     
As an integrating non-viral gene transfer system, transposons are emerging as an 
attractive gene delivery method to facilitate prolonged gene expression, and may be 
another alternative strategy for long-term expression with neonatal gene therapy.
484,485
 
Originally discovered by Barbara McClintock, transposons are non-infectious, mobile 
genetic elements that can integrate their genetic cargo into the host DNA.
486
 There are 2 
classes of transposons: i) retrotransposons which undergo transposition via mRNA 
transcript intermediates using a “copy and paste” mechanism, and ii) DNA transposons 
which are transposed using a “cut and paste” mechanism.487,488 Naturally occurring DNA 
transposable elements have 2 inverted repeats that flank a sequence encoding the 
recombinase protein, transposase.
489
 For DNA transposition to occur, transposase must 
precisely recognise and bind to the inverted repeat sequences, in order to catalyse 
movement of the intervening DNA sequence from one chromosomal site to another in the 
host genome.
485,490
 To utilise transposon technology as a gene transfer tool, dual vector 
systems have been developed consisting of a plasmid containing donor DNA sequence of 
interest flanked by transposon inverted repeats, with encoded transposase provided in 
trans.
488,491
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DNA transposons have been applied successfully for both ex vivo and in vivo gene 
therapy in pre-clinical models of a number of liver-related diseases including 
Haemophilia A
492,493
 and B
494
, Tyrosinemia Type I
495
, Crigler Najjar Type 1
496
, 
Mucopolysaccharidoses
497-499
 and Type I diabetes mellitus
34
. Furthermore, transposons 
have been recently approved for clinical use to genetically modify T-lymphocytes to 
target tumour cells for treatment of B-cell lymphoid malignancies.
500,501
 Other ex vivo 
approaches include gene modification of primary and progenitor human cells for 
therapeutic purposes and for reprogramming somatic cells to generate induced pluripotent 
stem cells.
502-504
 
The Sleeping Beauty (SB), piggyBac (PB) and Tol2 elements represent the most 
promising DNA transposons for gene therapy applications.
484,485,488
 All 3 systems have 
demonstrated appreciable transposition in mammalian and human cells, and are capable 
of providing prolonged transgene expression, though with variable efficiencies.
505,506
 A 
comparative analysis demonstrated that under non-restrictive conditions, the SB and PB 
transposon systems had similar transpositional activity, but were more efficient than 
Tol2.
506
 However, discordant reports regarding the relative efficiencies of SB and PB 
systems suggest that this may be influenced by the target cell type, and specific 
transposase deployed. Frequent improvements have been made to both systems by 
generating newer and more efficient transposases through codon-optimisation and hyper-
active mutations.
507-509
 Nonetheless, a major limitation of SB is its greater sensitivity to 
overexpression inhibition, in which overconcentration of SB transposase hinders 
transpositional activity by quenching the reaction and sequestering transposase in foci 
within the cytoplasm, nucleoplasm or nucleoli.
506,510-512
 Other advantages of PB over SB 
are the ability to efficiently mobilise large genetic cargo, up to 100 kb
513
, compared with 
less than 10 kb with SB,
514,515
 and seamless excision of transposons without leaving any 
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molecular “footprint”, unlike SB that introduces a TA dinucleotide duplication at the site 
of integration and excision.
516-518
  
One of the major challenges shared by all the transposon systems is achieving efficient in 
vivo delivery of the transposon and transposase to the target cell. For transposition to 
occur in the nucleus, transposon and transposase need to traverse extracellular and 
intracellular barriers. This is effectively achieved by coupling with a non-viral or viral 
vector. To protect nucleic acids from degradation by nucleases in the circulation and 
extracellular matrix, and to aid cellular uptake, non-viral vehicles such as 
polyethylenimine (PEI) and nanoparticles have been used to deliver transposons to the 
liver in vivo.
492,519
 Physical methods such as hydrodynamic injection have also been 
applied to transfect hepatocytes in situ.
520-522
 
Hydrodynamic injection has been widely used as a proof-of-concept approach in 
therapeutic small rodent models in vivo.
523-525
 This procedure performed in mice involves 
rapid, systemic infusion of a large volume of DNA solution, equivalent to approximately 
8-10% of its body weight, via the tail vein. The hydrodynamic pressure generated by the 
rapid, high-volume injection facilitates uptake of infused DNA by up to 10% of 
hepatocytes, through expanded and ruptured liver sinusoidal endothelium.
525
 Although 
hydrodynamic injection via the systemic circulation is generally well tolerated in rodents, 
safe and effective clinical application is not likely to be feasible, as the heavy fluid 
overload may cause cardiac congestion and induce cardiac dysfunction. To address this 
limitation, modifications have been recently explored such as localised delivery with 
much reduced volumes and speed, and by using balloon catheters to isolate the liver 
vasculature.
526,527
 However, disturbances to cardiovascular dynamics, transient 
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myocardial ischaemia, arrhythmias and cardiac dysfunction, as well as limited 
effectiveness remain a concern.
527,528
  
Gene therapy strategies toward PFIC3 are likely to require an in vivo gene transfer 
approach, since primary hepatocytes are difficult to propagate and maintain in vitro, 
differentiating stem cells to fully mature hepatocytes is challenging, and presently, 
hepatocyte transplantation has limited efficacy.
529
 Despite recent improvements in non-
viral gene delivery methods, transfection efficiencies with in vivo approaches reported to 
date remain substantially below that which can be achieved using viral vectors.
124,530
 
Through their highly evolved mechanism for efficient cellular uptake and intracellular 
trafficking, recombinant viral vectors such as herpes simplex viruses and adenoviruses 
have also been employed to deliver transposons into cells in vivo.
494,531,532
 Integrase-
deficient lentiviruses and recombinant AAV vectors have also been used in vitro.
533,534
  
Given that rAAV has many attributes that make it a promising hepatic gene transfer 
candidate, it may also be a suitable vehicle for delivering transposons for in vivo liver-
targeted gene therapy. However, as well as conferring efficient gene transfer to target 
cells, coupling a recombinant viral gene delivery system with transposon technology also 
imposes some of its inherent shortcomings including potential immunogenic risks. 
Furthermore, AAV‟s limited packaging capacity will also restrict the size of genetic cargo 
that can be transposed. Additionally, there is the need to independently deliver 
transposase in trans. If rAAV is also used to encode a piggyBac transposase expression 
cassette, relatively high vector doses are likely to be required to meet the challenge of 
two-hit kinetics, since both transposon and transposase vector particles need to transduce 
individual hepatocytes for piggyBac transposase-mediated integration to occur. 
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In this chapter, two strategies are explored to overcome loss of rAAV episome-derived 
transgene expression, in order to correct the PFIC3 disease phenotype in Abcb4
-/-
 mice: i) 
vector re-administration of conventional rAAV encoding hABCB4, and ii) a novel, hybrid 
rAAV-piggyBac transposon system devised to integrate a codon-optimised hABCB4 
expression cassette into hepatocytes of neonatal mice in vivo. The hybrid rAAV-piggyBac 
transposon vector system was also used to evaluate the therapeutic potential of 3 
described hABCB4 transcript variants, in order to determine the optimal configuration for 
a PFIC3 therapeutic vector. The efficacy of this hybrid model was further evaluated in the 
context of delaying the initial age of therapy, in order to better represent the typical 
ascertainment pattern of clinical PFIC3 cases, as universal newborn or pre-symptomatic 
genetic screening is currently not widely available for this disorder. 
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5.2. MATERIALS AND METHODS 
5.2.1. Construction of Hybrid rAAV-piggyBac Transposon Proviral Constructs 
5.2.1.1. pAAV2.pBRsh.LP1.cohABCB4 
In order to package a piggyBac transposon as a rAAV vector, piggyBac inverted repeat 
sequences were subcloned into a rAAV proviral construct containing a custom-
synthesised, codon-optimised hABCB4 coding sequence. PiggyBac inverted repeats are 
binding sites for piggyBac transposase to mediate integration and excision of the 
intervening sequence into the genome via a cut and paste mechanism.  
A hybrid rAAV-piggyBac transposon proviral construct (pAM.LSP1.mOTC+TRS, Table 
2.5) was produced in our laboratory from sequence previously reported.535,536 However, 
when combined with an expression cassette encoding hABCB4 coding sequence, the 
addition of the piggyBac inverted repeat sequences (pBRSI, 313 bp; pBRSII, 235 bp) 
contained in this donor plasmid would have exceeded the AAV packaging capacity by at 
least 15%. Therefore, short piggyBac inverted repeat sequences were amplified by PCR 
from this donor plasmid, based on sequences reported to facilitate effective transposition 
by Meir et al.
537
 These short piggyBac inverted repeat sequences, 5‟TRsh (67 bp) and 
3‟TRsh (40 bp), were subcloned downstream of the 5‟ AAV2 ITR and upstream of the 3‟ 
AAV2 ITR, respectively, flanking the expression cassette containing hABCB4 coding 
sequence, as follows (Figure 5.1). 
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Figure 5.1: Flow diagram of molecular subcloning steps taken to generate 
pAAV2.pBRsh.LP1.cohABCB4 and pAAV2.pBRsh.LP1.eGFP. Detailed explanations 
of subcloning steps are described in Sections 5.2.1.1 and 5.2.1.2. AAV2 ITRs (Black 
boxes) flank the piggyBac transposons, which contain the transgene expression cassette. 
PiggyBac transposons, flanked by short piggyBac inverted repeat sequences (striped 
boxes), contain a liver-specific promoter/enhancer, LP1 (dark grey boxes), transgene as 
shown, and an SV40 polyadenylation signal (light grey boxes). Restriction enzyme digest 
sites are abbreviated as the following: AgeI, A; EcoRV, E; HindIII, H; MluI, M; SpeI, S; 
XbaI, X. Scale bar = 300 bp. 
 
The 5‟ short piggyBac inverted repeat sequence (5‟TRsh) was amplified by PCR from the 
5‟ end of pBRSII using primers, 5pBTRShort-F and 5pBTRShort-R, and the 3‟ short 
piggyBac inverted repeat sequence (3‟TRsh) was amplified from the 3‟ end of pBRSI 
using primers, 3pBTRShort-F and 3pBTRShort-R (Chapter 2, Table 2.6). The 5‟TRsh 
PCR product containing SpeI and EcoRV sites at the 5‟ end and a SpeI site at the 3‟ end 
was TA subcloned into a pGEM
®
-T Easy cloning vector, propagated in chemically-
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competent E. coli (JM109, Promega) and digested at flanking SpeI sites. This fragment 
was subcloned into a prepared recipient plasmid digested at a SpeI site immediately 
upstream of LP1 transcriptional control unit sequence, which also had an XbaI site at the 
3‟ end. The 5‟TRsh with LP1 was then excised from the resulting plasmid by digesting at 
flanking EcoRV and XbaI sites. Fragments containing 5‟TRsh sequence in the correct 
orientation and position with respect LP1 were selected using agarose gel electrophoresis 
(5‟TRsh with LP1, 536 bp; fragment without 5‟TRsh, 467 bp). A 536 bp fragment was 
then subcloned into a recipient pAAV2.LP1.hABCB4v3 plasmid, prepared by digesting at 
corresponding EcoRV and XbaI sites.  
Using a similar strategy, the 3‟TRsh PCR product containing a MluI sites at the 5‟end, 
and AgeI and MluI sites at the 3‟ end was also TA subcloned into a pGEM®-T Easy 
cloning vector, propagated in chemically-competent E. coli (JM109) and digested at 
flanking MluI sites. The 3‟TRsh fragment was then subcloned into a recipient plasmid, 
prepared by restriction site digest at a MluI site immediately downstream of a SV40pA 
sequence, which had an upstream HindIII site. Fragments containing the SV40pA with 
3‟TRsh, digested at flanking HindIII and AgeI sites were 199 bp in length. If the 3‟TRsh 
fragment inserted in the incorrect orientation, digestion of the resulting plasmid at HindIII 
and AgeI sites would result in a 151 bp fragment containing the SV40pA sequence only. 
The 199bp fragment, size-selected by agarose gel electrophoresis, was then subcloned 
into a pAAV2.LP1.hABCB4v3 plasmid containing the 5‟TRsh at corresponding HindIII 
and AgeI sites downstream of hABCB4. 
In order to improve transgene expression, codon-optimised hABCB4 coding sequences 
(cohABCB4) were custom synthesised with an optimised Kozak consensus sequence 
immediately upstream of the start codon (GenScript USA Inc., NJ, USA). As described in 
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Chapter 1, there are 3 known transcript variants found in the human liver, that result from 
alternate splicing. Transcript variant A (Genbank Acc. No. NM_000443.3) is 3849 bp in 
length. Transcript variant B (Genbank Acc. No. NM_018849.2) uses an alternate in-frame 
splice site in the 3‟ coding region that results in an additional 21 bp relative to variant A. 
Whereas, transcript variant C (Genbank Acc No. NM_018850.2) lacks an alternate in-
frame exon, compared to variant A, resulting in a protein (isoform C) that is 47 amino 
acids shorter than isoform A. Little is known about the relative phospholipid floppase 
activity of each of the isoforms or potential alternate intracellular functions.  
To compare their in vivo phospholipid floppase activity, cohABCB4 sequences were 
custom synthesised in several parts. Each of the translated proteins from the 3 known 
splice variants has common amino acid sequence at the N terminus. Therefore, a custom-
synthesised common 5‟ sequence was designed, alongside 3‟ sequences for each of the 3 
known transcript variants. Using a common HpaI site 2567 bp from the start codon, the 
common upstream fragment was combined with each of the variant 3‟ fragments to 
produce a codon-optimised version of each of the known transcript variants. These were 
digested at flanking XbaI and HindIII sites and subcloned into pAAV2.LP1.hABCB4v3 
containing both 5‟ and 3‟ TRsh sequences to replace existing hABCB4. 
Each of the cohABCB4 transposon proviral constructs (Figure 5.2) were verified by 
restriction site mapping and Sanger sequencing. A plasmid map of a transposon proviral 
construct containing cohABCB4 variant A coding sequence and indicating position of 
unique restriction enzyme sites is shown (Figure 5.3a). Plasmids containing variant B and 
C coding sequences have identical configuration.  
Recombinant AAV vector stocks, packaged in a serotype 8 capsid, were generated from 
each of the plasmid constructs containing cohABCB4 transcript variants and short 
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piggyBac inverted terminal repeats, using a triple plasmid transfection system in HEK 
293 cells (Section 2.4). These were designated rAAV2/8.pBRsh.LP1.cohABCB4-varA, 
rAAV2/8.pBRsh.LP1.cohABCB4-varB and rAAV2/8.pBRsh.LP1.cohABCB4-varC. The 
genomes of each variant rAAV produced were approximately 105-106% wild-type AAV 
size. 
 
Figure 5.2: AAV2 proviral constructs containing short piggyBac inverted repeats. 
Each construct has identical configuration except for the transgene sequence. AAV2 ITRs 
(Black boxes) flank the piggyBac transposons, which contain the transgene expression 
cassette. PiggyBac transposons are flanked by short piggyBac inverted repeat sequences 
(striped boxes), for recognition and binding of piggyBac transposase to facilitate 
transposition. Each expression cassette contains a liver-specific promoter/enhancer, LP1 
(dark grey boxes), transgene as shown, and an SV40 polyadenylation signal (light grey 
boxes). Sequence length and proportion to wild-type AAV genome length is indicated. 
Scale bar = 300 bp.   
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Figure 5.3: Plasmid maps of pAAV2.pBRsh.LP1.cohABCB4-var A (a) and 
pAAV2.pBRsh.LP1.eGFP (b). The position of unique restriction enzyme sites are 
marked on the plasmid maps as follows: EcoRV (E), SpeI (S), XbaI (X), HindIII (H), ClaI 
(C), MluI (M), and AgeI (A). Each plasmid contains an ampicillin resistance gene (Amp-
R) for selection. ITR, inverted terminal repeats; 5‟TRsh and 3‟TRsh, 5‟ and 3‟ short 
piggyBac inverted repeats, respectively; LP1, liver specific promoter; SV40pA, Simian 
virus 40 polyadenylation sequence. Plasmid maps were generated using EZ Plasmid Map 
v9.1.
539
  
 
5.2.1.2. pAAV2.pBRsh.LP1.eGFP 
To test the hybrid rAAV-piggyBac transposon vector system with the short transposon 
inverted repeats in vivo, an eGFP reporter construct was produced. An eGFP coding 
sequence was amplified by PCR using primers eGFP-F and eGFP R (Table 2.6), and a 
previously constructed plasmid, pAM.EFlα.eGFP (Table 2.5), as the template. The PCR 
product consisted of an eGFP coding sequence with an optimised Kozak consensus 
sequence, and an XbaI and HindIII sites flank the 5‟ and 3‟ ends, respectively. This was 
TA subcloned into a pGEM
®
-T Easy cloning vector, propagated in chemically-competent 
E. coli (JM109), excised using XbaI and HindIII digests, purified by gel extraction and 
inserted into a recipient AAV2 proviral construct containing short transposon inverted 
repeats, prepared by removing a cohABCB4 coding sequence using paired XbaI and 
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HindIII digests. Recombinant AAV vector stocks were produced using the eGFP 
transposon proviral construct and packaged in the serotype 8 capsid. This vector was 
designated rAAV2/8.pBRsh.LP1.eGFP (eGFP transposon proviral construct, Figure 5.2; 
Plasmid map, Figure 5.3b). 
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5.3. RESULTS 
5.3.1. Therapy to Neonatal Mice Results in Rapid Loss of Vector in the Growing 
Liver 
Homozygous neonates were injected on Day 1 of life with rAAV2/8.LP1.hABCB4v2 via 
the intraperitoneal route at a dose of 1 × 10
12
 vg per mouse (n = 7). Liver samples were 
obtained from 4 mice at 1 week of age and the remaining 3 mice were analysed at 2 
weeks of age. Mice at these ages were too small to be able to obtain adequate bile 
samples for meaningful analyses. 
Molecular transduction was detected by quantitative PCR, measuring vector copies in 
RNase-treated DNA extracted from bulk liver samples using primers directed towards the 
hABCB4 transgene. Vector copy numbers were normalised against genomic GAPDH 
copies and expressed as vector copies per diploid genome equivalent (vg/DGE) (Section 
2.6.1). 
Neonatally-injected homozygotes had a mean normalised vector copy number of 84.2 ± 
17.7 vg/DGE in the liver at 1 week of age, compared with 13.1 ± 4.2 vg/DGE at 2 weeks 
of age (Mean ± SEM, p = 0.02). This represented a 6.4-fold drop in detectable liver-wide 
vector genomes between 1 and 2 weeks of age. The 2 week old cohort had a 3.9 fold 
higher mean liver mass compared with their 1 week old litter mates (0.59 g vs 0.15 g). 
This data is consistent with observations made by Cunningham et al.,
181
 and highlight the 
challenge of achieving sufficient gene transfer to maintain therapeutic efficacy in the face 
of rapid liver growth following neonatal vector administration.  
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5.3.2.  Vector Re-delivery to Juvenile Mice Fails to Prevent the Development of 
Chronic Liver Disease 
Vector re-administration at later time points may compensate for the fall in transgene 
expression following initial neonatal rAAV delivery, and maintain adequate therapeutic 
effect. To determine efficacy of a vector re-administration strategy, neonatal 
homozygotes were injected with rAAV2/rh10.LP1.hABCB4v2 via the intraperitoneal 
route at a dose of 1 × 10
12
 vg per mouse on Day 1 of life, and then received a 2
nd
 dose of 
vector at 2 weeks of age, which was packaged in another hepato-tropic capsid from 
serotype 8 (rAAV2/8.LP1.hABCB4v2) via the intraperitoneal route at a dose of 1 × 10
12
 
vg per mouse (n = 6). Liver and bile samples were obtained at 6 weeks of age for 
analysis. 
Despite receiving a second dose of vector at 2 weeks of age, 6-week old mice had similar 
mean normalised vector copies recovered from their liver as 2-week old mice injected at 
birth (Mean ± SEM, 11.3 ± 1.7 vg/DGE), suggesting likely continual vector loss 
following the 2
nd
 dose. This resulted in increased mean biliary PC concentrations to 5.9% 
wild-type concentrations (Figure 5.4). However, this was insufficient to prevent liver 
disease onset. Treated mice exhibited hepatosplenomegaly (Liver mass: 10.9 ± 0.2 % bw; 
Spleen mass: 0.72 ± 0.05 % bw) and abnormal liver histology (Figure 5.5). 
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Figure 5.4: Biliary PC concentration of mice that received 2 doses of rAAV vectors 
at birth and 2 weeks of age. 6-week old Abcb4
-/-
 mice (black column, n = 6) received 
rAAV2/rh10.hABCB4 vector 1 × 10
12
 vg/mouse at birth and rAAV2/8.hABCB4 vector 1 
× 10
12
 vg/mouse at 2 weeks of age. There was a small, but significant, increase in biliary 
PC concentration, equivalent to 5.9% wild-type levels. This was >5-fold higher than 
untreated homozygous controls (white column). Error bars represent mean ± SEM. 
 
 
Figure 5.5: Histology images of 6-week old mice that received received 2 doses of 
rAAV vectors at birth and 2 weeks of age. Abcb4
-/-
 mice that received 
rAAV2/rh10.hABCB4 vector 1 × 10
12
 vg/mouse at birth and rAAV2/8.hABCB4 vector 1 
× 10
12
 vg/mouse at 2 weeks of age (n = 6), had abnormal liver histology at 6 weeks of 
age. FFPE liver sections stained with haemotoxylin and eosin (H&E) showed periportal 
inflammation, bile ductular proliferation, and early bridging fibrosis, which was similar to 
untreated controls at the same age. Males and females displayed similar abnormalities. 
Scale bar = 50 µm.  
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5.3.3. Hybrid rAAV-piggyBac Transposon Vector Strategy 
A hybrid rAAV-piggyBac transposon vector strategy was developed in order to overcome 
loss of episomal vector following neonatal delivery. Utilising piggyBac transposon 
technology permitted increased integration of the hABCB4 expression cassette into the 
genome, whilst rAAV allow efficient transduction of hepatocytes in vivo. Construction of 
the hybrid proviral constructs are described (Section 5.2.1). 
In order to permit somatic integration of cohABCB4 transposons, these were co-
administered with a rAAV vector encoding piggyBac transposase under a liver specific 
promoter and pseudo-serotype with AAV serotype 8 capsid (rAAV2/8.LSP.pBase), 
previously constructed and produced with in our laboratory (Figure 5.6). This piggyBac 
transposase coding sequence was derived from that originally isolated from the genome 
of the cabbage looper moth, Trichoplusia ni, and shown to be highly active in mammalian 
cells.
536
  
 
Figure 5.6: Schematic diagram of rAAV vector expression cassette encoding 
piggyBac transposase under a liver-specific promoter. A piggyBac transposase coding 
sequence (1785 bp; Genbank Acc No. DQ236240.1) with kozak element around the start 
codon is expressed under a liver-specific promoter-enhancer containing 2 copies of a 
human apolipoprotein E enhancer (apoE) and a human alpha-1 antitrypsin promoter 
(hAAT). The expression cassette is flanked by AAV2 ITRs (black boxes), and also 
contains a woodchuck hepatitis post-transcriptional regulatory element (WPRE) and a 
bovine growth hormone polyadenylation signal (pA). Scale bar = 300 bp 
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5.3.3.1. Functional validation of the hybrid rAAV-piggyBac transposon vector system 
using an eGFP reporter.  
To functionally validate the hybrid rAAV-piggyBac transposon vector system with short 
piggyBac transposon inverted repeats, the rAAV encoded eGFP transposon 
(rAAV2/8.pBRsh.LP1.eGFP) was injected intraperitoneally into neonatal mice on Day 1 
of life at a dose of 5 × 10
11
 vg/mouse (n = 14). Half of this group received co-
administered rAAV encoding piggyBac transposase (rAAV2/8.LSP.pBase) at a dose of 5 
× 10
10
 vg/mouse (ratio 10:1, transposon:transposase) (pBase-positive). The remaining 7 
neonates did not receive co-administered transposase (pBase-negative).  
Mice were culled at 2 time points and liver samples were obtained for molecular and 
histological analysis. Three mice from each group were analysed at 3 weeks of age, and 
the remaining 4 mice from each group were analysed at 8 weeks of age. 
Molecular transduction was detected by quantitative PCR measuring vector copies in 
RNase-treated DNA extracted from bulk liver samples, using primers directed towards 
eGFP transgene, as previously described (Section 2.6.1). Vector DNA copies were 
normalised against genomic GAPDH copies, and expressed per diploid genome 
equivalent (DGE). A comparison between groups that received co-administered piggyBac 
transposase vector (pBase-positive) and those that received eGFP transposon vector alone 
(pBase-negative) revealed a 9.7- and 10.7-fold higher mean normalised vector copy 
number in the liver of pBase-positive groups at 3 and 8 weeks, respectively (Figure 5.7). 
A relatively low level of detectable liver vector copy numbers in the pBase-negative 
groups were consistent with a low rate of genomic integration of conventional rAAV 
vectors without piggyBac transposase-mediated DNA transposition.  
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Figure 5.7: Mean normalised vector copies in the liver of pBase-positive and pBase-
negative mice. Mice were intraperitoneally inoculated on Day 1 of life with either eGFP 
transposon & piggyBac transposase rAAV vectors (black bars) or eGFP transposon vector 
alone (grey bars) (n=7 per group). Liver DNA analysis was performed on 3 mice from 
each group at 3 weeks of age and the remaining 4 mice from at 8 weeks of age. Error bars 
represent mean ± SEM. 
 
Cryo-preserved liver sections from both groups at both time-points were analysed for 
eGFP expression using flurorescence microscopy (Figure 5.8). For orientation of the liver 
histology, 5µm sections were counterstained with glutamine synthetase using a red 
flurophore to mark pericentral hepatocytes (Section 2.6.7.2). Fluorescent microscopy 
images show widespread and markedly higher number of eGFP expressing hepatocytes in 
samples from mice that received co-administered piggyBac transposase, compared with 
the group that did not, at 3 and 8 weeks of age. This is indicative of transposase-mediated 
integration events in the pBase-positive groups. Clustering of eGFP-expressing 
hepatocytes of similar fluorescence intensity in the 8-week pBase-positive murine livers 
also suggests proliferation of hepatocytes in which somatic integration of the eGFP 
transposon had occurred. Sporadic small clusters of eGFP-positive hepatocytes are also 
seen in the 8-week pBase-negative samples, demonstrating the low rate of non-
transposase-mediated integration of conventional rAAV vectors.   
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Figure 5.8: pBase-positive liver sections show substantially more eGFP-expressing 
hepatocytes compared with pBase-negative sections. Five µm section made from cryo-
preserved liver samples obtained at 3 and 8 weeks post-inoculation, from male and female 
mice that received either rAAV encoding eGFP transposon co-administered with 
piggyBac transposase vector (pBase-positive) and those that received eGFP transposon 
rAAV vector alone (pBase-negative) at birth were examined using a flurorescent 
microscope. Sections were counter-stained with glutamine synthetase to mark pericentral 
hepatocytes using an Alexa 594 secondary antibody. Scale bar = 50 µm.  
 
Enhanced GFP expression was quantified by measurement of fluorescence emission from 
50 mg of liver protein lysates. Quantities were calculated based on a standard curve 
prepared by serial dilutions of known quantities of recombinant GFP (BioVision Research 
Products, USA) and expressed as µg eGFP per mg liver protein (Section 2.6.4).  
Consistent with the levels of normalised liver-wide vector copies and observations made 
on flurorescent microscopy, pBase-positive liver samples had significantly higher eGFP 
expression compared with pBase-negative samples (p < 0.001 for 3 and 8 week groups) 
(Figure 5.9a). When the difference in liver vector copies were taken into account, relative 
eGFP expression from pBase-positive group were 4.9- and 9.9-fold higher than pBase-
negative group at 3 and 8 weeks, respectively. However, statistical significance was 
reached only with the 8 week old group comparison (Figure 5.9b). These results indicate 
significantly higher eGFP expression from vector genomes integrated via piggyBac 
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transposase than via non-transposase mediated integration, assuming that by 3 weeks of 
age the majority of episomal forms were lost, as previously reported.
181
   
 
Figure 5.9: Comparison of hepatic eGFP expression between pBase-positive and 
pBase-negative mice. (a) Liver eGFP expression of mice at 3 and 8 weeks of age, 
transduce at birth with eGFP transposon + transposase vectors (black columns) were 
compared with transposon only recipients (grey columns). (n ≥ 3 per group) (b) The 
relative specific activity of recovered liver vector genomes from each group was 
expressed as eGFP expression per normalised vector genome copy. Statistical 
significance was determined by unpaired Student‟s t-test (p values as shown). Error bars 
represent mean ± SEM.     
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5.3.3.2. Treatment efficacy using different hABCB4 splice variants 
A hybrid rAAV-piggyBac transposon vector strategy was applied to correct the liver 
disease phenotype in the Abcb4-knockout mouse model. The strategy was based on that 
employed in the eGFP model, used to functionally validate this system, as described 
above. In place of the eGFP reporter, rAAV vectors encoding a cohABCB4 transgene 
were constructed (Section 5.2.1.1). There are 3 known, naturally-occurring transcript 
variants of human ABCB4 due to differences in splicing.
333
 In order to determine which 
splice variant would be most effective for therapeutic application, three hybrid rAAV 
vectors encoding each of the 3 splice variants was produced and compared. The relative 
phosphatidylcholine floppase activity of each of the splice variants is currently unknown. 
Neonatal homozygous pups were injected on Day 1 of life with rAAV vector containing 
one of the variant cohABCB4 transposons at a dose of 5 × 10
11
 vg/mouse co-administered 
with 5 × 10
10
 vg/mouse rAAV2/8.LSP.pBase (n = 4 per group). Liver, blood and bile 
samples were collected from each mouse at 4 weeks of age. 
Molecular analysis of the transduced liver samples showed that 4-week old Abcb4
-/-
 mice 
that received either cohABCB4 variant A or B transposon vectors at birth had similar 
mean normalised vector DNA copies diploid genome equivalent (DGE) detectable in bulk 
liver samples by quantitative PCR, whereas the mean was a near 2-fold higher in Abcb4
-/-
 
mice that received variant C transposon vector (Figure 5.10a). However, variant A vector 
had approximately doubled the relative transcriptional activity compared with either 
variant B or C. This was determined by calculating the mean relative mRNA transcripts 
per normalised vector copy in bulk liver tissue (Figure 5.10b). Relative mRNA transcript 
copies were determined using a two-step quantitative reverse-transcriptase PCR on 
DNase-treated total RNA extracted from bulk liver samples (Section 2.6.3).  
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Figure 5.10: Comparative molecular analysis of variant transposon groups. DNA 
and RNA were extracted from liver samples of 4-week old mice that received 5 × 10
11
vg 
of hybrid rAAV-transposon vector encoding either cohABCB4 variant A, B or C, co-
administered with 5 × 10
10
vg of rAAV-piggyBac transposase vector by intraperitoneal 
injection at birth (n = 4 per group). (a) Vector genome copies were quantified for each 
variant group by qPCR and values normalised against genomic GAPDH copies. Relative 
mRNA transcript copies from murine liver samples were measured from extracted 
DNase-treated liver RNA by qRT-PCR and normalised against β-actin transcripts. (b) The 
relative transcriptional activity was determined by dividing relative mRNA transcript 
copies with normalised vector copy data. Error bars represent mean ± SEM. 
Abcb4
-/-
  mice that received rAAV2/8 vector containing a cohABCB4 variant transposon, 
co-administered with rAAV2/8.pBase, had a raised mean biliary phosphatidylcholine 
(PC) concentration above background homozygous levels, which reached statistical 
significance by unpaired Student‟s t-tests (Figure 5.11). However, mice that received 
variant A hybrid vector had a significantly higher mean biliary PC concentration (mean ± 
SEM, 11.40 ± 2.79 mM), which was 4.9- and 7.0-fold higher than mice that received 
either variant B (2.33 ± 0.63 mM, p = 0.0423) or variant C (1.62 ± 0.21 mM, p = 0.0316) 
hybrid vector, respectively. Even after adjusting for the level of molecular transduction, 
mean biliary PC concentrations per normalised vector copy (NVC) in the variant A group 
was 4.1- and 20.1-fold higher than variant B or C, respectively (p < 0.05) (Figure 5.11b). 
This indicates that isoform A (variant A transgene product) has significantly superior 
canalicular phosphatidylcholine floppase activity compared to the other variant isoforms. 
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Figure 5.11: Biliary phosphatidylcholine concentration differs between mice that 
received different cohABCB4 transcript variant vectors. Abcb4
-/-
 mice that received 
either variant cohABCB4 hybrid vectors at birth had significantly elevated biliary 
phosphatidylcholine (PC) concentration (a) at 4 weeks of age above background untreated 
homozygous concentration (Cont.). However, mice that received variant A had a 4.9 and 
7.0 fold higher phosphatidylcholine concentration compared with mice that received 
either variant B or variant C hybrid vector (p = 0.0423 & p = 0.0316) respectively. (b) To 
indicate the specific activity of each variant vector, biliary PC concentrations were 
adjusted for the level of molecular transduction by dividing biliary PC concentration by 
normalised vector copies recovered from liver samples of each mouse. n = 4 per group. 
Statistical significance was determined using unpaired Student‟s t-tests. Error bars 
represent mean ± SEM. 
The level of biliary phosphatidylcholine concentrations of variant A recipients was 
sufficient to prevent the onset of liver disease. Compared to untreated age-matched 
homozygous controls, mice that received cohABCB4 variant A transposon vector had 
significantly lower relative liver (4.9 ± 0.4% body weight, bw) and spleen mass (0.47 ± 
0.05% bw), similar to that seen in wild-type mice (mean ± SEM: liver mass 5.5 ± 0.5% 
bw, spleen mass 0.43 ± 0.05% bw). By contrast, mice that received either cohABCB4 
variant B or variant C exhibited hepatosplenomegaly, similar to untreated homozygotes 
(Figure 5.12). Correspondingly, variant B and C mice had elevated serum liver enzymes 
and bile acids, indicative of cholestatic liver disease, compared with variant A mice that 
had near normal liver biochemistry (Figure 5.13). 
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Figure 5.12: Comparative mean relative liver and spleen mass. Mice that received 
hybrid rAAV-piggyBac transposon vector encoding cohABCB4 transcript variant A had 
lower mean relative liver (a) and spleen (b) mass compared with mice that received either 
variant B or variant C hybrid transposon vector, which were similar to untreated 
homozygous controls. Statistical significance was determined using unpaired Student‟s t-
tests. Error bars represent mean ± SEM. 
 
 
 
Figure 5.13: Comparison of serum liver biochemistry. Four-week old mice that 
received cohABCB4 variant A rAAV-transposon vector with piggyBac transposase vector 
at birth (diagonally striped columns) had lower (a) serum alanine aminotransferase 
(ALT), (b) alkaline phosphatase (ALP) and (c) serum bile acid concentration, compared 
to age-matched mice that received an equivalent doses of either variant B (dotted 
columns) or C (horizontally striped columns) transposon vector systems, or untreated 4-
week old homozygous controls (white columns). Error bars represent mean ± SEM. 
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To examine liver samples for the development of cholestatic liver disease and fibrosis, 
formalin-fixed, paraffin-embedded (FFPE) liver samples were sectioned and stained with 
haemotoxylin & eosin (H & E) and Sirius Red, and examined using a light microscope 
(Zeiss Axio Imager A1) (Section 2.6.6.4). 
Histopathologic assessment revealed increased mixed inflammatory infiltration around 
the periportal zones and incomplete portal-portal fibrous septa in liver samples from 4 
week old mice that had received hybrid cohABCB4 variant B or C transposon vector 
together with rAAV.LSP.pBase at birth. However, mice that had received rAAV 
containing cohABCB4 variant A vector with piggyBac transposase vector exhibited near 
normal liver histology (Figure 5.14). 
The above results indicate that for a given input vector dose, variant A had significantly 
higher phosphatidylcholine floppase activity compared with either of the other variants, 
despite at least equivalent levels of molecular transduction. This resulted in minimal liver 
disease, evidenced by near normal liver histology, lower serum markers of liver disease 
and absence of hepatosplenomegaly. Therefore, ongoing phenotype correction 
experiments were performed using the variant A hybrid vector system. 
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Figure 5.14: Representative liver histopathology images from 4-week old mice 
inoculated with either Variant A, B or C rAAV-transposon vector system. Abcb4
-/-
 
mice were injected at birth with hybrid rAAV-piggyBac transposon encoding a 
cohABCB4 transcript variant transgene co-administered with rAAV2/8.pBase. At 4 
weeks of age, liver histology of mice that received cohABCB4 variant A vector are near 
normal, in contrast with liver histology from age-matched mice that received either 
cohABCB4 variant B or C vector that exhibit periportal inflammation, bile ductular 
proliferation and portal-portal fibrous septa. Scale bar = 50µm. 
 
5.3.4. Successful Prevention of Chronic Liver Disease Onset with a Single Injection 
of a Hybrid rAAV-piggyBac Transposon Vector Encoding Codon-Optimised 
hABCB4 Variant A Delivered at Birth 
Further evaluation of cohABCB4 variant A hybrid vector system was undertaken to 
determine the medium and long term therapeutic efficacy in the Abcb4
-/-
 mouse model. 
Homozygous neonates were injected at birth with the same doses of hybrid transposon 
and transposase vectors (rAAV2/8.pBRsh.LP1.cohABCB4-var A 5 × 10
11
 vg/mouse & 
rAAV2/8.LSP.pBase 5 × 10
10
 vg/mouse). Liver, bile and serum analyses were performed 
at 8, 12 and 16 weeks of age, in addition to data collected at 4 weeks as described (pBase-
positive, n ≥ 4 per age group). To assess whether the transposon vector alone conferred 
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therapeutic benefit, a group of neonatal Abcb4
-/-
 mice were injected with 
rAAV2/8.pBRsh.LP1.cohABCB4-var A at 5 × 10
11
 vg/mouse without piggyBac 
transposase vector on Day 1 of life (pBase-negative, n = 9). Liver and bile samples were 
obtained for analyses from 6 mice at 4 weeks of age and from the remaining 3 mice at 12 
weeks of age.  
5.3.4.1. Analysis of liver transduction 
Liver vector copies were detected in RNase-treated DNA extracted from transduced liver 
samples by quantitative PCR, using primers directed towards the cohABCB4 transgene, 
and normalised against liver genomic GAPDH copies (Section 2.6.1).  DNase-treated 
total RNA was also extracted from liver samples for relative mRNA transcript copy 
determination by two-step quantitative reverse-transcriptase PCR (Section 2.6.3). 
Quantitation of relative mRNA transcript copies were normalised against liver β-actin 
transcripts from each sample.  
Molecular analysis of liver samples from transduced mice at 4 and 12 weeks of age 
showed that Abcb4
-/-
 mice that received hybrid rAAV-cohABCB4 variant A transposon 
vector co-administered with transposase vector at birth had 34.5- and 7.7-fold higher 
normalised vector copies, compared to age-matched homozygotes that received 
cohABCB4 transposon vector alone (n ≥ 3 per group) (Figure 5.15a).  However, this was 
not found to be statistically significant due to large variability in vector copy numbers 
within groups. Nevertheless, there was correspondingly higher number of mRNA 
transcripts detected in pBase-positive than pBase-negative samples (Figure 5.15b). The 
transcriptional activities from cohABCB4 transposon vector administered with and 
without piggyBac transposase vector were similar (Figure 5.15c). The level of molecular 
transduction is similar in pBase-positive samples across all timepoints. There was no 
 Chapter 5: Phenotype Correction of the PFIC Type 3 Mouse Model In Vivo 
191 
 
precipitous loss of detectable vector observed over time, in contrast to observations made 
following conventional rAAV neonatal therapy.
181
 Transcription also appeared stable 
over time without substantial transgene silencing.  
 
 
Figure 5.15: Molecular analysis of pBase-positive and pBase-negative liver samples. 
DNA and RNA were extracted from liver samples of mice that received hybrid rAAV-
transposon vector encoding cohABCB4 variant A co-administered with rAAV-piggyBac 
transposase vector (pBase-positive, black columns), or rAAV-cohABCB4 variant A 
transposon vector alone (pBase-negative, white columns) by intraperitoneal injection at 
birth (n ≥ 3 per group). Mean vector genome copies (a), quantified by qPCR and 
normalised against genomic GAPDH copies, were higher in pBase-positive than pBase-
negative groups. There were also correspondingly higher relative mRNA transcripts (b) 
detected in pBase-positive liver samples. However, the relative transcriptional activity (c), 
determined by dividing relative mRNA transcript copies by normalised vector genome 
copies, was similar between rAAV-transposon vectors concurrently delivered with or 
without piggyBac transposase-encoded rAAV. Error bars represent mean ± SEM.  
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5.3.4.2. Bile composition of pBase-positve and pBase-negative homozygous mice. 
In this PFIC3 treatment model, raised biliary PC content above background homozygous 
levels is attributable to vector-derived cohABCB4 expression
540
, and thus a direct 
indicator of therapeutic efficacy of this hybrid rAAV-piggyBac transposon vector system. 
Analyses of biliary PC concentrations were performed using a colourmetric assay, as 
previously described (Section 2.6.5.1). 
Compared to untreated Abcb4
-/-
 controls, pBase-positive mice that received vector 
encoding cohABCB4 variant A transgene have significantly elevated mean biliary PC 
concentration at all timepoints, equivalent to 55-75% wild-type levels (n ≥ 4 per group, 
unpaired Student‟s t-test, p < 0.007) (Figure 5.16). Mean concentrations were also higher 
than disease-free heterozygous controls (mean ± SEM: 8.18 ± 2.16 mM, 48% wild-type). 
A small, yet statistically significant elevation of biliary PC concentration was also 
demonstrated in pBase-negative mice. However, this was insufficient to prevent 
development of liver pathology (Sections 5.3.4.3 & 5.3.4.4). pBase-positive mice had 
biliary PC concentrations 21.1- and 10.6-fold higher than their age-matched pBase-
negative counterparts at 4 and 12 weeks, respectively (p = 0.0031 and p < 0.0001, 
respectively). These results were consistent with molecular analyses, indicating 
significantly higher detectable liver vector copies and mRNA transcripts, and hence 
higher expression in pBase-positive than pBase-negative vector recipients. 
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Figure 5.16: Mean biliary phosphatidylcholine concentration of birth-treated 
cohorts. pBase-positive mice (diagonally striped columns) had significantly higher mean 
biliary phosphatidylcholine concentration at all timepoints, compared with either 
untreated homozygous controls (white column) or pBase-negative mice (dotted columns). 
Statistical significance was determined by unpaired Student‟s t-test. Error bars represents 
SEM. 
 
Endogenous biliary PC excretion is directly dependent on the biliary bile salt (BS) 
excretion.
18,540,541
 A strong curvilinear relationship between biliary BS and PC output has 
previously been demonstrated amongst wild-type and Abcb4
+/-
 mice.
542
 The amount and 
hydrophilicity of the endogenous bile salt pool influences biliary phospholipid excretion 
by both transcriptional and post-transcriptional mechanisms including regulation of 
ABCB4 expression, hepatic PC biosynthesis, increased trafficking of mdr2 from 
intracellular pools to the canalicular membrane, and increased extrusion of PC-enriched 
vesicles from the exoplasmic leaflet of canalicular membranes.
280,328,543-545
 These are 
protective mechanisms against the cytotoxic effects of high bile salt concentration.
342
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To examine the relationship between biliary BS excretion and exogenous vector-derived 
biliary PC excretion in this rAAV-piggyBac cohABCB4 var A therapeutic model, biliary 
BS concentration was plotted against biliary PC concentration. There was a weak linear 
relationship between biliary BS and PC concentration (Figure 5.17). 
Since an increase in biliary bile salt excretion also leads to increased PC excretion, at 
least in part through post-translational mechanisms, the biliary PC to BS ratio was 
compared between pBase-positive, pBase negative and control homozygous groups. Total 
bile acid concentrations (mM) in bile samples were determined by a quantitative 
enzymatic cycling assay (Section 2.6.5.2). The ratio of biliary PC concentration to biliary 
bile acid concentrations were calculated for each individual mouse sample, and expressed 
as a percentage of mean wild-type control ratios.  
pBase-positive groups at all time-points had significantly higher mean PC:BS, ranging 
from 44.7 to 63.6% wild-type levels (% wt), compared with untreated controls (Figure 
5.18). Consistent with biliary PC concentrations, the pBase-negative groups had a small, 
but statistically significant increased mean PC:BS, compared with untreated homozygotes 
(mean ± SEM: 2.67 ± 0.61% wt vs 0.53 ± 0.21% wt, p = 0.03). 
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Figure 5.17: Correlation between biliary phosphatidylcholine and bile salt 
concentrations. A weak linear relationship was observed between biliary 
phosphatidylcholine (PC) and bile salt concentrations, assayed on gallbladder bile 
samples. (Pearson‟s correlation coefficient, R2 = 0.1293, p = 0.0096; n = 51)  
 
 
 
 
Figure 5.18: Biliary phosphatidylcholine to bile salt ratio. pBase-positive groups at all 
timepoints had significantly higher mean biliary phosphatidylcholine to bile salt ratios 
(PC:BS; means represented by horizontal lines), compared with untreated homozygous 
controls (left-most group). pBase-negative mice also had a small but significant increase 
in PC:BS. Statistical significance of differences between groups compared with untreated 
homozygous controls was determined by unpaired Student‟s t-tests. Symbols: * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
  
 Chapter 5: Phenotype Correction of the PFIC Type 3 Mouse Model In Vivo 
196 
 
Biliary cholesterol excretion is also tightly coupled with biliary PC excretion. Transgenic 
mice bred onto a homozygous Abcb4-knockout background, expressing human MDR3 at 
a level sufficient to prevent liver disease demonstrated significantly elevated biliary 
cholesterol excretion compared with non-transgenic Abcb4
-/-
 mice.
342
 Therefore, 
gallbladder bile samples from pBase-positive, pBase-negative and untreated homozygous 
control mice were analysed for cholesterol concentration using a quantitative colorimetric 
assay, based on cholesterol esterase hydrolysis, and free cholesterol conversion to cholest-
4-ene-3-one by cholesterol dehydrogenase (Section 2.6.5.3). Biliary cholesterol 
concentrations were compared between groups (Figure 5.19). pBase-positive mice had an 
elevated biliary cholesterol concentration compared with untreated control. The pBase-
negative group also had an increased mean biliary cholesterol concentration, but this was 
not statistically significant.   
 
Figure 5.19: Biliary cholesterol concentration. pBase-positive groups (diagonally 
striped columns) at all timepoints had significantly higher mean biliary cholesterol 
concentration, compared with untreated homozygous controls (white column) or pBase-
negative samples (dotted column). Statistical significance of differences between groups 
compared with untreated homozygous controls was determined by unpaired Student‟s t-
tests. ** p ≤ 0.01. Error bars represent mean ± SEM. 
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5.3.4.3. Anthropometry and serum biochemistry 
Enlargement of the liver and spleen, termed hepatosplenomegaly, is commonly associated 
with the development of liver disease. pBase-positive mice at 4, 8, 12 and 16 weeks of 
age exhibited normal liver and spleen mass, comparable to age-matched wild-type mice 
(Figure 5.20). However, Abcb4
-/-
 mice that received cohABCB4-var A transposon vector 
alone had hepatosplenomegaly, similar to age-matched, untreated, homozygotes, 
indicative of liver disease development. 
 
Figure 5.20: Relative mean liver and spleen mass of pBase-positive and pBase-
negative groups. Liver and spleens mass were expressed as a percentage of total body 
weight (%bw). pBase-positive mice (open black triangles) had relative mean liver (a) and 
spleen (b) mass, similar to wild-type control animals (solid grey circles). Whereas pBase-
negative groups (black diamonds) exhibited hepatosplenomegaly, comparable or 
exceeding that of homozygous controls (open grey circles). Error bars represent mean ± 
standard deviation (n  3 per group). 
 
Serum biochemical markers including alanine aminotransferase (ALT), alkaline 
phosphatase (ALP) and total serum bile acids of pBase-positive groups at all ages were 
reduced compared with untreated Abcb4
-/-
 mice of similar ages, indicating reduced liver 
inflammation and cholestasis (Figure 5.21). 
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Figure 5.21: Mean serum markers of cholestatic liver disease. pBase-positive groups 
(open black triangles) are all ages had lower serum biochemical markers of liver disease 
including (a) serum alanine aminotransferase (ALT), (b) alkaline phosphatase (ALP) and  
(c) total bile acid concentrations, compared with untreated homozygous mice (open grey 
circles). Error bars represent mean ± SEM (n  3 per group). 
 
 
5.3.4.4. Liver histopathology and immunohistochemistry 
Of the 18 mice that received hybrid rAAV vectors encoding cohABCB4 variant A 
transposons with co-administered piggyBac transposase vector at birth, 16 mice exhibited 
near normal liver histology with absence of liver fibrosis and minimal or scant periportal 
inflammation (Figure 5.22). No substantial differences were observed between male and 
female treated mice. In contrast, the histology of age-matched untreated homozygous 
controls demonstrated advanced liver disease with cirrhosis and progressive architectural 
distortion with age. 
Liver histology obtained from two pBase-positive female mice aged 8 and 12 weeks 
showed fibrous septa bridging portal tracts, but only mild periportal inflammation (Figure 
5.23a). Although, the extent of liver inflammation and fibrosis observed in liver sections 
appeared less compared to untreated homozygotes at the same age. Both mice had 
relatively normal liver and spleen mass, but elevated liver biochemistry (Figure 5.23b). 
Further analyses demonstrated that both mice had lower numbers of normalised liver 
vector copies detected and consequently, lower biliary phosphatidylcholine 
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concentrations, compared with treated mice of the same age (Figure 5.23b). A reduced 
level of transduction such that the threshold for complete phenotype correction was not 
achieved, possibly due to incomplete injection, could explain why there was reduced 
efficacy with only partial correction of liver disease. 
 
Figure 5.22: Representative histology images of pBase-positive liver samples 
compared with age-matched untreated controls. Consecutive 4 µm liver sections were 
made from formalin-fixed, paraffin-embedded tissue samples, obtained from the largest 
left lateral lobe of the liver, and stained with haemotoxylin and eosin (H & E), and Sirius 
red/fast green dye. Near normal liver histology was demonstrated with pBase-positive 
samples (a), in contrast to the development of cirrhosis with bile ductular proliferation, 
widespread inflammatory infiltration and architectural distortion of untreated 
homozygous control liver or pBase-negative liver sections (b). Scale bar = 50 µm. 
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Figure 5.23: pBase-positive mice that developed liver disease. (a) Liver histology of 
liver obtained from 2 pBase-positive mice, aged 8 and 12 weeks, respectively, showed 
histological evidence of liver disease including portal-portal fibrous septa, mild periportal 
mixed inflammatory infiltrate and bile duct proliferation. Scale bar = 50 µm. (b) Analysis 
of normalised vector copies (NVC) recovered from liver samples and biliary 
phosphatidylcholine (PC) concentrations from these 2 mice indicate that the level of 
transduction and transgene expression achieved was below the means of their age-
matched treated peers. Both mice had relatively normal liver and spleen size, but elevated 
liver biochemistry. Mean ± SEM for pBase-positive age-matched peer groups are shown 
in parentheses. Abbreviations: vector genomes per diploid genome equivalent, vg/DGE; 
percentage body weight, % bw; Alanine aminotransferase, ALT; Alkaline phosphatase, 
ALP. 
 
To localise vector-derived MDR3 protein on liver sections, immunohistochemistry using 
an antibody that specifically binds to human MDR3 without binding murine mdr2 (P3II-
26, LifeSpan Biosciences Inc., USA) was performed, though with very limited success. 
The primary antibody is a mouse monoclonal IgG2b isotype, and high, non-specific 
background staining could not be prevented by using Mouse-on-Mouse blocking reagents 
(M.O.M blocking kit, Vector Laboratories Inc., USA) performed according to the 
manufacturer‟s instructions, and/or using a γ-2b heavy-chain specific secondary antibody 
(Goat anti-mouse IgG2b-FITC conjugate at 1:50 dilution, Southern Biotechnology 
Associates Inc., USA). Obvious positive marking was only visualised on liver sections 
from mice that achieved a high level of transduction (Figure 5.24). 
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Figure 5.24: Immunohistochemistry to mark hABCB4 in transduced pBase-positive 
liver. Five µm sections were prepared from cryopreserve liver samples of pBase-positive 
mice, treated with mouse-on-mouse blocking reagents (M.O.M blocking kit), and marked 
with anti-hABCB4 mouse monoclonal IgG2b antibody (P3II-26) at a 1:20 dilution, and 
FITC-conjugated goat anti-mouse IgG2b secondary antibody at a 1:50 dilution. Sections 
were also counterstained with DAPI. A section from the same liver with only secondary 
antibody and M.O.M. blocking applied is shown for comparison.  Scale bar = 50 µm.  
 
Other anti-human MDR3 antibodies, made in different species, were also tested. For 
example, a rabbit polyclonal anti-MDR3 IgG (Abcam Inc., USA) did not have sufficient 
specificity for the human protein as it also bound mutant and wild-type mdr2 protein 
produced from the disrupted and wild-type ABCB4 genes, respectively (Figure 5.25). 
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Figure 5.25: Immunohistochemical staining using a rabbit polyclonal anti-ABCB4 
IgG. Four μm liver sections were prepared from formalin-fixed paraffin-embedded tissue 
samples from pBase-positve 4 week old male mouse treated at birth, and from wild-type, 
heterozygous and homozygous control murine liver for comparison. Sections were 
incubated with a rabbit polyclonal anti-ABCB4 IgG at a dilution of 1:50, followed by 
incubation with biotinylated donkey anti-rabbit IgG at a dilution of 1:1000, signal 
amplification using VectaStain
®
 Elite ABC reagent, colour development using 3,3‟-
diaminobenzidine substrate (brown) and counter-staining with haemotoxylin (purple). 
This rabbit anti-ABCB4 polyclonal IgG appeared to bind to both wild-type and mutant 
mdr2 protein in control animals, making it difficult to visualise vector-derived hABCB4 
gene product against high background staining of mutant mABCB4 in homozygotes. 
Scale bar = 50 μm. 
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5.3.4.5. Long-term phenotype correction is observed up to 9 months of age 
Preliminary long-term efficacy data was collected from two 9-month old female mice 
given rAAV2/8.pBRsh.LP1.cohABCB4-var A 5 × 10
11
 vg/mouse, co-administered with 
rAAV2/8.LSP.pBase 5 × 10
10
 vg/mouse on Day 1 of life. Liver vector copy number 
analysis, and serum and biliary biochemical analyses are shown (Table 5.1).  Both mice 
had biliary PC concentrations equivalent to approximately 44% wild-type concentrations, 
and exhibited no enlargement of liver or spleen, and low serum ALT and ALP. Serum 
bile acids were moderately elevated, which was incongruent with other liver disease 
parameters. Liver histology showed minimal liver pathology (Figure 5.26). Importantly, 
neither mouse had macroscopic or microscopic evidence of liver tumour formation, in 
contrast to 7 out of 8 (87.5%) 9-month old untreated homozygotes examined. Untreated 
Abcb4
-/-
 mice inevitably develop hepatocellular carcinoma by 16 months of age.
339,340
 
Further collection of long-term efficacy data is in progress. 
Table 5.1: Liver, bile and serum analyses from 9-month old pBase-positive mice 
treated at birth. 
Age 9 months Adult Abcb4
-/-
  
Control  
(Mean ± SEM) Mouse #29 #30 
Normalised Vector 
Copies per DGE 
4.37 4.38 - 
Biliary PC 7.49 mM 7.59 mM 0.13 ± 0.06 mM 
Biliary PC: BS (% wt) 27.7% 30.2% 1.3 ± 0.6% 
Liver Mass (% bw) 4.3% 4.3% 8.2 ± 1.0% 
Spleen Mass (% bw) 0.4% 0.4% 0.7 ± 0.09% 
ALT (U/L) 57 50 186.6 ± 46.4 
ALP (U/L) 81 82 305.2 ± 92.8 
Bile Acids (µmol/L) 42.1 26.0 65.6 ± 29.1 
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Figure 5.26: Histology images of liver tissue from 9 month old pBase-positive 
females. Absence of significant liver pathology is demonstrated in both female mice (#29 
& #30) that received hybrid vector encoding cohABCB4 var A with co-administered 
transposase rAAV vector at birth. Images from homozygous 9 month old untreated 
female control are shown for comparison. Scale bar = 50 µm. 
 
5.3.5. Delaying Therapy Results in Incremental Loss of Efficacy 
As it is a relatively rare disorder, universal newborn or pre-symptomatic genetic screening 
of PFIC type 3 is not widely available, at present. Individuals with PFIC type 3 typically 
present with symptoms such as jaundice, may exhibit clinical signs of cholestasis and 
have variable degrees of liver disease at diagnosis. Therefore, initiation of gene therapy 
prior to the onset of liver pathology may not be possible in many cases. To more 
accurately reflect the ascertainment pattern of PFIC3 cases, a delayed treatment model 
was evaluated. 
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Abcb4
-/-
 mice were injected intraperitoneally with rAAV2/8 vector containing 
cohABCB4 variant A transposon 5 × 10
11
 vg/mouse, co-administered with rAAV2/8 
encoding piggyBac transposase 5 × 10
10
 vg/mouse at 1, 2, 3 or 4 weeks of age (n = 4 per 
group). Males and females were included in each group. Liver, bile and blood samples 
were collected for analysis at the termination of experiments, at 8 weeks of age. 
All groups had significantly elevated mean biliary PC concentrations above that of 
untreated controls (Figure 5.27). However, comparison between treatment groups 
demonstrated an incremental loss of efficacy with delaying age of vector administration, 
from 76% wild-type biliary PC concentrations when inoculated at birth to 27% when 
treated at 4 weeks of age. 
 
Figure 5.27: Mean biliary phosphatidylcholine concentration is incrementally 
reduced with delaying age at inoculation of therapeutic rAAV-transposon vectors. 
(a) Compared with untreated homozygous controls, all groups had significantly elevated 
mean biliary PC concentrations (n ≥ 3 per group). However, mice inoculated at a later age 
had a proportionally lower biliary PC concentration compared with the birth-treated 
cohort. Error bars represent mean ± SEM. (b) Correspondingly, there was also a drop in 
PC:BS with delayed age at inoculation. Each black circle represents an individual mouse 
sample, and horizontal lines represent means. Statistical significance was determined by 
unpaired Student‟s t-tests: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.  
Comparison of the liver and spleen mass at 8 weeks of age demonstrated that mice 
inoculated with therapeutic vectors prior to 3 weeks did not develop hepatosplenomegaly 
(Figure 5.28). Administration of hybrid rAAV-transposon system encoding cohABCB4 at 
 Chapter 5: Phenotype Correction of the PFIC Type 3 Mouse Model In Vivo 
206 
 
3 and 4 weeks of age resulted in enlargement of liver and spleen by adulthood, similar to 
untreated homozygous adults. Compared to mice treated earlier, mice treated at 3 and 4 
weeks of age also had elevated serum alanine aminotransferase, alkaline phosphatase and 
bile acids, in keeping with the liver disease development (Figure 5.29). Consistent with 
anthropometric and serum biochemistry data, mice that received hybrid rAAV-transposon 
vector co-administered with piggyBac transposase vector at 3 and 4 weeks of age showed 
histological evidence of liver pathology at 8 weeks (Figure 5.30).  
Figure 5.28: Mice inoculated with therapeutic hybrid vector before 3 weeks of age 
had no hepatosplenomegaly. Whole livers and spleens were weighed at the termination 
at the experiment at 8 weeks of age and expressed as a percentage of total body weight (% 
bw). Compared to untreated controls, mice that received hybrid rAAV-cohABCB4 var A 
transposon vector with transposase vector at birth, 1 and 2 weeks of age had significantly 
lower liver and spleen mass, which was similar to wild-type mice. Mice inoculated at 3 
and 4 weeks of age exhibited hepatosplenomegaly, similar to untreated homozygotes. 
Statistical significance was determined by unpaired Student‟s t-tests: * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. Error bars represent mean ± standard deviation. 
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Figure 5.29: Comparison of serum biochemical markers of cholestatic liver disease. 
With delaying the age of inoculation, there was an apparent incremental increase in mean 
(a) serum alanine aminotransferase (ALT), (b) serum alkaline phosphatase (ALP) and (c) 
serum bile acids. However, comparisons with untreated controls were not statistically 
significant, as determined by unpaired Student‟s t-test, except serum ALT of birth-treated 
group compared to control (p = 0.047). Serum samples were sufficient to perform serum 
bile acid analysis for only 2 out 4 mice from 4-week group, and therefore the error bar is 
not reported. Error bars represent mean ± SEM.   
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Figure 5.30: Histology images of liver sections from delayed treatment cohorts. (a) 8 
week old Abcb4
-/-
  mice that received hybrid rAAV-transposon and transposase vectors 
after 2 weeks of age show histopathological features of cholestatic liver disease such as 
mixed inflammatory infiltration in and between portal tracts, bile ductular proliferation 
and bridging fibrosis. Consistent with biliary PC concentration, serum liver disease 
markers and anthropometric data, mice that received therapy later have more advanced 
features of liver disease at 8 weeks. (b) Representative liver histology images from 
control homozygotes at 8 weeks, as well as aged 1 to 4 weeks (age at inoculation), are 
shown for comparison. Scale bar = 50 µm. 
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5.3.5.1. Increasing vector doses delivered at 3 and 4 weeks of age is sufficient to halt but 
not  fully reverse liver disease 
One possible explanation for the fall in therapeutic efficacy with increased age of 
administration is that younger mice received proportionally higher vector doses per 
kilogram of body weight. To evaluate whether higher doses administered at 3 and 4 
weeks of age will halt or reverse liver disease, a high dose equivalent on a per kilogram 
basis to that received by 1 week old mice in the previous experiments was administered to 
3 and 4 week old Abcb4
-/-
 mice (rAAV2/8.pBRsh.cohABCB4 var A 1.3 × 10
14
 vg/kg with 
rAAV2/8.pBase 1.3 × 10
13
 vg/kg), n = 4 per group. Liver, bile and blood samples were 
obtained for analysis at 8 weeks of age. 
This resulted in a high level of molecular transduction with 28- and 36-fold increase in 
detectable normalised vector copies per diploid genome equivalent (DGE) in mice that 
received high doses, compared with standard doses, at 3 and 4 weeks, respectively (Table 
5.2). However, there was only modest trend towards higher biliary PC concentration, 
suggesting possible partial block in either transgene expression or biliary PC floppase 
activity (Table 5.2). Nevertheless, mice that received high dose vector had only mild 
enlargement of liver and spleen mass, and less derangement of liver biochemistry than 
standard dose recipients at the same age. However, liver histology was not completely 
normal. Although, compared to mice that received standard doses at the same age features 
of liver pathology were less prominent. In liver sections of high dose recipients, there was 
mild periportal fibrosis with thin fibrous tracts and scant inflammation (Figure 5.31). 
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Table 5.2: Comparison of liver transduction, bile composition, anthropometry and 
liver biochemistry between standard and high vector dose recipients.  
Age at Inoculation 3 weeks 4 weeks Abcb4
-/-
 
Control Vector Dose Standard High Standard High 
Normalised Vector 
Copies per DGE 
1.08 ± 0.68 30.3 ± 6.1
**
 1.39 ± 0.51 49.9 ± 25.1 - 
Biliary PC (mM) 6.46  ± 1.68 9.04 ± 1.52 4.72 ± 1.71 8.48 ± 2.90 0.13 ± 0.06 
Biliary PC:BS (% wt) 18.4 ± 4.1 34.4 ± 5.0 17.0 ± 5.1 37.8 ± 12.7 1.3 ± 0.6 
Liver Mass (% bw) 7.0  ± 1.5 4.5 ± 0.3
*
 7.3 ± 1.7 5.8 ± 2.2 8.2 ± 1.0 
Spleen Mass ( % bw) 0.6 ± 0.17 0.6 ± 0.13 0.7 ± 0.17 0.6 ± 0.14 0.7 ± 0.09 
ALT (U/L) 162.5 ± 58.0 59.3 ± 3.8 281.0 ± 127.4 107.8 ± 51.3 186.6 ± 46.4 
ALP (U/L) 302.3 ± 81.6 150.0 ± 7.9 339.3 ± 103.0 254.3 ± 81.6 305.2 ± 92.8 
Bile Acids (µmol/L) 37.5 ± 24.3 39.7 ± 24.2 39.7
#
 26.8 ± 11.4 65.6 ± 29.1 
Values reported are mean ± SEM. Abbreviations and Symbols: DGE, diploid genome equivalent; PC, 
phosphatidylcholine; BS, bile salt; % wt, percentage wild-type; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; #only 2 samples available for analysis, therefore SEM not reported. Statistical significance of comparison 
between age-matched standard and high dose groups were determined by unpaired Student‟s t-tests: * p < 0.05, ** p < 
0.01. 
 
 
 
Figure 5.31: Liver histology of standard and high dose recipients. Representative 
images of liver sections from 8 week old mice that received high dose hybrid rAAV-
transposon vector at 3 and 4 weeks of age showed only slight periportal inflammation and 
fibrosis with slender fibrous septa between portal tracts, compared with 8 week old mice 
that received standard doses at equivalent respective ages. Scale bar = 50 µm.  
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5.4. DISCUSSION 
The experiments described in this chapter demonstrate successful correction of the 
chronic liver disease phenotype in the Abcb4
-/-
 mouse model using in vivo liver-targeted 
gene therapy with a hybrid rAAV-piggyBac transposon vector system. This novel, hybrid 
vector system was developed to facilitate long-term transgene expression in the context of 
neonatally-administered rAAV vectors via piggyBac transposase-mediated integration of 
the therapeutic expression cassette in vivo.  
A single intraperitoneal injection of rAAV encoding codon-optimised hABCB4 variant A 
transposon, co-delivered with rAAV encoding piggyBac transposase at birth permitted 
long-term phenotype correction with near-absence of liver pathology, up to 9 months 
post-inoculation. Stably elevated biliary phosphatidylcholine concentration was 
demonstrated in all animals that received both transposon and transposase vectors, with 
most showing absence of hepatosplenomegaly, low serum markers of liver disease and 
near normal liver histology. Mice with only partial correction had reduced vector 
transduction. Though only preliminary long-term efficacy data is presently available, the 
lack of hepatic tumour formation at 9 months is reassuring, given that almost 90% of 
observed homozygous controls at the same age had macroscopic and microscopic 
evidence of liver tumours, and that hepatocarcinogenesis is a universal outcome observed 
in this mouse model.
339
 Importantly, adverse and off-target effects have not been 
observed to date in any hybrid vector injected mice, up to 9 months post-inoculation. 
More long-term data is awaited. 
Whilst in humans, rapid genetic screening to detect selected ABCB4 gene mutations 
(among a panel of others responsible for heritable cholestatic conditions) is used to make 
genetic diagnoses in symptomatic PFIC3 patients, use of such tools for pre-symptomatic 
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population screening is currently not available.
546
 Thus, symptomatic patients may have 
variable degrees of liver pathology at diagnosis. Experiments described in the previous 
chapter show reduced transduction and transgene expression, and therefore potentially 
reduced efficacy in the presence of established liver pathology. A delayed treatment 
model was also evaluated, in order to predict whether patients with a degree of liver 
pathology at the time of vector administration would still benefit from hybrid rAAV-
piggyBac transposon gene therapy. 
Delaying the initial age of hybrid vector administration resulted in an incremental loss of 
efficacy. However, normal liver histology was observed in young, adult homozygotes 
treated with both cohABCB4-encoding transposon and transposase rAAV vectors at 2 
weeks of age or earlier. Abcb4
-/-
 mice injected at 3 weeks had only partial correction of 
liver disease with abnormal liver biochemistry and early bridging fibrosis on FFPE liver 
sections at 8 weeks of age. Though younger mice received proportionally higher vector 
doses on per body weight basis, the dose of transposon vector administered to mice from 
birth to 4 weeks (≥ 3 × 1013 vg/kg) was substantially higher than rAAV2/8 pseudo-
serotyped vector doses capable of facilitating high transduction efficiency in juvenile 
animal models, and that which has been previously reported to confer near 100% 
transduction of adult murine liver.
181,454,459
 Increasing the transposon vector dose 
delivered to 3 and 4 week old Abcb4
-/-
 mice to 1.3 × 10
14 
vg/kg, whilst maintaining the 
transposon:transposase ratio at 10:1, led to improvement in therapeutic efficacy. 
However, liver pathology could not be completely reversed. Furthermore, substantially 
higher doses places greater demands on vector production systems, could have a greater 
propensity to induce host immunity, and would escalate the frequency of integration and 
therefore also potentially increase the rate of insertional mutagenesis. 
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With the caveat that older mice had pre-existing liver pathology when vector was 
delivered, the delayed treatment model experiments permitted effective dose titration, 
thus providing a way of estimating the threshold for phenotype correction. Based on the 
bile composition from these mice, the threshold for correction of liver pathology in 
Abcb4
-/-
 mice lies between 38 and 46% of wild-type biliary PC concentration, or between 
18 and 32% wild-type PC:BS ratio, below which bile becomes toxic. These findings are 
consistent with that of previous reports using transgenic and hepatocyte transplant Abcb4-
knockout murine models.
18,342
 Smith et al., demonstrated that transgenic mice with 
hepatocytes, expressing hABCB4, generated 25% wild-type biliary phospholipid output 
(measured as nmol/min/100g body weight) and 19% wild-type PC:BS on a homozygous 
Abcb4
-/-
 background, which was insufficient to prevent onset of liver pathology.
342
 The 
authors concluded that thresholds for liver disease prevention were between these levels 
and that previously described in disease-free heterozygotes (78% wild-type biliary 
phospholipid output and 65% wild-type PC:BS
401
). In another study, male Abcb4
-/-
 mice 
fed on a standard chow diet, that underwent transplantation with transgenic hepatocytes 
expressing hABCB4 at 6 weeks of age, showed stable PC:BS of approximately 21% wild-
type levels and reduced liver pathology up to 50 weeks post-transplantation.
18
 
Lack of efficacy with rAAV-transposon vector alone verified that piggyBac transposase-
mediated integration of the hABCB4 expression cassette was necessary to prevent onset 
of liver disease in neonatally-treated mice. Since administering the rAAV-transposon 
vector alone is predicted to perform like conventional rAAV gene therapy, a small subset 
of transposon vector was likely to have spontaneously integrated in a transposase-
independent manner, whilst remaining episomal rAAV-transposon vectors was 
expectedly degraded as a consequence of hepatocellular proliferation during liver growth. 
Hence, a small but significant increase in biliary PC concentration was demonstrated in 
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pBase-negative mice, up to 5.6% wild-type concentrations. However, this was insufficient 
to prevent liver disease. 
Likewise, the majority of cells transduced with rAAV encoding piggyBac transposase 
were likely to lose transposase activity within the first few weeks, depending on the 
rapidity of rAAV episome degradation and transposase half-life (estimated to be 
approximately 12 hours in HeLa cells
547
). A small subset of transposase provirus probably 
integrated into the genome. Persistent transposase expression from integrated provirus can 
cause multiple transposition cycles, which could lead to eventual loss of transposons and 
thus, therapeutic transgene expression, and may increase potential damage to the genome 
through aberrant chromosomal break repair and recombination events.
547,548
 Thus, to add 
to the biosafety and efficacy of this hybrid vector system, a further advancement may be 
to deliver a more labile source of transposase to allow only transient expression. This 
could be achieved by using transposase-encoding mRNA, which has a short intracellular 
half-life of a few hours.
547,549
 Such a strategy has been successfully applied in vivo to 
correct the disease phenotype in a hereditary tyrosinemia type I mouse model via 
sleeping-beauty mediated transposition
550
, as well as to cultured cells via piggyBac 
mediated transposition
547
. Both examples demonstrated persistent transposon expression 
using in vitro-transcribed, transposase-encoding mRNA as a source of recombinase 
activity.  
The majority of piggyBac transposon gene transfer systems are based on insect-derived, 
wild-type piggyBac transposons which have a length of 2472 bp, and comprises 2 
terminal domains flanking a transposase encoding domain.
551
 In piggyBac vectors, 
transposase is replaced by the transgene of interest. Transposase is provided in trans to 
catalyze the excision and re-integration of the transposon from one DNA source to 
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another.
552
 In wild-type piggyBac transposons, each flanking terminal domains are 
divided into an inverted repeat (IR) sequence and an internal domain, which partially 
overlaps with transposase coding sequence.
551,553
 The 35 base pair 5‟IR and 63 base pair 
3‟IR sequences are required for precise excision and re-integration of the intervening 
DNA into TTAA sites.
489,551,554
 The 5‟ internal domain contains a putative promoter that 
drive transposase expression.
553
 Both inverted repeat sequences and internal domains are 
reported to be necessary for successful and efficient transposition.
551,554-556
 However, it 
was recently reported that internal domain sequences may be provided in trans alongside 
the transposase sequence in a helper vector.
554
 
In order to accommodate the 3.9 kb cohABCB4 coding sequence and cis-activating 
piggyBac transposon terminal domain sequences within the rAAV packaging capacity in 
our hybrid transposon vector, previously reported short 5‟ and 3‟ piggyBac inverted 
repeat sequences was utilised to flank the therapeutic expression cassette.
537
 To validate 
that these short piggyBac inverted repeats could facilitate effective transposition in vivo, 
transgene expression from a rAAV-eGFP transposon vector system was evaluated 
(Section 5.3.3.1). PiggyBac transposase was encoded in a separate rAAV helper vector 
under the transcriptional control of a strong liver specific promoter. Non-overlapping 
internal domain sequences were not included in either the rAAV transposon or helper 
vectors. Nevertheless, effective transposition was demonstrated with both the cohABCB4 
and eGFP transposon vector systems. Meir et al., also found effective transposition by 
using an exogenous CMV promoter to drive piggyBac transposase expression and 
eliminating the majority of the terminal domain sequences in donor plasmids with 
inclusion of only short inverted repeats.
537
 Thus, in contrast to a recent report
554
, only 
short inverted repeat sequences are sufficient for effective transposition by piggyBac 
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transposase, and the majority of internal domain sequences are not essential either in cis 
or in trans. 
The hybrid rAAV-transposon vector system was also used to evaluate the relative PC 
floppase function of 3 naturally occurring transcript variants of the human ABCB4 gene, 
in order to determine the most effective cohABCB4 therapeutic vector configuration. As 
described in Chapter 1, these 3 known transcript variants result from alternate in-frame 
splicing of pre-mRNA transcripts, and may translate into 3 different MDR3 isoforms with 
structural variations including altered membrane topology.
333,334
 This could lead to 
differences in the relative PC floppase activity of each of the known isoforms, which has 
not previously been defined. 
Use of the hybrid rAAV-piggyBac transposon vector system allowed assessment of their 
relative PC floppase function on a null Abcb4
-/-
 background. An attempt to evaluate 
changes in biliary PC concentration in sufficiently transduced heterozygous adults using 
conventional rAAV vectors proved difficult to interpret as small changes in biliary PC 
concentration as a result of modest PC floppase activity could not be clearly distinguished 
from background variability in PC concentrations amongst heterozygotes. Analysis of 
samples from 4 week old Abcb4
-/-
 mice that received a hybrid vector encoding one of the 
transcript variant coding sequences together with transposase vector at birth demonstrated 
that, after adjusting for differences in transduction, variant A vector resulted in a 4- and 
20-fold higher mean relative biliary PC concentration, compared to variant B and C, 
respectively (Figure 5.10b). Importantly, this was sufficient to prevent onset of liver 
disease, in contrast to either Variant B or C recipients. Thus, for a given input vector 
dose, isoform A conferred higher phosphatidylcholine concentration in bile. These results 
are consistent with anticipated differences in protein structure based on in silico 
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modelling,
333,334
 and suggest that isoform A is likely to have higher PC floppase activity 
at the canalicular membrane. However, differences in biliary PC output could also be due 
to differences in post-transcriptional modification that could result in increased 
accumulation of other isoforms in the endoplasmic reticulum and other organelles, 
different isoforms may be disproportionately marked for proteasomal degradation, and 
there could be disparity in the efficiencies of intracellular protein trafficking, such as 
shuttling from intracellular pools to the canalicular membrane. Furthermore, Isoform B 
and C may perform additional, yet unidentified functions in hepatocytes, but this remains 
to be further explored.  
A major and inherent challenge with any integrating vector system is minimising the risk 
of genotoxicity. Integrated sequences may disrupt surrounding endogenous gene function 
and regulation with potentially undesired consequences such as predisposing to apoptosis 
or immortalisation.
557
 Though most integration events do not promote oncogenesis, if an 
integration event affected proto-oncogene or tumour suppressor gene expression, 
neoplastic transformation may occur. The risk of insertional mutagenesis is influenced by 
the preferential pattern and frequency of integration events.  
Genome-wide integration site analyses indicate that piggyBac transposon integrations are 
not random, and preferentially occur within coding regions especially of actively 
transcribed genes, near transcriptional start sites and CpG islands, with affinity for open 
chromatin structures.
505,537,558-560
 Although piggyBac transposase targets integration at 
TTAA tetranucleotide sequences, non-canonical integration sites have also been observed 
at low frequency.
537,558
 To date, the majority of piggyBac transposon integration site 
pattern analyses have been conducted using cell culture models.
537,559-561
 However in a 
therapeutic setting, long-term in vivo animal studies are necessary to better appreciate 
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how such patterns relate to the tumorigenic risks, particularly in a disease specific 
context. Abcb4
-/-
 mice inevitably develop hepatocellular carcinomas
339
, but correcting the 
liver pathology using rAAV-transposons may significantly alter hepatocarcinogenesis. 
Therefore, any potential risk of insertional mutagenesis related to the vector system would 
need to be interpreted in this context. Nevertheless, long-term studies are essential to 
understanding how treating this model with the hybrid rAAV-transposon vector system 
may change the frequency and timing of hepatic tumour formation. These studies are 
underway with only preliminary data available from two 9-month old birth-treated mice 
as described (Section 5.3.4.5). 
Evaluation of a hybrid lentiviral-sleeping beauty transposon vector system showed that its 
integration profile closely resembled that of sleeping beauty rather than lentiviral 
patterns.
533
 As the rAAV-piggyBac hybrid system described in this thesis is novel and 
previously unreported, it is yet unknown whether its integration profile would differ from 
that of conventional piggyBac transposons. Long-term studies to characterise the 
integration pattern and frequency, and to estimate the extent of insertional mutagenic risk 
of this hybrid vector system are currently in progress. 
Nevertheless, a degree of risk of genotoxicity is inherent in this integrating rAAV-
piggyBac hybrid system. A thorough understanding of this risk and devising strategies to 
minimise it will be an important next step in evaluating whether this powerful system is 
translatable to the clinic. Such strategies will be discussed in the next chapter.
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CHAPTER 6: GENERAL DISCUSSION, FUTURE DIRECTIONS, 
AND FINAL CONCLUSIONS 
This thesis focussed on the development of rAAV-mediated gene therapy strategies 
towards treating Progressive Familial Intrahepatic Cholestasis type 3 in an Abcb4-
knockout (Mdr2
-/-
) murine model. In exploring gene replacement strategies for this 
condition, aspects of host- and vector-related factors influencing rAAV vector 
transduction and hABCB4 expression were evaluated, in order to optimise vector design, 
delivery and timing of administration for maximal therapeutic benefit.  
Transducing the liver with rAAV2/8 vectors encoding hABCB4 led to significant 
increases in biliary phosphatidylcholine concentration in disease-free heterozygous, but 
not homozygous adults. Though a greater than 30-fold rise in molecular transduction of 
homozygous adult male livers was demonstrated when rAAV vector genome size was 
reduced to 5 kb or smaller, blunted rAAV-mediated liver transduction was observed in all 
homozygous adults, irrespective of vector genome size, when compared with disease-free 
adults (Abcb4
+/+
 and Abcb4
+/-
) (Chapter 3). Changing the route of administration had no 
tangible effect on rAAV transduction in homozygous adults. Although intra-arterial route 
testing via hepatic artery injection was not technically feasible in mice, an advantage with 
using this route has been shown in larger animal models of experimental fibrosis
449
, and 
potential efficacy may also be possible in humans.  
In comparison to age-matched, disease-free wild-type mice, limited rAAV transduction 
was observed in Abcb4
-/-
 juvenile mice, especially in the presence of established liver 
pathology (Chapter 4). However, the mechanisms underlying this are not fully 
understood. Potential blocks in rAAV delivery and hepatocyte transduction could occur at 
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several levels. Disease-related alterations in hepatic architecture due to periportal and 
perisinusoidal fibrosis causing portal hypertension with shunting and reduced access to 
the hepatocyte cell surface, changes in the density of cell surface receptors and co-
receptors required for receptor-mediated rAAV endocytosis, deviations in intracellular 
trafficking pathway utilisation and altered DNA methylation patterns leading to transgene 
silencing, could all contribute to diminished rAAV transduction and transgene expression. 
Furthermore, potential increased hepatocellular proliferation may lead to episomal loss 
during cell cycling. However, each of these should be empirically assessed. Dissecting the 
mechanisms underpinning blunted rAAV transduction in Abcb4
-/-
 mice may lead to the 
development of novel strategies to overcome these potential barriers and thus, improve 
rAAV transduction in this and related settings.  
Adjuvants to alleviate these blocks prior to gene transfer may broaden the potential 
candidates for gene therapy to include those with pre-existing liver damage. Previous 
studies of vector transduction in experimental models of liver fibrosis offer important 
insights into the contribution of hepatic fibrogenesis and inflammation, and suggest that 
adjuncts including type I collagen inhibitors
448
 and demethylating agents
221
, could 
improve rAAV transduction in the presence of established liver disease. Though there is a 
scarcity of effective, long-lasting antifibrotic therapies currently approved for clinical 
application, many are being investigated in experimental settings. Some agents have been 
shown to be effective in this Mdr2-knockout model – e.g. insulin-like growth factor 
binding protein-5 overexpression
562
, dual FXR/TGR-5 agonist
347
, and 24-nor-
Ursodeoxycholic acid
343
. Evaluation of these and other fibrolytic therapies alongside 
rAAV gene therapy would further establish a proof of concept.  
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In homozygotes, maximal efficacy was achieved prior to onset of liver disease, optimally 
in neonates (Chapter 4). However, an essential challenge with neonatal vector delivery is 
maintaining therapeutic benefit in the setting of rapid liver growth and hepatocellular 
proliferation, leading to loss of transgene expression, as a consequence of rAAV episomal 
degradation and dilution.
181
 Delaying the age of vector administration, in order to bypass 
the most rapid growth phase of murine livers may increase gene transfer stability
181,459
, 
but this must be weighed against waning rAAV-mediated hepatocyte transduction 
efficiency in Abcb4
-/-
 mice. Whilst, re-administrating rAAV vectors at later time points 
may counterbalance the loss of transgene expression to an extent, induced humoral 
immunity against rAAV vectors is likely to blunt the therapeutic effect of subsequent 
vector doses.
54,563,467
  
To overcome the challenge of treating neonates with conventional rAAV, a hybrid rAAV-
piggyBac transposon vector system was developed to promote greater somatic integration, 
and allow persistent, stable hABCB4 expression in vivo. Though viral delivery systems 
have been combined with transposon technology
494,531-534
, as yet a vector system using 
rAAV vectors to deliver piggyBac transposons in vivo has not, to our knowledge, been 
previously reported, nor has efficient in vivo delivery of piggyBac transposons to rescue a 
disease phenotype been demonstrated. Using this novel, hybrid vector system, onset of 
liver disease was prevented in homozygous neonates and juveniles up to 2 weeks of age, 
in whom biliary phosphatidylcholine concentration was restored (Chapter 5). Concurrent 
elevation of biliary cholesterol concentrations and improved phosphatidylcholine-to-bile 
salt ratios were also demonstrated.  
Using relatively high vector doses of 1.3 × 10
14
 vg/kg per mouse, 3 to 4 week old 
homozygous mice with a degree of liver inflammation and portal fibrosis at the time of 
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inoculation, had partial phenotype correction (Chapter 5). However, by administrating at 
least 6.2 × 10
13
 vg/kg per mouse at an earlier age, a single therapeutic injection was 
sufficient for complete phenotype correction, extending into adulthood. Demonstrable 
long-term benefit with this hybrid system negated the need for vector re-administration in 
young Abcb4
-/-
 mice. Preliminary data also indicated possible reduction in the incidence 
of hepatocellular carcinoma formation at 9 months of age, but ongoing long-term studies 
are necessary to confirm these observations. 
This hybrid rAAV-piggyBac transposon encoded a codon-optimised hABCB4 cDNA of 
transcript variant A, which was demonstrated to confer greater increase in biliary 
phosphatidylcholine concentration for a given level of molecular transduction, compared 
to either of the other 2 known transcript variants. As far as we are aware, the relative in 
vivo phosphatidylcholine floppase functions of each of the three known transcript variants 
have not been previously reported. The importance of selecting the most effective 
transcript variant for gene therapy vector design is underscored by the fact that without 
this foreknowledge, the transgene used in earlier experiments described in Chapter 3 and 
vector re-administration experiments in Chapter 5 was a hABCB4 cDNA of transcript 
variant B. Although, using a variant A transgene may have improved the outcomes in 
these experiments, overall conclusions are unlikely to change, especially given the vast 
differences in molecular transduction and biliary phosphatidylcholine concentrations 
observed in transduced homozygous adults, compared with disease free wild-type or 
heterozygous adults. 
This current hybrid rAAV-transposon vector system has the potential to offer infants and 
children with PFIC3 an effective and reliable alternative treatment to liver transplantation. 
Furthermore, this promising hybrid system provides a unique platform for treating other 
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diseases that necessitates early/neonatal therapy. In fact, a similar hybrid vector design 
has been employed in our laboratory to correct two urea cycle defects using murine 
models of ornithine transcarbamylase deficiency and citrullinemia type 1 (Cunningham 
SC et al., manuscript in preparation).  
Addressing translational challenges, outlined in Chapter 1, will be necessary for 
therapeutic success in the clinic. One of the biggest challenges in translating pre-clinical 
efficacy of small rodent models to effective human application is achieving adequately 
efficient rAAV transduction. Studies based on non-human primates predict that lower 
efficiency of gene transfer and lower expression for a given dosage may be reasonably 
expected.
469,564
 In the face of two-hit kinetics, this hybrid vector system places even 
greater demands on rAAV gene transfer efficiencies, since transduction of hepatocytes 
with both rAAV vector particles encoding the hABCB4 transposon and piggyBac 
transposase are required for transposase-mediated integration of the hABCB4 expression 
cassette. Furthermore, based on findings in this Abcb4
-/-
 murine model reported in 
Chapter 5, a relatively high level of liver transduction in homozygotes, sufficient to 
increase biliary PC concentrations to approximately 40% wild-type levels, is needed for 
full phenotype correction. Therefore, optimising vector design and delivery to maximise 
transduction and transgene expression will be vital for success. Important considerations 
include: (i) refining vector design to maximise transgene expression within rAAV 
packaging constraints, (ii) choosing capsids serotypes that would efficiently transduce 
human hepatocytes
184
, (iii) optimising vector doses as well as determining the ideal 
transposon-to-transposase vector ratio in order to avoid transposase overexpression 
inhibition
510
, and (iv) minimising persistent piggyBac transposase expression by 
delivering a more labile source of transposase such as mRNA to permit only transient 
expression, in order to avoid loss of transposons and reduce potential DNA damage 
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through recurrent excision-reintegration cycles
547
. Back titration of vector doses to 
determine the minimum requirement for complete phenotype correction is also important 
as high vector dose requirements would correspondingly place a greater burden on vector 
production systems, especially given hABCB4-encoding rAAV vector production issues 
described in Chapter 3. 
Additionally, host-vector immune interactions have also been shown to be a significant 
hurdle to achieving adequate efficacy in humans.
43,469,565
 Understanding and modulating 
immune responses that may diminish potential efficacy of this hybrid system are 
imperative. Initiation of therapy early in immune ontogeny, such as in neonates, may 
favour immune tolerance toward transgene product and capsid.
224
 Lessons learnt from 
extensively investigated facets of host immunity directed against shared immunologic 
targets (i.e., rAAV capsid and transgene protein product) may also be applicable to this 
hybrid system.
565
 Examples of potential strategies to circumvent host immunity include 
the use of novel engineered vector capsids to evade pre-existing neutralising rAAV 
antibodies, and the cautious use of immunomodulation therapy.
565,566
  
Moreover, evaluating safety issues, particularly in relation to the risk of insertional 
mutagenesis, will allow further refinement in vector design before clinical application.  
Whilst establishing the risk of genotoxicity arising from hybrid vector integration is the 
first step, some level of risk is inherent to any vector system with integrative capacity. 
Long-term safety and efficacy studies in this mouse model, which are in progress, will 
specifically provide a greater appreciation of its impact on hepatocellular carcinogenesis: 
both potential reduction due to correction of liver disease, and possible genotoxicity from 
insertional mutagenesis. Furthermore, long-term follow-up together with insertion site 
analyses may allow correlation between potential oncogenic hot spots and a functional in 
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vivo readout of tumour formation, should malignancy arise from insertional mutagenic 
events. The revelation from early γ-retroviral gene therapy clinical trials of the potential 
for integrating vectors to activate endogenous oncogenes through its positional effects
567
, 
led to the development of strategies to assess and reduce vector-mediated genotoxicity. 
Considering similar strategies to improve the biosafety of this integrating hybrid rAAV-
piggyBac transposon system are also important.  
One approach is to modify the pattern of integration in a site-specific manner. Several 
strategies to introduce a bias into piggyBac transposase-mediated integrations have been 
pursued include tethering site-specific endonucleases to transposase. Site-directed 
endonucleases such as zinc finger and transcription activator-like effector DNA binding 
domains fused to piggyBac transposase may direct transpositions into user-defined, 
potential “safe-harbour” chromosomal locations. A study assessing the predilection of an 
engineered zinc finger protein fused to piggyBac transposase for integration into a 
specific chromosomal site in HEK 293 cells demonstrated a high degree of targeting 
could be achieved by selecting TTAA-rich chromosomal target sites.
568
 However, this 
study used an artificially created, chromosomally inserted sequence, enriched with 14 
TTAA site within a 500 bp window surrounding the zinc finger target site. This artificial 
“hot spot” also included a kanamycin/neomycin selection cassette, which placed the 
target site in close proximity to the transcriptional start site of an actively transcribed 
gene, and was inserted into a region of open chromatin. Thus, other confounding factors 
were also introduced that could favour piggyBac transposon integrations at this 
site.
505,537,558,559
 
Customised transcription activator-like effector (TALE)-directed piggyBac transposition 
to target a putative genomic “safe harbour” within the first intron of the endogenous C-C 
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motif receptor 5 (CCR5) gene facilitated successful targeted integration, though at very 
low frequency, approximately 0.01% of total stably transfected cells.
569
 However, this 
also came at the expense of halving the piggyBac transposase activity, when compared to 
transposase without a coupled targeting construct. Therefore, adaptations aimed at 
improving targeting efficiency including selecting TTAA-rich “safe harbours”, and 
optimising transposase activity such as using a hyperactive piggyBac transposase, are 
likely to be required for effective site-specific piggyBac transposition using targetable 
nucleases.   
Another strategy to improving the biosafety of hybrid rAAV-piggyBac transposons is to 
lessen the risk of oncogene transcriptional activation from heterologous enhancer read-
through. Chromatin insulators are naturally-occurring DNA elements that have the ability 
to block the activating effects of enhancers by preventing their interaction with 
neighbouring promoters when positioned between them.
570-573
 Thus, the use of insulator 
with an integrating vector system such as transposons may reduce inadvertent endogenous 
proto-oncogene activation.
574-576
 A prototypical chromatin insulator mapped to a DNase 
hypersensitive site in the chicken β-globin loci (cHS4) has been demonstrated to reduce 
the rate of lentiviral vector-mediated genotoxicity by approximately 6-fold.
577
 Genetic 
insulators have also been employed to prevent transgene silencing with retroviral vectors 
by utilising its ability to block heterochromatin repression, thus leading to increased 
transgene expression.
578,579
 However, cHS4 insulators incorporated into sleeping beauty 
and piggyBac transposons led to initial increase in transgene expression, but prolonged 
protective effects were not observed.
580
 Reduced transgene expression by as much as 50% 
has also been demonstrated with insulated vectors.
574
 A further consideration with 
incorporating chromatin insulators into hybrid rAAV-piggyBac vectors are imposed 
rAAV packaging constraints, which may already be at or near capacity due to large 
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transgenes (e.g. hABCB4). Although, cHS4 enhancer blocking activity has been mapped 
to a 42 bp DNA-binding site for a conserved transcriptional repressor, extended 400 bp 
sequences are reported to be needed to obtain full cHS4 insulator barrier activity, at least 
with γ-retroviral and lentiviral vector integrations.571,581 
Appreciating how this hybrid vector system may potentially be used to treat patients with 
PFIC3 requires an understanding of risk-vs-benefit in this disease-specific context. The 
patients who are most likely to benefit from this therapy are those with severe null 
mutations that lead to absence or near-absence of biliary phosphatidylcholine output, who 
are unresponsive to ursodeoxycholate therapy and most likely to require liver 
transplantation during infancy or childhood. These patients would have the most 
favourable benefit-to-risk ratio. Better understanding of the correlation between specific 
mutations and likely outcomes including disease progression and likelihood of need for 
liver transplant will help identify potential ideal candidates for this therapy in the future.  
Although using this integrating hybrid vector system is likely to confer a degree of 
vector-mediated genotoxicity, which could promote tumour formation, hepatocellular 
carcinoma (HCC) risk, associated with untreated chronic cholestatic liver disease related 
to PFIC disorders
288
, may be reduced by hybrid gene therapy. Whilst liver transplantation 
to treat end-stage liver failure would also eliminate this HCC risk, post-transplant 
immunosuppression is additionally associated with risk of other malignancies including 
lymphoproliferative disease that may affect up to 4-15% of paediatric liver transplant 
recipients.
582-584
 Furthermore, liver transplantation and the need for lifelong 
immunosuppression are associated with other risks and potential morbidities including 
susceptibility to infection, renal impairment, cardiovascular abnormalities, surgical 
complications, and allograft rejection with risk of whole graft loss.
5-7
 Reducing vector-
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related genotoxicity using such strategies as those described above could further improve 
the benefit-to-risk ratio.  
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6.1. FINAL CONCLUSIONS 
The research presented in this thesis demonstrate, for the first time, that liver-targeted 
gene therapy using a hybrid rAAV-piggyBac transposon vector system can effectively 
treat chronic cholestatic liver disease in a murine model of Progressive Familial 
Intrahepatic Cholestasis type 3. Blunted rAAV transduction of hepatocytes in this Abcb4-
knockout mouse model is a significant barrier to establishing therapeutic efficacy using 
conventional rAAV. However, the mechanisms for this have yet to be fully defined. 
Complete phenotype correction was achieved when hybrid vector was administered prior 
to development of periportal fibrosis and inflammation, but relatively high doses were 
necessary to halt liver pathology, once it had progressed beyond this point. When hybrid 
vector was delivered early, a single therapeutic inoculum was sufficient to provide stable, 
long-term hABCB4 expression at levels necessary to maintain normal liver histology and 
biochemistry, well into adulthood. Additionally, preliminary data indicated possible 
reduction in HCC risks. 
This powerful hybrid vector system has the potential to offer infants and children with 
PFIC3 a relatively safe, effective and reliable alternative treatment to liver 
transplantation. Future work should be directed towards evaluating and addressing safety 
issues, and surmounting translational challenges to improve efficacy in the human setting, 
in order to refine vector design prior to clinical application.  
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